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Abstract    
 
Insulin resistance contributes to and precedes the development of type 2 diabetes. 
Insulin-stimulated microvascular perfusion and glucose uptake in skeletal muscle are 
important components of glucose homeostasis, and are impaired during insulin 
resistance. Epidemiological studies suggest that regular green tea consumption may 
lower the risk for developing type 2 diabetes. Whether green tea or its components 
could be used as an alternative treatment for type 2 diabetes is not known. The primary 
aim of this thesis was to investigate the effects of epigallocatechin gallate (EGCG), a 
green tea polyphenol, on vascular function and glucose metabolism in skeletal muscle. 
The direct vascular and metabolic actions of EGCG in skeletal muscle were assessed in 
situ using the isolated, constant-flow perfused rat hindlimb. In this study, four different 
doses of EGCG were studied: 0.1, 1, 10, and 100 µM. EGCG (1 – 10 µM) caused nitric 
oxide synthase (NOS)-dependent vasodilation against 5-hydroxytryptamine (5-HT). 
However, EGCG-mediated vasodilation was independent of PI3-kinase or AMP-kinase 
activation. EGCG had no direct effects on muscle glucose uptake in the presence or 
absence of insulin at any of the doses tested. This indicates that EGCG has direct 
vascular, but not metabolic, actions in skeletal muscle.  
Since EGCG had direct vascular effects in muscle its effects on microvascular 
perfusion and insulin-mediated glucose metabolism in vivo were then investigated. The 
acute and chronic effects of EGCG on vascular function and glucose metabolism were 
investigated in normal healthy and diet-induced insulin resistant rats in vivo under 
anaesthesia. Hyperinsulinaemic euglycaemic clamp was used to determine the acute 
and chronic effects of EGCG on whole body insulin sensitivity. In the acute studies, 
EGCG was infused intravenously to increase plasma EGCG to 10 µM. Acute EGCG 
stimulated muscle microvascular perfusion in both healthy and insulin resistant rats, but 
was not additive to insulin-stimulated microvascular perfusion. Acute EGCG did not 
stimulate muscle glucose uptake or enhance insulin-stimulated muscle glucose uptake. 
However, acute EGCG treatment improved whole body insulin sensitivity (glucose 
infusion rate, GIR) by 12% in insulin resistant rats but not healthy rats.  
xi | P a g e  
 
In the chronic studies, high fat-fed rats were given EGCG in their drinking water (200 
mg.kg
-1
.d
-1
) for 4 weeks to determine whether EGCG could prevent the development of 
insulin resistance. Chronic EGCG treatment improved whole body insulin sensitivity 
(GIR) by 21% and insulin-stimulated muscle glucose uptake by 67%. However, chronic 
EGCG treatment had no effect on muscle microvascular perfusion. This suggests that 
chronic EGCG treatment improved glucose metabolism, without altering vascular 
function of insulin resistant rats. 
The data from this thesis demonstrate that acute and chronic EGCG treatment exhibit 
distinct vascular and metabolic effects in vivo in rats. Acute EGCG treatment 
stimulated microvascular perfusion, but not glucose uptake in skeletal muscle. Chronic 
EGCG treatment improved whole body and muscle insulin sensitivity, but not muscle 
microvascular perfusion. Together these data provide a mechanistic insight into the 
potential anti-diabetic effects of chronic EGCG treatment, and support its development 
as a promising new therapeutic agent for prevention of insulin resistance and type 2 
diabetes. 
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Diabetes is a chronic disease affecting more than 371 million people globally (1). 
Diabetes is characterised by high circulating glucose levels, which can lead to damage 
to blood vessels, heart, eyes, kidneys, and nerves. There are three major types of 
diabetes, including type-1 diabetes, type 2 diabetes, and gestational diabetes. Of all the 
cases of diabetes, 85 – 95% are type 2 diabetes (1). Type 2 diabetes is associated with 
older age, physical inactivity, obesity, hypertension, hypercholesterolaemia, 
hyperlipidaemia, and cardiovascular disease (2). In 2012, the International Diabetes 
Federation estimated as many as 183 million people worldwide with type 2 diabetes 
were unaware of their conditions and therefore remained undiagnosed (1). This is 
mainly due to diabetes being asymptomatic until the later stages of the disease. 
Appropriate blood glucose management using lifestyle and pharmaceutical approaches 
in the early stage of diabetes is vital to prevent complications that arise from this 
disease. 
 
1.1 Insulin 
Insulin is a 51-amino acid hormone synthesized and secreted by pancreatic β-cells in 
response to elevated blood glucose levels. It is responsible for post-prandial fuel storage, 
which increases glucose uptake into insulin sensitive tissues (skeletal muscle and 
adipose tissue) and reduces glucose output from liver into bloodstream. Besides its role 
in regulating glucose and lipid metabolism, insulin also has important haemodynamic 
actions. 
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1.1.1 Signalling pathway of insulin 
The insulin receptor is a transmembrane receptor with an extracellular ligand binding 
domain and an intracellular tyrosine kinase domain.  Upon activation by binding of 
insulin, the insulin receptor phosphorylates insulin receptor substrate (IRS) family 
members, leading to the activation of phosphatidylinositol 3-kinase (PI3-K) signalling 
pathway (3). Another important action of insulin is the activation of SHC, which in turn 
activates the mitogen-activated protein kinase (MAPK) branch of insulin signalling 
pathway (3) (Figure 1.1).  
The downstream signalling molecules of the PI3-K branch include PDK and Akt. This 
PI3-K branch pathway is responsible for the metabolic actions of insulin in liver, 
adipose tissue, and skeletal muscle, as well as nitric oxide (NO) production by 
phosphorylation of endothelial NO synthase (eNOS) in endothelial cells to mediate 
vasodilation. The MAPK branch of the insulin signalling pathway includes RAS, RAF, 
MEK, and this pathway regulates mitogenesis, differentiation, and cell growth, as well 
as the endothelin-1 (ET-1) production in endothelial cells to mediate vasoconstriction. 
 
1.1.2 Haemodynamic actions of insulin 
 
1.1.2.1 Insulin signalling in vascular endothelium 
The vascular endothelium is the first tissue that insulin encounters after it is secreted by 
pancreatic β-cells (4). Vascular endothelium acts primarily as a semi-permeable barrier 
that regulates transport of macromolecules such as insulin into the interstitial space (4). 
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Furthermore, in the presence of insulin, the endothelium stimulates the production of 
NO (4; 5), a potent vasodilator, and ET-1 (6), a potent vasoconstrictor (Figure 1.1). It 
has been proposed that a healthy endothelium has a balanced production of NO and ET-
1 for maintaining a healthy vascular tone, and a disruption in this balance is associated 
with insulin resistance, hypertension and type 2 diabetes (4; 6; 7).  
In the early 2000s, Quon and colleagues elucidated the insulin signalling pathway in 
vascular endothelial cells leading to NO production. To activate NO production in 
vascular endothelial cells, insulin binds to the insulin receptor, which in turn 
phosphorylates Tyr kinase (Figure 1.1). Activation of the insulin receptor resulting in 
stimulation of the signalling cascade, involves IRS, PI3-K, PDK, and Akt. Activated 
Akt phosphorylates human eNOS at Ser
1177
 (or Ser
1179
 in bovine eNOS), stimulating the 
activity of eNOS and production NO from vascular endothelium (4; 5; 8-10). 
In addition to the NO production, insulin stimulates ET-1, a potent vasoconstrictor. ET-
1 production from the vascular endothelium opposes the vasodilator actions of NO. To 
date, little is known about the mechanisms of insulin-stimulated ET-1 production from 
the vascular endothelium. Quon and colleagues have reported that ET-1 stimulation by 
insulin in vascular endothelium is mediated via a distinct pathway from that of the 
insulin-stimulated NO pathway (11-13). ET-1 stimulated by insulin is MAPK-, but not 
PI3-K-dependent (11-13). Inhibition of MAPK has been reported to reduce the 
vasoconstrictor effects of insulin and favour the vasodilation actions by insulin (14).  
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Figure 1.1 Insulin signalling pathway. The insulin signalling pathway has two 
branches, the PI3-K branch and the MAPK branch. The PI3-K branch of the insulin 
signalling pathway is responsible for the NO production in endothelial cells, and acts 
on the skeletal muscle, adipose tissue, and liver for the metabolic actions of insulin. 
The MAPK branch of the insulin signalling pathway is responsible for the ET-1 
production in endothelial cells, and regulates mitogenesis and growth. Adapted from 
Muniyappa (3). 
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  1.1.2.2 Insulin-mediated vasodilation 
The vascular actions of insulin have been documented since the late 1930’s (15). 
Insulin is reported to dose-dependently increase total blood flow in skeletal muscle and 
this is paralleled by an increase in insulin-mediated muscle glucose uptake (16). NO 
plays an important role in mediating insulin-stimulated vasodilation in skeletal muscle. 
Both insulin stimulated increases muscle blood flow and muscle glucose uptake were 
inhibited when NOS and NO production were inhibited by NOS inhibitors, N
ω
-nitro-L-
arginine-methyl ester (L-NAME) or N
G
-monomethyl-L-arginine (L-NMMA) (17; 18). 
Therefore it has been postulated that insulin increases blood flow to skeletal muscle to 
enhance the delivery of insulin and glucose to skeletal muscle, thereby increasing 
glucose uptake into the skeletal muscle. Roy et al. (19) showed that NOS inhibition by 
L-NAME reduced whole body glucose disposal rate and muscle glucose uptake by 16% 
and 50% respectively in rats in vivo. It is important to note that NOS inhibition, 
however, had no effects on basal or insulin-stimulated muscle glucose uptake in vitro in 
both isolated soleus (red fibre type) and extensor digitorum longus (white fibre type) 
muscles (19), indicating NOS does not play a role in myocyte insulin action. 
The importance of vasodilation on glucose uptake was questioned when some 
vasodilators increased total blood flow to skeletal muscle but did not enhance muscle 
glucose uptake. These include adenosine (20), epinephrine (21), bradykinin (22; 23), 
sodium nitroprusside (24), and low dose insulin-like growth factor 1 (IGF-1) (25). To 
date, the only known vasodilator, besides insulin, that increases both total blood flow to 
skeletal muscle and muscle glucose uptake was methacholine (23; 26). Baron and 
colleagues (26) proposed that site-specific vasodilation may be related to the 
vasodilator’s metabolic actions. 
7 | P a g e  
 
On the other hand, other studies showed that a physiological dose of insulin (3     
mU.min
-1
.kg
-1
) stimulated muscle glucose uptake without increasing total blood flow in 
muscle (18; 27). Baron and colleagues proposed that insulin, besides increasing total 
blood flow, could also increase capillary flow and density of perfused capillaries in 
skeletal muscle, which in turn increase the perfused muscle mass that was involved in 
glucose metabolism (28). The increases in capillary flow and density of perfused 
capillaries have since been known as microvascular (or capillary) recruitment (Figure 
1.2). However, microvascular recruitment could not be measured directly in Baron’s 
study due to the lack of available techniques. 
   
1.1.2.3 Vascular distribution in skeletal muscle  
It has been generally established that, groups of capillaries, not individual blood vessels, 
are the fundamental functional unit within the skeletal muscle (29; 30). Terminal 
arterioles in the skeletal muscle are responsible for regulation of the blood flow 
distribution of the capillaries unit (instead of each individual capillary) within the 
muscle microvasculature (31; 32). It has been postulated that larger arterioles (≥ 50 µm 
diameter) control the resistance, hence flow through the skeletal muscle, while distal 
arterioles (~ 10 ‒ 40 µm diameter) function similar to pre-capillary sphincters that 
regulate flow distribution within the muscle microvasculature (30). It is understood that 
not all capillaries in a resting muscle are perfused (33; 34), instead the muscle 
microvasculature undergo vasomotion (35; 36), in which the blood vessels constrict 
periodically to evenly distribute blood flow through various capillary modules in 
skeletal muscle. Furthermore, studies have suggested the existence of two distinct 
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circulatory systems in skeletal muscle (37-41), which are known as the nutritive flow 
route and non-nutritive flow route.  
The flow distribution between the nutritive and non-nutritive flow routes in the skeletal 
muscle is tightly regulated to meet the metabolic demands. The nutritive flow route is 
in close contact with the myocytes, and plays an important role to supply nutrients to 
the myocytes for metabolic needs (42) (Figure 1.2). The non-nutritive flow route 
supplies the connective tissues in muscle (43) as well as adipocytes (44), and this flow 
route has been proposed to serve as a functional reserve for the myocytes (41; 45) 
(Figure 1.2). In the basal or resting states, the blood is shunted through the non-nutritive 
flow route, during increased metabolic demand it now goes through the nutritive flow 
route. Flow re-distribution from non-nutritive to nutritive flow routes during an 
increased metabolic demand is known as microvascular recruitment. 
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Figure 1.2 Schematic diagram of nutritive and non-nutritive flow routes in 
muscle.  
Nutritive flow route is thought to be in close contact with the skeletal muscle cells, 
while non-nutritive flow route is thought to be closely associated with connective 
tissues such as intramuscular septa and tendons.  
At resting (basal) state, nutritive flow route in the skeletal muscle is minimally 
perfused ( ) to maintain basal metabolism. However, in the presence of insulin or 
exercise, nutritive flow route in the skeletal muscle is highly perfused (  + ). 
Modified from Borgstrom et al. (46) 
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1.1.2.4 Insulin-mediated microvascular recruitment 
Insulin appears to increase recruitment of microvascular vessels by either maintaining 
microvascular perfusion or increasing flow and thus overall increasing microvascular 
perfusion. In the late 1990s, collaborating researchers from the Universities in 
Tasmania and Virginia developed two major techniques to assess microvascular 
perfusion in vivo in skeletal muscle (21; 42; 47): metabolism of exogenously infused 1-
methylxanthine (1-MX) by xanthine oxidase (21; 27; 48-51), and contrast enhanced 
ultrasound (CEU) (18; 27; 47; 48; 52; 53).  
The metabolism of 1-MX, developed by Rattigan and colleagues (21), was the first 
technique available for measuring microvascular perfusion. The metabolism of 
exogenously infused 1-MX was used to measure the perfused capillary surface area in 
muscle (also known as microvascular perfusion) (21). In the constant-flow perfused rat 
hindlimb, 1-MX has no vasoactive activity (51). 1-MX is metabolised by the 
endogenous enzyme xanthine oxidase present in the muscle microvasculature into 1-
methylurate (54; 55). Xanthine oxidase is only present in the micro- but not macro-
vasculature, therefore higher microvascular perfusion will result in higher 1-MX 
extraction. However, clearance of 1-MX from blood by other tissues (eg. liver) is very 
rapid, so it is necessary to partially inhibit the endogenous xanthine oxidase activity. 
Allopurinol is a specific xanthine oxidase competitive inhibitor which is metabolized to 
form oxypurinol which in turn partially inhibits the xanthine oxidase activity. 
Oxypurinol also lowers the KM of xanthine oxidase for 1-MX (56), allowing saturation 
of xanthine oxidase even at the levels that occur with the arteriovenous difference in 1-
MX across the leg muscle vascular bed, thus making 1-MX metabolism independent of 
flow and only dependent on surface area (exposure to xanthine oxidase amount). 
Arterial and venous plasma concentrations of 1-MX, 1-methylurate, and oxypurinol are 
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readily measured by reverse-phase high performance liquid chromatography (HPLC). 
The disappearance (or metabolism) rate of the 1-MX is an indication of the perfused 
capillary surface area in skeletal muscle.  
Later, studies reported that myocardial (57) and renal (58) capillary blood volume can 
be measured using CEU technique. This technique involves the simultaneous 
ultrasound imaging and intravascular administration of gas-filled microbubbles. These 
microbubbles have similar rheology to that of erythrocytes, and they generate an 
acoustic signal during their microvascular transit through an ultrasound beam (59). 
Microbubbles are infused intravenously to reach an arterial steady state concentration 
before images are acquired. When steady state is achieved, microbubbles within the 
imaged region are destroyed with pulses of high power acoustic energy. Following this 
destructive pulse, replenishment of microbubbles provides the information about the 
capillary flow rate and capillary blood volume (57; 60). This myocardial CEU 
technique was then adapted for measurement of microvascular flow rate and 
microvascular blood volume within the skeletal muscle microvasculature (47; 48; 61). 
The use of CEU for measurement within the muscle microvasculature is described in 
detail in Chapter 2. 
Using these techniques, Rattigan and colleagues have reported that the insulin-mediated 
microvascular recruitment in skeletal muscle is independent of the increase in total 
blood flow (21) and occurs before augmentation of total blood flow (48). Furthermore, 
insulin-mediated microvascular recruitment precedes the activation of insulin signalling 
pathway in muscle myocytes for its metabolic action as well as insulin-mediated 
muscle glucose uptake (18). One study (27) also showed that insulin dose-dependently 
(1 – 10 mU.min-1.kg-1) stimulated muscle glucose uptake, however insulin-stimulated 
microvascular recruitment reached maximal at the lowest dose of insulin (1 mU.min
-
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1
.kg
-1
). Epinephrine increased total blood flow similar to that of the insulin but did not 
increase 1-MX metabolism and muscle glucose uptake (21). Bradykinin and 
methacholine both are potent vasodilators, but only the latter increased insulin-
mediated microvascular recruitment and muscle glucose uptake (23). These findings 
indicated that microvascular recruitment was potentially an important event for 
stimulation of muscle glucose uptake. Studies (18; 53) have shown that when insulin-
mediated microvascular recruitment was blocked by a systemically infused nitric oxide 
synthase inhibitor, L-NAME, there was a 40% reduction of muscle glucose uptake. 
Taken these together, this research has shown that insulin-mediated microvascular 
recruitment is NOS-dependent, and it is independent to insulin-mediated vasodilation in 
larger blood vessels. Insulin-mediated microvascular recruitment significantly 
contributes to insulin-stimulated muscle glucose uptake. 
 
1.1.3 Metabolic actions of insulin 
Skeletal muscle is the largest tissue in the human body and is responsible for 80 –  90% 
of glucose storage in the postprandial states in healthy humans (62; 63). In order for the 
muscle to store glucose as glycogen, glucose is required to be transported into muscle 
cells. In the 1950s, insulin’s metabolic actions on muscle became evident when insulin 
was reported to increase the rate of glucose uptake into muscle and adipose tissues (64; 
65). Of all the subtypes of glucose transporters, glucose transporter type 4 (GLUT4) is 
the major isoform expressed in skeletal muscle and adipose tissue, and is responsible 
for the uptake of glucose molecules into these tissues (66-70). In the basal state, 
GLUT4 is pooled and stored within the cell, often referred to as GLUT4 storage 
vesicles (71). Upon the binding of insulin to its receptor, the PI3-K signalling pathway 
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is activated, which includes the activation of downstream signalling pathway PDK1 and 
Akt. Following the activation of Akt, AS160 is phosphorylated and released from the 
GLUT4 vesicles, resulting in docking of GLUT4 to the cell membrane (72). In addition 
to promoting glucose uptake in skeletal muscle and adipose tissues, insulin regulates 
glucose metabolism by decreasing gluconeogenesis and glycogenolysis in liver. Similar 
to insulin action on muscle and adipose tissue, insulin action on liver is mediated via 
the PI3-K signalling pathway. Following the activation of PDK1 and Akt, the 
CREB/CBP/Torc2 complex is disrupted (73-75), leading to the inhibition of liver 
gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase) (76), resulting in inhibition of liver gluconeogenesis. 
Interestingly, the pathway by which insulin mediates its metabolic actions overlaps the 
insulin-mediated vasodilation pathway, suggesting there is an important association 
between the insulin’s vascular and metabolic actions. 
 
1.2 Insulin resistance 
In the 1960-70s, the term “insulin resistance” was introduced and defined as a condition 
where insulin loses its efficiency to stimulate glucose disposal into tissues, in particular 
skeletal muscle (77). Insulin resistance is characterised by impaired glucose tolerance, 
in which insulin-sensitive tissues including liver and muscle fail to response to insulin. 
Insulin fails to suppress liver glucose production, and fails to increase muscle glucose 
uptake. Insulin resistance is a fundamental characteristic of type 2 diabetes, and insulin 
resistance usually precedes the development of type 2 diabetes (Figure 1.3).  
As mentioned previously, insulin possesses important haemodynamic actions, where by 
insulin stimulates microvascular perfusion in skeletal muscle. Research at the Menzies 
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Research Institute Tasmania has reported that insulin resistance is associated with 
diminished insulin-mediated microvascular perfusion (or microvascular dysfunction). 
Acute insulin resistance induced by α-methylserotonin (50) and tumour necrosis factor 
α (TNFα) (78; 79) reduces insulin-mediated hindleg glucose uptake and this is strongly 
associated with a reduced microvascular perfusion, and is independent of femoral artery 
blood flow changes. Furthermore, animal models of insulin resistance, including high 
fat diet (HFD)-induced insulin resistance rats (80), obese Zucker rats (81), and Zucker 
diabetic fatty (ZDF) (52) rats display impaired insulin-mediated microvascular 
recruitment and muscle glucose uptake. More recently, it was reported that impaired 
insulin-mediated muscle glucose uptake during mild insulin resistance states can result 
from impaired insulin-mediated microvascular perfusion (82), and impairment in 
insulin-mediated microvascular perfusion can be developed independently of myocyte 
insulin resistance (82). Furthermore, it was showed that impaired insulin-mediated 
microvascular perfusion precedes the development of macrovascular (resistance blood 
vessels) dysfunction (82) (Figure 1.3). 
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Figure 1.3 Natural history of type 2 diabetes.  
Insulin resistance precedes the development of diabetes. During the early insulin 
resistance state, there is an elevated plasma insulin concentration to maintain 
normoglycaemia. However, pancreatic β-cells eventually fail to secrete an adequate 
amount of insulin to maintain normoglycaemia, which results in increased fasting 
plasma glucose concentrations. Untreated, this will progress to uncontrolled 
hyperglycaemia and be diagnosed as type 2 diabetes. Microvascular dysfunction is 
an early event in insulin resistance, and develops before macrovascular dysfunction 
occurred. Modified from Cefalu (83).  
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1.3 Tea derived from Camellia sinensis 
Currently, there are several types of medications and treatments available for blood 
glucose management in diabetics. Besides the injections of incretin mimetics, in 
Australia, there are six classes of oral medications used for treating type 2 diabetes, 
including biguanides, sulphonylureas, thiazolidinediones, meglitinides, α-glucosidase 
inhibitors, and dipeptidyl peptidase-4 inhibitors (84). However, these medications lose 
their effectiveness over time, and often the doses are increased and/or used in 
combination, and eventually insulin injections may be required. More recently, 
complementary and alternative medicine (CAM) has increased in popularity among the 
community to prevent or treat a broad range of diseases, including cardiovascular 
disease, depression, stress, diabetes, etc. Tea has been used to prevent and treat a 
variety of cancers, including breast (85), liver (86), and prostate (87) cancers. However, 
whether or not tea should be used as a CAM for diabetes treatment remains debatable. 
Tea is one of the most widely consumed beverages in the world, second only to water. 
There are three major classes of tea, including green, black, and oolong, which are all 
derived from the plant Camellia sinensis. Green tea and oolong tea are widely 
consumed in Asian countries, while black tea is predominantly consumed in Western 
countries. Since ancient times, green tea consumption has been lauded for its health-
promoting effects. Increasing evidence shows that the health-promoting effects of green 
tea are attributed to the high polyphenol content.  
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1.3.1 Health benefits of polyphenols  
Polyphenols are found in plants, mainly in fruits (grape, blueberry, cherries, plums, 
strawberries, cocoa, etc), vegetables (potato, tomato, lettuce, onion, etc) and also tea 
(88; 89). Polyphenols are essential for plant morphology, growth and reproduction, 
protection against ultraviolet radiation, and resistance to pathogens (90). There are a 
number of factors that are known to affect the plant polyphenol content, such as plant 
variety, soil composition, geographic location, weather condition, and storage 
conditions (91). Polyphenols are classified according to the number of phenol rings in 
their chemical structure. The five major classes of polyphenols include phenolic acids, 
stilbenes, flavonoids, lignans, and tannins (88) (Figure 1.4). Accumulating evidence 
shows that polyphenol-rich plants possess health-promoting effects, including cancer 
prevention (92-95), neuroprotection (96; 97), improve cardiovascular and metabolic 
health (98-100), and lower the risk of type 2 diabetes (101-106). Among all the 
polyphenol-rich plants, green tea and its flavan-3-ols has been most extensively studied 
for their health promoting effects. 
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Figure 1.4 Polyphenol classification. 
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1.3.2 Green tea 
Tea is categorised into different classes based on the degree of tea fermentation (or leaf 
oxidation) during processing. During tea fermentation, flavan-3-ols, the bioactive 
polyphenols in tea leaves, undergo polyphenol oxidase-dependent oxidative 
polymerisation, resulting in the formation of theaflavins and thearubigins (107). Green 
tea is unfermented and contains the highest concentration of flavan-3-ols. Oolong tea is 
a partially fermented product and therefore contains a mixture of flavan-3-ols, 
theaflavins, and thearubigins. Black tea is the most fermented tea, and as a result, 
contains abundant theaflavins and thearubigins, and limited or no flavan-3-ols. There 
are five major types of flavan-3-ols in green tea (Figure 1.5), including catechin, 
epicatechin, epicatechin gallate, epigallocatechin, and epigallocatechin gallate (EGCG). 
Table 1.1 outlines the composition of the main polyphenols in green tea, where EGCG 
is the most abundant polyphenols accounting for 33-50% of green tea polyphenols (107; 
108).  
For decades, research has been focused on the potential anti-cancer activities of green 
tea and green tea polyphenols (93-95; 109; 110), where encouraging in vitro and in vivo 
data have been established. Additionally, much evidence shows that green tea has anti-
inflammatory (111; 112), anti-viral (113; 114), and neuroprotective (96; 115) effects. In 
recent years, extensive research has been carried out to investigate the potential health-
promoting effects of green tea in cardiovascular and metabolic health (98; 116-120). 
Research suggests that the aforementioned health-promoting effects of green tea are 
attributed mainly to EGCG (110; 112-115).  
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Figure 1.5 Major flavan-3-ols and their chemical structure in green tea. Modified 
from Lin et al. (107) 
 
 
 
Table 1.1 Composition of major polyphenols in green tea. 
 
 
 
 
 
 
  
Polyphenols % of total polyphenol 
Catechin 2 
Epicatechin 6 
Epicatechin gallate 6-12 
Epigallocatechin 20-30 
Epigallocatechin gallate 33-50 
21 | P a g e  
 
1.4 Green tea and type 2 diabetes 
 
1.4.1 Epidemiology studies 
Recently, emerging evidence from epidemiological studies show that tea (including 
both green tea and black tea) consumption is associated with reduced risk for type 2 
diabetes (101-106). However, this is debated as not all studies have found this 
association (121; 122). 
In 2009, two meta-analysis by Huxley et al. (123) and Jing et al. (124) suggested that, 
compared to non-tea drinkers, tea (green and black tea) consumption of 3 –  4 cups (or 
more) per day was associated with 17 – 35 % lower risk for type 2 diabetes. 
Furthermore, a study in a British cohort (102) showed that tea (green and black tea) 
consumption of > 3 cups per day was associated with a 34% lower risk of diabetes. 
Among Japanese adults, Iso et al. (106) reported an inverse association between green 
tea consumption and risk for type 2 diabetes. This study suggested that high green tea 
consumption (≥ 6 cups.d-1) lowers their risk for type 2 diabetes by 33% compared to 
those who drink < 1 cup per week. Recently, a meta-analysis by Zheng et al. (125) 
reported that green tea catechins treatment for ≥ 12 weeks, but not shorter term (< 12 
weeks), was associated with lower fasting blood glucose. On the other hand, Oba et al. 
(121) failed to uncover an association between green tea consumption and reduced risk 
of diabetes in Japanese. Furthermore, the Singapore Chinese Health Study (122) did not 
find an association between green tea consumption and the reduced risk for type 2 
diabetes. However, these studies are correlative and do not directly address the effect of 
green tea consumption of metabolic outcomes. 
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1.4.2 Clinical studies 
 
1.4.2.1 Oolong Tea 
Some studies have assessed the metabolic effects of oolong tea in patients with type 2 
diabetes. A study by Shimada et al. (126) reported that oolong tea treatment for 4 
weeks significantly increased plasma adiponectin levels by 9.9% and lowered 
haemoglobin A1c (HbA1c) levels by 3.3% in patients with various coronary risk factors. 
There was a slight, but not significant, decrease in the plasma glucose levels. In this 
study, each patient received 45.4 mg.day
-1
 of EGCG from the oolong tea for 4 weeks. 
Hosoda et al. (127) used a higher dose of oolong tea treatment (EGCG 386 mg.d
-1
) for 
4 weeks and reported that plasma glucose was significantly lowered in type 2 diabetes 
patients compared to the control group. The mechanism of the anti-hyperglycaemic 
effects of the oolong tea is unclear. However, oolong tea seemed to have a 
concentration-dependent effect on glycaemic control.  
 
1.4.2.2 Green tea 
Since the 2000s, numerous clinical studies (116; 128-149) have been undertaken to 
investigate the metabolic effects of green tea or green tea extracts. In healthy subjects, 
acute green tea consumption was reported to enhance insulin sensitivity (148) and 
glucose tolerance (147). However, Josic et al. (139) reported that acute green tea 
consumption (containing 32.4 mg EGCG) did not have glucose and insulin lowering 
effects. Compared to the previous 2 studies, the EGCG and total polyphenol content in 
the green tea used in the latter study was markedly lower. Thus, there might be a dose-
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dependent effect of green tea (or EGCG) on glycaemic control. Conversely, chronic 
green tea extract (EGCG 150 mg.d
-1
) supplementation for 3 weeks lowered the total 
cholesterol: HDL ratio, but had no other metabolic effects in healthy subjects (135). 
Most (116; 130-134; 140-143), but not all (128; 129; 137; 149; 150), studies reported 
that body weight was reduced following chronic green tea or green tea extract treatment 
(range from 1 – 6 months of treatment) in overweight and obese subjects. Some studies 
have reported that following green tea or green tea extract treatment, there were 
reductions in plasma LDL levels (116; 130; 137; 141; 149; 150) and increased in 
plasma HDL levels (134; 137; 142; 149; 150). In postmenopausal women with 
impaired glucose tolerance, EGCG treatment (300 mg.d
-1
) for 12 weeks reduced plasma 
glucose by 5% (132). Recent studies have shown that green tea extract treatment 
(EGCG 208 mg.d
-1
) for 12 weeks reduced blood glucose (149) and insulin (150) levels 
significantly in obese subjects. In contrast, EGCG treatment (800 mg.d
-1
) for 8 weeks 
had no effects on insulin sensitivity and glucose tolerance in overweight and obese men 
in another study (129). 
In patients with type 2 diabetes, green tea extract (polyphenols 240 mg.d
-1
, EGCG 
content not reported) treatment for 8 weeks increased plasma adiponectin levels 
significantly (144). Another study (138) used a much higher dose of green tea extracts 
(EGCG 856.8 mg.d
-1 
for 16 weeks) and reported the homeostasis model assessment of 
insulin resistance (HOMA-IR), HbA1c, and fasting insulin levels were reduced 
significantly in type 2 diabetic patients. Furthermore, waist circumferences in the 
subjects treated with green tea extracts were reduced by 3%. Conversely, Ryu et al. 
(146) showed that metabolic markers including blood lipids, glucose, insulin, and 
adiponectin levels were not altered following 4 weeks of green tea treatment 
(polyphenol content not reported). Similarly, another study (136) reported that green tea 
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treatment (544 mg.d
-1
 polyphenols, EGCG content unknown) for 2 months had no 
apparent effects on metabolic markers such as fasting serum glucose and insulin, 
HbA1c, and HOMA-IR. 
Overall, the outcomes from the different clinical trials have not been conclusive. The 
discrepancies between results are likely due to small study populations, poor diet 
control during the study period, poor oral bioavailability of catechins (151-155), and/or 
poor study design. Nonetheless, Brown et al. (129) suggested that EGCG 
supplementation may play a more important role in prevention of insulin resistance and 
type 2 diabetes rather than as a therapeutic treatment for these conditions. Table 1.2 
summarizes the acute and chronic effects of EGCG in human. Taken together, these 
data indicate that animal studies are essential in order to effectively assess the dosage 
and mechanism of actions of EGCG to optimally design clinical trials. 
 
1.4.3 Animal studies 
Several studies have investigated the anti-diabetic effects of green tea in rodents, 
including normal healthy  (156-158), and insulin-resistant models, such as fructose fed 
rodents (159; 160), high-fat fed mice (98; 158; 161-163), diabetic (db/db) mice (147; 
164; 165), ZDF rats (164), spontaneously hypertensive rats (SHRs) (120), and Otsuka 
Long-Evans Tokushima Fatty (OLETF) rats (166; 167). Table 1.2 summarizes the acute 
and chronic effects of EGCG in animals. 
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1.4.3.1 Studies in healthy animals 
In healthy rats, green tea treatment for 3 weeks significantly reduced both the 
epididymal and abdominal adipose tissue weight (157). Besides that, plasma lipid 
profile, including free fatty acids, total cholesterol, HDL and LDL were significantly 
lowered by chronic green tea treatment. Interestingly, this study showed that following 
green tea treatment, muscle glucose uptake and GLUT4 translocation were significantly 
enhanced (157). In this study, total plasma EGCG levels reached ~40 nM, however, the 
amount of catechins provided to the rats were not detailed. Another study by Wu and 
Colleagues (156) showed that following 12 weeks of green tea treatment (mixed 
catechins 56 mg.d
-1
, EGCG 37.5 mg.d
-1
) in rats, significantly lowered fasting plasma 
glucose, insulin, free fatty acid, and triglyceride levels . In addition, glucose tolerance 
and insulin sensitivity in these rats were enhanced following the green tea treatment, 
and this might be in part attributable to the increased insulin sensitivity in adipocytes 
(156). Interestingly, Ashida et al. (157) showed that glucose uptake in adipose tissue 
was reduced by 80% following green tea treatment, while the former study (156) 
showed a 40% increase in glucose uptake in adipocytes. In mice fed green tea (EGCG 
610 mg.L
-1
) for 14 weeks, fasting blood glucose levels were lowered while serum lipid 
levels were not affected (158). In addition, glucose tolerance and muscle glucose 
uptake in these green tea treated mice were not altered but the adipose tissue glucose 
uptake was significantly reduced (158). It is too early to draw conclusions on the effects 
of green tea or EGCG in healthy animals due to the limited studies conducted. 
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1.4.3.2 Studies in insulin resistant animals 
Green tea, green tea extract or EGCG treatments have been reported to ameliorate diet-
induced insulin resistance in rodents (98; 158-163) and genetically-derived diabetes in 
rats (120; 147; 164-167). Green tea treatment (EGCG 1 g.L
-1
 in drinking water) for 12 
weeks improved glucose tolerance in fructose-fed rats (159). Green tea treated fructose-
fed rats have lower fasting plasma triglycerides than non-treated rats (159). Besides that, 
insulin mediated GLUT4 translocation and glucose uptake in adipocytes in the fructose-
fed rats were restored by green tea treatment (159). Another study showed that green 
tea treatment (EGCG 150 or 300 mg.kg
-1
.d
-1
) dose-dependently reversed insulin 
resistance induced by fructose-fed in hamster (160). In this study, animals were fed 
with fructose for 2 weeks before green tea was administered with the fructose for a 
further 4 weeks. This study (160) reported that green tea (or EGCG) dose-dependently 
increased fasting serum adiponectin, reduced fasting serum insulin and triglycerides, 
while having no effect on fasting glucose levels. Similarly, Bose et al. (161) treated 
insulin resistant mice for 4 weeks with EGCG (3.2 g.kg
-1
 diet) after 9 weeks of high fat 
feeding, and reported a significant reduction in fasting blood glucose following the 
EGCG treatment (insulin levels not reported). However, the food intake of the mice 
was not reported, and therefore it is unclear how much food (EGCG) was consumed by 
the mice each day. Studies by Li et al. (160) and Bose et al. (161) suggested that insulin 
resistance could be reversed by EGCG treatment in a dose-dependent fashion. 
Several studies have assessed the chronic (10 – 24 weeks) metabolic effects of green 
tea or EGCG in high fat-fed rodents.  Chronic green tea treatment in high fat-fed mice 
for 14 weeks (EGCG 609.7 mg.L
-1
) (158) and 22 weeks (EGCG 2 mg.kg
-1
.d
-1
) (162) 
have significantly reduced body weight and adipose tissue weight, improved glucose 
tolerance, GLUT4 translocation in muscle, and muscle glucose uptake, and reduced 
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fasting plasma glucose. Similar findings were reported (161) where chronic EGCG 
treatment (3.2 g.kg
-1
 diet)  for 16 weeks in high fat-fed mice reduced body weight, 
adipose tissue weight, fasting plasma glucose, insulin, and HOMA-IR. Body weight 
and adipose tissue weight reduced significantly in high fat-fed mice following 10 weeks 
of EGCG treatment (50 mg.kg
-1
.d
-1
) (163). Besides that, EGCG treatment (163) 
lowered fasting serum glucose and insulin in high fat-fed mice, thus improved 
quantitative insulin sensitivity check index (QUICKI, a surrogate index of insulin 
sensitivity). In these chronic studies (158; 161-163), the effects of green tea or EGCG 
treatment on body weight and fasting plasma glucose were apparent from week 7 
onwards. On the other hand, chronic green tea (polyphenol content not reported) and 
EGCG (1 mg.kg
-1
.d
-1
) treatment for 24 weeks in high fat-fed rats did not alter body 
weight, but increased fat-free mass significantly (98). In the high fat-fed rats, plasma 
biochemistries including glucose, HDL, LDL and triglycerides were not altered by 
green tea or EGCG treatment (98). However, green tea or EGCG treatment 
significantly improved glucose tolerance in the high fat-fed rats (98). Given the similar 
metabolic effects of the green tea and EGCG in these studies, this suggested that the 
amelioration of high fat-induced insulin resistance by green tea treatment might be 
attributed to EGCG.  
One study (164) showed that db/db mice, a type 2 diabetes mouse model, treated with 
EGCG (100 mg.kg
-1
.d
-1
) for 2 weeks improved glucose tolerance, while EGCG 
treatment at a lower dose (30 mg.kg
-1
.d
-1
) was not as effective. Wolfram et al. (164) 
also showed that EGCG treatment for 7 weeks could dose-dependently (EGCG 0.25 – 1 
g.kg
-1
 diet) improve glucose tolerance and reduced plasma glucose in db/db mice. 
Another study (165) also reported that db/db mice treated with EGCG (1 g.kg
-1
 diet) for 
10 weeks significantly improved glucose tolerance and reduced plasma glucose. 
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Interestingly, acute green tea treatment (mixed catechins 21.6 mg.kg
-1
, EGCG 16.8 
mg.kg
-1
) lowered the blood glucose in db/db mice, but not wild type mice (147). 
SHRs (7) and OLETF rats (168) are insulin resistant animal models with endothelial 
dysfunction. Green tea catechins and EGCG have been reported to improve endothelial 
function in SHRs (120; 169) and OLETF rats (166; 167). EGCG treatment (200   
mg.kg
-1
.d
-1
) for 3 weeks reduced fasting plasma glucose, increased QUICKI and plasma 
adiponectin in SHRs (120). EGCG treatment prevented the development of insulin 
resistance and reduced systolic blood pressure significantly in SHRs (120). Recently, 
Jang et al. (163) showed that EGCG treatment (50 mg.kg
-1
.d
-1
) for 10 weeks improved 
high fat diet-induced endothelial dysfunction in mice. In OLETF rats, green tea 
catechins (25 – 30 mg.kg-1.d-1) treatment for 12 weeks lowered blood pressure and 
fasting blood glucose and insulin in the rats (166; 167). Green tea catechins reduced the 
reactive oxygen species (ROS) formation and vascular activity of nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase in thoracic aorta of OLETF rats (166; 167). 
TNFα administration, which induces NADPH oxidase and the formation of ROS (170; 
171), has been reported to inhibit insulin-mediated microvascular recruitment (78; 79) 
and impair endothelial function during insulin resistant state (170; 171). These studies 
implicated that EGCG could prevent the development of insulin resistance by 
improving endothelial function. A major limitation in most of these aforementioned 
animal and human studies is the lack of reporting on circulating concentrations of 
EGCG. 
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Table 1.2 Summary of acute and chronic effects of EGCG in human and animal 
studies. 
Treatment details (eg. dose, length, and animal models) are described in 1.4.2 and 1.4.3. 
OGTT: oral glucose tolerance test; ↑: improve; ↓: reduce; --: no effects 
  
 Treatment Subjects Effects Ref 
Human 
Acute Healthy 
↑ OGTT 
↑ Insulin sensitivity 
147 
148 
Chronic 
Healthy -- 135 
Obese 
↓ Fasting plasma glucose 
↓ Fasting plasma insulin 
↓ HOMA-IR 
149 
150 
149; 150 
Type 2 diabetes 
↓ Fasting plasma insulin 
↓ HOMA-IR 
138 
Animal 
Acute 
Healthy -- 147; 238 
Insulin 
resistance 
↑ OGTT 238 
Type 2 diabetes ↓ Fasting blood glucose 147 
Chronic 
Healthy 
↓ Fasting plasma glucose 
↓ Fasting plasma insulin 
156; 158 
Insulin 
resistance 
↓ Body weight 
↓ Adipose tissue weight 
↓ Fasting plasma glucose 
↓ Fasting plasma insulin 
↑ OGTT 
↑ QUICKI 
↑ Endothelial function 
158; 161-163 
158; 161-163 
161; 163; 166; 167 
160; 161; 163 
98; 159 
120; 163 
120; 163; 166; 167 
Type 2 diabetes 
↓ Fasting plasma glucose 
↑ OGTT 
147; 164; 165 
164; 165 
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1.5 Mechanism of action of EGCG 
 
 1.5.1 Metabolic actions of EGCG 
There is mounting evidence from in vitro studies suggesting that EGCG has insulin-
mimetic metabolic actions on myocytes (157; 172; 173) and hepatocytes (174; 175). In 
isolated myocytes, green tea and EGCG stimulate GLUT4 translocation and results in 
increased glucose uptake (157; 158; 172). Similar to insulin, EGCG has been reported 
to stimulate muscle glucose uptake via the PI3-K/Akt signalling pathway in cultured 
myotubes (172; 173; 176). However, there is no evidence of EGCG activating the PI3-
K/Akt pathway by activating the insulin receptor (172). On the other hand, EGCG at 
high doses (> 20 µM), but not a lower dose (10 µM) (173), was shown to stimulate 
muscle glucose uptake by the activation of adenosine monophosphate-activated protein 
kinase (AMPK) (176; 177). Interestingly, EGCG could stimulate glucose uptake in 
cultured myocytes in the absence of insulin (157; 158; 172; 173; 176; 177), indicating 
that EGCG has an insulin-mimetic action in muscle cells. 
EGCG has been shown to suppress hepatic gluconeogenesis in cultured hepatocytes. At 
high doses (> 25 µM), EGCG suppresses hepatic gluconeogenesis through the same 
pathway as insulin, where EGCG activates IRS-1/ PI3-K/Akt, resulting in inhibition of 
PEPCK and G6Pase gluconeogenic enzyme activity (175). In contrast, EGCG at a 
lower dose (1 µM) suppresses hepatic gluconeogenesis via the AMPK pathway. In 
cultured hepatocytes treated with EGCG, AMPK is activated by ROS and 
Ca
2+
/calmodulin-dependent protein kinase kinase (CaMKK) pathway (174). Given that 
EGCG at a dietary dose (< 10 µM) acts independent to that of insulin, EGCG might 
enhance insulin’s inhibition of gluconeogenesis (Figure 1.6). 
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1.5.2 Vascular actions of EGCG 
Previous studies have shown that EGCG is a potent vasodilator in isolated aortic ring 
(178; 179), bovine ophthalmic artery (180), coronary artery ring (181), and mesenteric 
vascular bed (119). EGCG-mediated vasodilation is endothelium-dependent in isolated 
vessels including rat aortic ring (178; 182), bovine ophthalmic artery (180), and porcine 
coronary ring (181). Furthermore, EGCG stimulates NO production in cultured 
vascular endothelial cells, via the PI3-K/Akt/eNOS pathway (119; 178-181) (Figure 
1.6). Interestingly, formation of ROS in endothelial cells is essential for activation of 
the PI3-K pathway by EGCG (119; 181). In contrast to the vasodilation effects, EGCG 
at high concentrations (≥ 100 µM) induces endothelium-independent vasoconstriction 
in isolated aortas (178; 183-185). However, it should be noted that plasma EGCG in 
human is ~ 1 µM following consumption of 8 ‒ 16 cups of green tea (EGCG 800 mg.d-1) 
(151; 186). Previous studies (119; 178; 180; 181) showed that EGCG-mediated 
vasodilation is noticeable within a dietary range (0.1 – 10 µM). Taken together, these 
studies suggested that high doses of EGCG elicit opposing effects to that of low doses 
of EGCG, and this is important to take into consideration for the design of clinical 
studies. 
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Figure 1.6 Mechanism of action of EGCG in various tissues. Signalling molecules 
in common for both insulin and EGCG are in blue. Signalling molecules in green are 
EGCG-specific. Arrows indicate activation while Ts indicate inhibition of the 
following step in the pathway. ** indicate pathways activated by EGCG at high 
doses (>20 µM). Some components of the pathways (eg. IRS) have been omitted for 
clarity. 
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1.6 Study aims 
Skeletal muscle is the largest tissue in the human body and is responsible for 80 - 90% 
of glucose storage in the postprandial states in healthy humans (62; 63). Insulin-
mediated microvascular perfusion contributes to 40% of insulin-stimulated glucose 
uptake in skeletal muscle in vivo (53; 78). Insulin resistance is a fundamental 
characteristic of type 2 diabetes, and includes impaired insulin action on skeletal 
muscle, liver and muscle microvasculature. 
There is mounting evidence from in vitro studies suggesting that EGCG stimulates 
glucose uptake in cultured myocytes, which are beneficial for the prevention and 
treatment of insulin resistance and type 2 diabetes. Studies have also suggested that 
EGCG mimics both vascular and metabolic actions of insulin in vitro. Whether EGCG 
stimulates microvascular perfusion in vivo to mediate its metabolic action on skeletal 
muscle has not been previously investigated.  
In the current thesis, the main hypothesis is that EGCG has insulin-mimetic and/or 
insulin-sensitizing effects in vivo on vascular function to improve glucose metabolism 
in skeletal muscle. Three specific aims were developed in the current thesis to test this 
hypothesis: 
1. To explore whether EGCG has direct vascular and metabolic actions in skeletal 
muscle in situ. 
2. To explore whether acute EGCG treatment has insulin-mimetic or insulin-
sensitizing actions on microvascular blood flow and glucose metabolism in 
muscle in healthy and high fat fed insulin resistant rat models in vivo. 
3. To determine whether chronic EGCG treatment can ameliorate high fat diet-
induced insulin resistance in vivo. 
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Chapter 2 
Methods & materials 
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2.1 Materials 
EGCG (97% purity) was a kind donation from Tea Solutions, Hara Office Inc., Tokyo, 
Japan. All chemicals were obtained from Sigma-Aldrich unless otherwise stated.  
 
2.2 Animal care 
Male Sprague-Dawley rats (4 weeks old) were obtained from the University of 
Tasmania Central Animal Facility. Animals were housed at 21 ± 2 °C with a 12h: 12h 
light: dark cycle. The rats were allowed free access to drinking water and food ad 
libitum. Animal were provided with normal chow from Specialty Feeds, Glen Forest, 
WA, Australia or Ridley Agriproducts, Corowa, NSW, Australia. Rats were randomly 
allocated to respective experimental diets at 5 weeks old of age (Table 2.1). Animals’ 
weight, food intake, and water intake were monitored daily during dietary interventions. 
The animal studies were not carried out in a blinded fashion. However, the animals 
were randomly assigned to each experimental group.  All experimental procedures were 
approved by the University of Tasmania Animal Ethics Committee (A11282 approved 
in 2010 and A13384 approved in 2013) and performed in accordance with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes – 
2004, 7
th
 Edition.  
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Table 2.1 Macronutrient content of experimental diets. 
 5FD 9FD 23FD 
Protein, % w/w 20 22 19 
Fat, % w/w 
Saturated fats, % total fat 
Monounsaturated fats, % total fat 
Polyunsaturated fats, % total fat 
4.8 
17.3 
38.5 
43.8 
9 
20.4 
36.6 
42.1 
22.6 
51.9 
38.9 
9.2 
Carbohydrate, % w/w 70.4 65.8 53.7 
Crude Fibre, % w/w 5.1 3.2 4.7 
Digestable Energy, kJ/g 14.0 13.2 19.9 
Source  Specialty Feeds 
Ridley 
Agriproducts 
Specialty Feeds 
 
2.3 Isolated constant-flow perfused rat hindlimb procedure 
 
2.3.1 Perfusion buffer 
The perfusion buffer used was an erythrocyte-free preparation consisting of Krebs-
Ringer bicarbonate buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, 25 mM NaHCO3, 2.5 mM CaCl2, and 8.3 mM glucose) containing 4% (w/v) 
bovine serum albumin (Bovogen Biologicals Pty Ltd, Vic, Australia). Buffer was 
filtered through a 0.45 µm pore size membrane before use.  
 
37 | P a g e  
 
2.3.2 Animal surgery 
The surgical procedures (Figure 2.1) were essentially as described previously (187), 
with additional details as outlined elsewhere (188). Male rats were used for perfused rat 
hindlimb experiments because isolation of flow to one leg is easier due to a less 
complex blood supply to the genitalia. In brief, an abdominal midline incision was 
performed, and the abdominal wall was incised from the pubic symphysis to the xipoid 
process. The following blood vessels and tissues were ligated: superior and inferior 
epigastric vessels, superficial epigastric vessels, internal spermatic vessels, iliolumbar 
vessels, left common iliac artery and vein, testicles, and bladder. The descending colon 
and jejunum were ligated, allowing the removal of the viscera. The descending aorta 
and vena cava were carefully separated and cannulated in between the renal and 
iliolumbar vessels with 20G and 18G catheters (Terumo) respectively. The animal was 
connected to the perfusion apparatus. Lastly, the animal was euthanized with an intra-
cardiac injection of pentobarbital sodium at a lethal dose.  
 
2.3.3 Perfusion apparatus 
Rat hindlimbs were perfused in a non-recirculating manner with perfusion buffer, using 
a Masterflex® peristaltic pump (Cole-Parmer, Vernon Hills, IL, USA) to ensure a 
constant flow rate of 0.5 mL.min
-1
.g
-1
 of perfused muscle (equivalent to 8 mL.min
-1
 for 
a 200 g rats). The perfusate was gassed with 95% O2: 5% CO2 in a silastic tube 
oxygenator. Experiments were conducted at 32 °C in a temperature-controlled cabinet, 
with the buffer temperature maintained by passage through a water-jacketed heat 
exchange coil. Test substances were infused into a small bubble trap located in the 
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arterial perfusion line. Perfusion pressure was constantly monitored via a pressure 
transducer located in the arterial line. The venous effluent was periodically sampled and 
the remainder discarded. Perfusion pressure was continually recorded using WinDaq 
data acquisition software (DataQ Instruments, Akron, OH, USA). This apparatus is 
illustrated in Figure 2.2. 
 
Figure 2.1 Schematic diagram of surgically isolated flow to rat single hindlimb. 
Adapted from Dora (189). 
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Figure 2.2 Perfusion apparatus. A single rat hindlimb was perfused in a 
temperature-controlled cabinet at a constant flow rate. Perfusion pressure was 
monitored through the pressure gauge. Adapted from Dora (189). 
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2.4 In vivo experiment in anaesthetized rats 
 
2.4.1 Animal surgery 
After 4 weeks of dietary treatment, animals were fasted overnight before experiments 
were conducted. Animals were anaesthetized with an intraperitoneal injection of 
pentobarbital sodium (5 mg.100g
-1
 body weight). A tracheostomy was performed to 
facilitate spontaneous respiration throughout the course of the surgery and experiment. 
Polyethylene cannulas (PE-58, Intramedic®) were surgically implanted into both left 
and right jugular veins for continuous infusion of anaesthetic and other intravenous 
infusions. A third cannula was inserted into the carotid artery for arterial blood 
sampling and monitoring mean arterial blood pressure (MAP; BLPR2 pressure 
transducer, World Precision Instruments, Sarasota, FL, USA). Small incisions (~2 cm) 
were made in the skin of the groin area of the right leg, and the epigastric artery and 
vein ligated. Then, the femoral artery was separated from the femoral vein and 
saphenous nerve. An ultrasonic flow probe (Transonic Systems, VB series 0.5 mm) was 
positioned around the femoral artery of the right leg just distal to the rectus abdominus 
muscle. The cavity in the leg surrounding the probe was filled with ultrasound 
conductive gel (Medical Equipment Services Pty Ltd) to provide acoustic coupling to 
the probe. The probe was then connected to the flow meter (Model T160 ultrasonic 
volume flow meter, Transonic Systems). This was in turn interfaced with an IBM 
compatible PC computer which acquired the data at sampling frequency of 100 Hz for 
femoral artery blood flow, heart rate, and mean arterial blood pressure using WinDaq 
data acquisition software (DataQ Instruments). Figure 2.3 is a schematic illustration of 
the surgery performed. 
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Completion of the surgery was followed by a 60-minute equilibration period to allow 
cardiovascular parameters to become stable and constant. The rats were maintained 
under anaesthesia for the duration of the experiment by continuous infusion of 
pentobarbital sodium (0.6 mg.min
-1
.kg
-1
). The rats were placed on the heating block to 
maintain their body temperature at 37 °C throughout the duration of the experiment. 
Upon completion of the experiment, the epididymal fat pad of the rats were removed 
and weighed. Other tissues including whole calf muscle, liver, heart, aorta, and femoral 
arteries were collected for further analysis. The rats were euthanized by exsanguination. 
The majority of our observations on microvascular responses have been obtained in 
male rats. Given that microvascular responses have the largest coefficient of variance, 
we continued using male rats to avoid possible gender specific variability. Using males 
for both types of experiment (perfused hindlimb and in vivo experiments) allowed for 
direct comparison. 
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Figure 2.3 Schematic diagram of the surgical cannulations for in vivo experiments. 
Modified from Mahajan et al. (23). 
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2.4.2 Hyperinsulinaemic euglycaemic clamp 
The hyperinsulinaemic euglycaemic clamp is a gold standard technique for assessment 
of whole body insulin sensitivity. Using this method, insulin (Humulin R, Eli Lilly, 
Indianapolis, IN) was constantly infused (10 mU.min
-1
.kg
-1
) while glucose (30% w/v 
solution) was infused at variable rate to maintain blood glucose level at basal for a 
period of 120 min. Insulin was diluted freshly prior to the experiment. Steady state 
glucose infusion rate (GIR) represents the whole body insulin sensitivity. 
 
2.4.3 Glucose and lactate determination 
A glucose analyser (Yellow Springs Instruments, Model 2700 Stat Plus) was used to 
determine blood glucose, blood lactate, plasma glucose and plasma lactate (by glucose 
oxidase method) concentrations during and at the conclusion of the experiments. A 
sample volume of 25 μL was required for each determination. 
 
2.4.4 Plasma insulin determination 
Rat plasma insulin concentrations before and after the hyperinsulinaemic euglycaemic 
clamp were determined from arterial blood samples using enzyme-linked 
immunosorbent assay (ELISA) kit (Mercodia, Uppsala, Sweden) in accordance with the 
manufacturer’s protocol. This ELISA kit has a minimum detectable concentration of 
12.18 pmol.L
-1
, where the specificity of this ELISA kit was: rat insulin – 100%; human 
insulin – 167%; human proinsulin – 75%; human C-peptide – < 0.05%; rat proinsulin – 
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7%; rat C-peptide – < 0.001%; IGF-1 – < 0.02%; IGF-II – <0.02%. The intra-assay 
variation was between 3.3%, while the inter-assay variation was 2%. 
This ELISA kit is a solid phase two-site enzyme immunoassay. The principle of this kit 
is based on the direct sandwich technique in which two monoclonal antibodies are 
directed against separate antigenic determinants on the insulin molecule. The 
microtitration well was coated with anti-insulin antibodies, in which these antibodies 
bind to the insulin in the samples. The peroxidise-conjugated anti-insulin antibodies 
then react with the bound insulin. A simple washing step after incubation removes 
unbound enzyme labelled antibody. The bound conjugate is detected by reaction with a 
substrate, 3,3’,5,5’-tetramethylbenzidine (TMB). The reaction is stopped by adding 
acid to give a colorimetric endpoint that is read spectrophotometrically at 450 nm. 
 
2.4.5 Plasma free fatty acids determination 
Rat plasma free fatty acid levels after dietary intervention was determined from arterial 
blood samples using a colorimetric assay (NEFA C kit, Wako Pure Chemical Industries, 
Osaka, Japan) in accordance with the manufacturer’s protocol. This kit has a 
measurable range of 0.05 – 2 mM free fatty acid. The principle of this method based on 
the enzymatic reactions by Acyl-CoA synthetase (together with coenzyme A and ATP) 
to convert free fatty acids in the sample to Acyl-CoA, AMP, and pyrophosphoric acid. 
Acyl-CoA is oxidized by Acyl-CoA oxidase to form 2,3-trans-enoyl-CoA and H2O2. 
H2O2 that was produced following the reaction formed a blue purple pigment following 
reaction with 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline, 4-aminoantipyrine, and 
peroxidase. Free fatty acid levels in the sample are determined from absorbance at 550 
nm. 
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2.4.6 Determination of plasma EGCG levels 
Plasma EGCG levels were determined as described by Fu et al. (190) with some 
modifications. Plasma (200 µL) was sampled at the end of the hyperinsulinaemic 
euglycaemic clamp and stored at -20 °C until assayed for EGCG levels. 10 µL of 
resorcinol (0.75 mg.mL
-1
; internal standard) and 10 µL of citric acid (20% w/v) were 
added to each plasma samples. The subsequent mixture was extracted twice with 
ethylacetate (400 µL) by vortex-mixing for 30 s and then centrifugation at 16,000 × g 
for 10 min at 4 °C. The upper organic phase was collected and evaporated under 
nitrogen in a 50 °C water bath. The residue was reconstituted in 100 µL of buffer 
consisting of 0.1 % citric acid and acetonitrile (83:17, v/v), followed by centrifugation 
at 16,000 × g for 10 min at 4 °C. EGCG extraction was 96 ± 4%. The supernatant (50 
µL) was subjected to reverse-phase high performance liquid chromatography (HPLC) 
for analysis. The analytes were eluted on a Gemini
®
 5 µm C18 110Å LC Column (250 
x 4.6 mm; Phenomenex) maintained at room temperature using an isocratic mobile 
phase composed of 0.1% citric acid and acetonitrile (83:17, v/v) running at 1 mL.min
-1
, 
and using a detection wavelength of 273 nm. Coefficient of variation for inter- and 
intra-day assay was 2% and 3% respectively. 
 
2.4.7 Measurement of muscle microvascular perfusion 
CEU imaging of skeletal muscle was performed as described previously (191) for 
determination of microvascular perfusion. A linear array transducer (L9-3) was 
positioned over the left hindlimb of the rat to image the adductor magnus and semi-
membranosus muscle groups. The probe was interfaced with an iU22 ultrasound 
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(Philips Medical Systems, Australia). Figure 2.4 shows a CEU image of the rat 
hindlimb. Low mechanical index (0.08) real-time imaging was performed. The acoustic 
focus and gain settings were optimized and held constant throughout the experiment. 
Octafluoropropane microbubbles (perflutren lipid microsphere, DEFINITY
®
, Lantheus 
Medical Imaging, Australia) were diluted 1:25 in saline and infused intravenously at 30 
µL.min
-1
 for 15 min to reach steady state before images were acquired. Figure 2.5 
shows the ultrasound images obtained at different time point during microbubbles 
infusion. When steady state was achieved, a high energy destructive pulse of ultrasound 
(mechanical index = 1.15) was transmitted to destroy microbubbles within the volume 
of muscle tissue being imaged. Following this destructive pulse, microbubbles 
replenished the vasculature in the volume of muscle tissue being imaged. 
Replenishment of microbubbles was captured for 45 s in real-time. This was repeated 
three times and the acoustic intensity for each time point averaged between the three 
consecutive loops. Digital images were analysed off-line using QLab (Philips Medical 
Systems, Australia). Images were background subtracted (0.5 s frames) to eliminate 
signal from larger blood vessels and tissue per se. Analysis of the data was performed 
identically for all rats. Replenishment curves (Figure 2.6) were used to determine the 
microvascular blood volume in skeletal muscle. Background-subtracted acoustic-
intensity versus time was fitted to the function: y = A (1-e
-β*(t-0.5)
), where: y is acoustic-
intensity at time t, A is plateau acoustic intensity (a measure of microvascular blood 
volume, MBV), and β is the filling rate by microbubbles (a measure of microvascular 
flow velocity).  
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Figure 2.4 Example of (A) ultrasound and (B) contrast enhanced ultrasound 
images of the upper thigh of the rat hindlimb in short axis. Muscle region is the 
region of interest during analysis. The connective tissue was used as reference point 
when positioning the probe. 
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Figure 2.5 Contrast enhanced ultrasound images at different time points of 
microbubble infusion. Panel A shows the CEU image at 0 min (i.e. no 
microbubbles). Panel B shows the CEU image at 5 min. Panel C shows the CEU 
image at 15 min, the steady state of microbubble infusion. Panel D shows the CEU 
image during the transmission of high energy destructive pulse of ultrasound . 
Panel E shows the CEU image after the destructive pulse (100 ms following the 
destructive pulse), few or no microbubbles in the muscle tissue. Panel F shows the 
CEU image 45 s after the destructive pulse, where the microbubbles have fully 
replenished the vasculature in the muscle tissue. 
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Figure 2.6 Representative microbubble replenishment curve. Background-
subtracted acoustic-intensity versus time was fitted to the function: y = A (1-e
-β (t-0.5)
). 
The plateau acoustic intensity of the curve, A, is a measure of MBV, while the filling 
rate of the microbubbles, β, is a measure of the microvascular velocity. 
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2.4.8 Muscle-specific glucose uptake 
Radiolabelled 2-[1-
14
C]-deoxy-D-glucose (
14
C-2-DG; specific activity 50 – 60 
mCi.mmol
-1
, American Radiolabelled Chemicals, Saint Louis, MO, USA) was used to 
assess muscle-specific glucose uptake as described previously (192). A 10 μCi bolus of 
14
C-2-DG in saline was administrated 10 min prior to the end of the experiment 
followed by a continuous 10-minute arterial blood withdrawal at 40 μL.min-1. From this 
10-minute blood withdrawal sample, 25 μL of plasma was collected to determine the 
plasma 
14
C-2-DG level. At the conclusion of the experiment, the whole calf muscle was 
removed, freeze-clamped in liquid nitrogen and stored at -80 °C until assayed for 
muscle 
14
C-2-DG uptake. 
The frozen muscles were ground under liquid nitrogen and approximately 100 mg of 
ground muscle was homogenized in 1.5 mL distilled water using a Heidolph silent 
crusher M (4,700 x g, Schwabach Germany). The homogenate was centrifuged at 
16,000 x g for 10 min at 4 °C, 
14
C-2-DG levels were determined from the 100 µL 
muscle aqueous extract after homogenization. Free and phosphorylated 
14
C-2-DG from 
muscle aqueous extract (1 mL) was separated using an anion exchange resin (AGI-X8; 
Bio-Rad Laboratories, CA, USA). Biodegradable counting scintillant (3 mL, 
Amersham, Arlington Heights, IL, USA) was added to the 25 μL of 14C-2-DG plasma 
samples and 100 μL of the muscle aqueous extract after homogenization. 16 mL of 
scintillant was added to the radioactive samples separated by the ion exchange 
chromatography. Radioactive counts (disintegrations per minute, dpm) were 
determined using a scintillation counter (LS6500 Beckman Coulter
TM
, USA). The 
radioactive counts of these samples which represent the glucose uptake into muscle 
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(R’g) were calculated as previously described in detail by others (193; 194) and 
expressed as μg.g-1.min-1. 
 
2.5 Akt Western blot 
Frozen calf muscle tissue were ground into a fine powder under liquid nitrogen. 
Approximately 50 mg of powered tissue was sonicated (UCD 300, Bioruptor® Plus, 
Diagenode, Liege, Belgium) at 4 °C for 3 min on high setting in solubilising buffer 
(1:60 w/v). The solubilising buffer consisted of 25 mM Tris, 2.6 M KF and 250 mM 
Na2EDTA at pH 8.0. The homogenate was centrifuged at 16,000 × g for 10 min at 4 °C 
to remove insoluble material and the protein concentration of the supernatants was 
determined using Bradford protein assay (Bio-Rad Laboratories, Hercules, CA, USA). 
An aliquot containing 10 μg protein was heated to 100 °C with an equal volume of SDS 
sample buffer and electrophoresed on a Novex
®
 10% Tris-Glycine Mini Gels 
(Invitrogen, CA, USA). Proteins were electrophoretically transferred to nitrocellulose 
membranes. After blocking with 5% low fat milk in Tris-buffered saline plus 0.1% 
Tween 20, membranes were incubated with 1:1000 rabbit anti-phospho-Ser
473
-Akt (p-
Akt, Cell Signalling, Danvers, MA, USA) or 1:1000 rabbit anti-Akt (Cell Signalling) 
overnight at 4 °C. Following this, the membranes were probed with 1:1000 anti-rabbit 
secondary antibody (Cell Signalling) for 1 h at room temperature. To visualise the 
bands equal volumes of West Pico Chemiluminescent Substrate (Thermo Fischer 
Scientific, Rockford, IL, USA) were mixed together and applied to the membrane. 
Band intensities were quantified by optical density using DScan EX software version 
3.1 (Scanalytics, Rockville, MD, USA). 
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2.6 Statistical analysis 
All data are expressed as means ± S.E.M. Two-way repeated measures ANOVA with 
Student-Newman-Keuls post hoc test was used to compare treatment groups over the 
time course of experiment. An unpaired Student’s t-test or a one-way ANOVA with 
Student-Newman-Keuls post hoc test was used, where appropriate, to make 
comparisons of differences between endpoint values. All tests were performed using 
the SigmaPlot 11 (
©
Systat Software Inc. 2008). 
For the constant-flow perfused hindlimb studies, 6 animals in each group will detect a 
20% increase in glucose uptake from baseline, or a 20% decrease in perfusion pressure 
from baseline (power = 0.8, alpha = 0.05). For in vivo studies, 8 animals in each group 
will detect a 30% difference (power = 0.8, alpha = 0.05) in microvascular perfusion. 
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Chapter 3 
Direct metabolic and vascular effects of 
EGCG in rat skeletal muscle 
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3.1 Introduction  
EGCG has been reported to have insulin-mimetic actions on muscle glucose 
metabolism and vasodilation in vitro. EGCG has been shown to stimulate GLUT4 
translocation in skeletal muscle (157; 158; 172) and muscle glucose uptake (157; 172; 
173) in vitro. On the other hand, EGCG has been demonstrated to be a vasodilator in 
vitro, and EGCG shares a common signalling pathway with insulin in mediating 
vasodilation (119; 120; 178-182). However, the metabolic and vascular effects of 
EGCG in an isolated perfused muscle preparation have not been previously 
characterised.  
One of the advantages to assess muscle glucose metabolism in an isolated perfused 
muscle preparation is to examine the myocyte-specific glucose uptake in the absence of 
changes in microvascular flow (such as microvascular recruitment). Furthermore, a 
perfused muscle preparation allows the metabolic actions of EGCG to be assessed in 
the absence of circulating factors (neural and humoral) that may modify the response to 
EGCG. It is important to note that isolated cells (C2C12 cells and L6 myotubes) and 
incubated muscle may possess the same advantages as the perfused muscle preparation. 
However, isolated cells are not especially insulin sensitive (suprapharmacological 
insulin concentrations are required to stimulate glucose uptake) (195) and not 
phenotypically identical to mature myocytes in skeletal muscle in vivo. In addition, 
incubated skeletal muscle receives the nutrients (glucose and insulin) and treatment 
substances (eg. EGCG) from the bathing incubation buffer through diffusion rather than 
delivered via vascular network (38; 196). 
In contrast, isolated blood vessel systems (eg. aorta, mesenteric vascular bed, and 
cultured vascular endothelial cells) may not respond to EGCG the same way as skeletal 
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muscle vasculature. Since skeletal muscle vasculature is the delivery system for 
myocytes in vivo, its responses are the most relevant for assessing the effects of EGCG 
on glucose delivery and disposal by muscle. Being a non-recirculating and isolated 
perfused system, it also allows infusion of vasoconstrictors and inhibitors that cannot be 
used in vivo due to secondary effects on other tissues or systems that may indirectly 
impact on vascular and metabolic actions of EGCG. Thus isolated perfused rat 
hindlimb system is more useful for dissecting the mechanism of action of EGCG. 
The aims of this study were to examine (i) whether EGCG stimulates muscle glucose 
uptake independent of changes in total muscle blood flow and (ii) whether EGCG has 
vasodilator properties in muscle vasculature. The constant-flow perfused rat hindlimb 
preparation was used in the present study to test these aims.  
 
3.2 Methods 
 
3.2.1 Animals 
Male Sprague-Dawley rats (n = 101) weighing 222 ± 3 g at 7 – 9 weeks old were used 
in this study. Animals were housed at 21 ± 2 °C with a 12h: 12h light: dark cycle. The 
rats were allowed free access to drinking water and food ad libitum. Rats were provided 
with normal chow from Specialty Feeds, Glen Forest, WA, Australia (5FD) or from 
Ridley AgriProducts, Vic, Australia (9FD) (See Table 2.1). Both 5FD and 9FD fed rats 
were used in this chapter due to a change in the standard rodent chow at the University 
of Tasmania animal facility. All experimental procedures were approved by the 
University of Tasmania Animal Ethics Committee (A11282) and performed in 
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accordance with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes – 2004, 7th Edition. 
3.2.2 Constant-flow perfused rat hindlimb: Metabolic studies 
 
3.2.2.1 Protocol 1 
The dose response effect of EGCG on muscle glucose uptake was assessed using the 
constant-flow perfused rat hindlimb preparation. The vasculature in the constant-flow 
perfused rat hindlimb system is fully dilated, making this an ideal preparation for 
studying muscle glucose uptake in the absence of vasodilation and thus augmentation 
of glucose delivery by insulin or EGCG. Surgery was carried out in the rats fed with 
9FD as described in 2.3.2. Dose response effects of EGCG on muscle glucose uptake 
were carried out according to the protocol outlined in Figure 3.1A. Following the 
surgery, rats were connected to the perfusion apparatus (See 2.3.3) and allowed a 30-
min equilibration period to allow washout of red blood cells. Rat hindlimbs were 
perfused at a constant flow rate of 0.5 mL.min
-1
.g
-1
 of perfused muscle. Insulin (final 
concentration 15 nM) or saline were present in the perfusion buffer reservoir when the 
rats were connected to the perfusion apparatus. EGCG was infused at 0.1, 1, 10 and 100 
µM in 15 min step-wise increments. Muscle glucose uptake was measured using 2-[1,2-
3
H(N)]-deoxy-D-glucose (
3
H-2-DG; specific activity 5 – 10 Ci.mmol-1, Perkin Elmer 
Inc.), where 
3
H-2-DG was added into the buffer reservoir (50 µCi.L
-1
) after the 
equilibration period. Perfusate effluent was collected every 15 min before and during 
the course of the experiment. Whole calf muscle was excised and freeze-clamped at the 
end of the experiment. 
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3.2.2.2 Protocol 2 
Another set of experiments was conducted to assess the effects of EGCG on muscle 
glucose uptake over a longer period of time. In this protocol, 10 µM EGCG was infused 
for a period of 60 min. This dose of EGCG was chosen because EGCG is not toxic to 
the rats in vivo at doses up to 12 µM (500 mg.kg
-1
.d
-1
) (197; 198). Furthermore, EGCG 
might require a longer period of time to activate the muscle signalling pathway, in 
which insulin requires ~20 – 30 min to fully activate the signalling cascade in muscle 
(18; 199). Surgery was carried out in overnight fasted 5FD rats as described in 2.3.2. 
Figure 3.1B outlines the experimental protocol of this study. In Protocol 2, saline or 
insulin (15 nM) infusion started after the equilibration period. EGCG was infused to a 
final concentration of 10 µM during the saline or insulin infusion. Perfusate effluent 
was collected every 10 min before and during the course of the experiment. 
14
C-2-DG 
(25 nCi.min
-1
; American Radiolabeled Chemicals Inc.) infusion started 30 min before 
the end of experiment for the determination of muscle glucose uptake. Whole calf 
muscle was excised and freeze-clamped at the end of experiment.  
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Figure 3.1 Experimental protocols of perfused rat hindlimb metabolic studies.  
Protocol 1: Rats were equilibrated for 30 min before the addition of 
3
H-2-DG (, 50 
µCi.L
-1
) into the buffer reservoir. Insulin (final concentration 15 nM) or saline were 
present in the buffer reservoir when the rats were connected to the perfusion apparatus. 
EGCG infusion started 15 min after the infusion of 
3
H-2-DG, at 0.1, 1, 10 and 100 µM in 
15 min step-wise increments. Perfusate effluent () was collected every 15 min before 
and after the experiment started. Whole calf muscle was excised () at the end of the 
experiment. 
Protocol 2: Rats were equilibrated for 30 min before saline or insulin (15 nM) infusion 
started. EGCG infusion (final concentration 10 µM) started the same time as saline or 
insulin infusion. Perfusate effluent () was collected every 10 min before and after the 
experiment started. 
14
C-2-DG (, 25 µCi.L-1) infusion started 30 min before the end of 
experiment. Whole calf muscle was excised () at the end of the experiment. 
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3.2.2.3 Hindlimb glucose uptake 
Glucose concentrations of the perfusion buffer and effluent were determined using a 
glucose analyser as described in 2.4.3. Hindlimb glucose uptake was calculated using 
the formula: ([Buffer Glucose]-[Effluent Glucose]) x Perfusion Flow Rate, and 
expressed as µmol.min
-1
. 
 
3.2.2.4 Muscle-specific glucose uptake (R’g) 
While hindlimb glucose uptake measures glucose disposal across the whole hindlimb, 
which consists of muscle tissue, as well as adipose, skin, bone and connective tissue, 
R’g indicates glucose disposal into muscle specifically. In protocols 1 and 2, 3H-2-DG 
or 
14
C-2-DG was used to measure R’g. At the end of experiment, 100 µL of perfusion 
buffer was collected to determine the influx 2-DG levels. Biodegradable counting 
scintillant (3 mL; Amersham, Arlington Heights, IL, USA) was added to the 100 μL of 
perfusion buffer samples. R’g was determined as described in 2.4.8. 
  
3.2.3 Constant-flow perfused rat hindlimb: Vascular studies 
Surgery was carried out in the 5FD rats as described in 2.3.2. Vascular studies in 
hindlimbs were carried out according to the protocol outlined in Figure 3.2. The 
vasculature in the constant flow perfused hindlimb system is fully dilated. Therefore, in 
order to study the potential vasodilatory response of EGCG, the hindlimb vasculature 
was pre-constricted with norepinephrine (NE, 0.6 or 5 µM) or 5-hydroxytryptamine (5-
HT, 0.15 – 0.24 µM) to increase perfusion pressure to approximately 70 – 150 mmHg. 
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These vasoconstrictors were chosen as they constrict at different sites in the vascular 
tree and each causes blood flow re-distribution through a different vascular pathway, 
termed nutritive and non-nutritive (38). 
The vasoconstrictors were infused 30 min prior to and during infusion of saline (vehicle) 
or EGCG (0.1, 1, 10, 100 µM in 15 min stepwise increments). At the end of each 
experiment, 500 µM sodium nitroprusside (SNP) was infused to assess maximal 
vasodilatory capacity of the isolated hindlimb, in order to determine the absence of 
oedema-mediated vasoconstriction which may mask the vasodilation effects of EGCG. 
Perfusion pressure was continually recorded using WinDaq data acquisition software 
(DataQ Instruments, Akron, OH, USA).  
 
 
Figure 3.2 Experimental protocol of perfused rat hindlimb vascular studies.  
Protocol 3: Rats were equilibrated for 30 min before infusion of vasoconstrictors (5-HT 
or NE) started. Rats were either infused with saline (vehicle) or EGCG (0.1, 1, 10, 100 
µM in 15 min stepwise increments) 30 min after the infusion of vasoconstrictor. Perfusate 
effluent () was collected before and every 15 min after the experiment started. At the 
end of each experiment, 500 µM SNP was infused to assess maximal vasodilatory 
capacity of the isolated hindlimb. 
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3.2.4 Statistical analysis 
All data are expressed as means ± S.E.M. Two-way repeated measures ANOVA with 
Student-Newman-Keuls post hoc test was used to compare treatment groups over the 
time course of the experiment. A one-way ANOVA with Student-Newman-Keuls post 
hoc test was used, where appropriate, to make comparisons of differences between 
endpoint values. All tests were performed using the SigmaPlot 11 (
©
Systat Software Inc. 
2008). 
 
3.3 Results 
 
 3.3.1 Metabolic effects of EGCG in perfused rat hindlimbs 
The effects of 4 different doses of EGCG (0.1, 1, 10, and 100 µM) on muscle glucose 
uptake were assessed. Hindlimb glucose uptake at 0 min was not different between 
saline and EGCG groups (1.51 ± 0.49 and 1.40 ± 0.37 µmol.min
-1
 respectively), and 
none of the EGCG doses (0.1 – 100 µM) tested stimulated hindlimb glucose uptake 
(Figure 3.3A and B). As expected, insulin stimulated hindlimb glucose uptake by 3.8 
fold (Figure 3.3C, p < 0.001 vs. saline), but this response was not altered at any dose of 
EGCG tested (Figure 3.3D). R’g was assessed at the end of the experiment using the 
isotopic glucose tracer 
3
H-2-DG. Compared to saline, insulin stimulated muscle glucose 
uptake by 3.6 fold (Figure 3.4, p < 0.001). EGCG alone did not alter muscle glucose 
uptake and did not augment insulin-stimulated muscle glucose uptake (Figure 3.4). 
Next, the metabolic effects of  a single dose (10 µM) of EGCG was assessed for 60 min 
(Protocol 2). At the end of the experiment, hindlimb glucose uptake in saline and 
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EGCG infused rats were not significantly different (2.26 ± 0.31 and 2.60 ± 0.34 
µmol.min
-1
 respectively) and did not change from baseline (Figure 3.5). Insulin 
stimulated hindlimb glucose uptake by 3.7 fold (p < 0.001 vs. saline), and this was not 
altered by EGCG (Figure 3.5). R’g was assessed at the end of the experiment using the 
isotopic glucose tracer 
14
C-2-DG. Compared to saline, insulin stimulated muscle 
glucose uptake by 7 fold (Figure 3.6, p < 0.001). EGCG alone did not alter muscle 
glucose uptake or augment insulin-stimulated muscle glucose uptake (Figure 3.6). 
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Figure 3.3 Dose-response effects of EGCG on hindlimb glucose uptake in 9FD rats. n 
= 8 in each group. Final concentration of insulin was 15 nM, EGCG was infused into the 
hindlimb to final concentrations of 0.1, 1, 10, and 100 µM in 15 min increments. Data not 
statistically significant from 0 min in all groups (repeated measures ANOVA). 
0.1 µM     1 µM       10 µM     100 µM 
0.1 µM    1 µM      10 µM     100 µM 
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Figure 3.4 Effect of EGCG on 
3
H-2-DG muscle glucose uptake in 9FD rats. Data 
represents R’g at the end of experiment, following cumulative of four doses of EGCG in 
the EGCG and EGCG + Insulin groups. n = 8 in each group. * p < 0.001 vs. Saline and 
EGCG groups (One-way ANOVA).  
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Figure 3.5 Effect of 10 µM EGCG on hindlimb glucose uptake in 5FD rats. Hindlimb 
glucose uptake was calculated from the differences in the glucose concentration of the 
buffer reservoir and perfusate outflow and multiply by the perfusion flow rate.  Saline,
- EGCG,  - Insulin, and  - EGCG + Insulin, n = 7 in all groups. * p < 0.001 Insulin 
and EGCG + Insulin vs. Saline and EGCG (Two-way repeated measures ANOVA). # p < 
0.001 Insulin vs. all other groups (Two-way repeated measures ANOVA). 
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Figure 3.6 Effect of 10 µM EGCG on 
14
C-2-DG muscle glucose uptake in 5FD 
rats. Data represents R’g at the end of experiment. n = 7 in each group. * p < 0.001 
vs. Saline and EGCG (One-way ANOVA). 
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3.3.2 Vascular effects of EGCG in perfused rat hindlimbs 
   
3.3.2.1 Low dose NE (0.6 µM, Type A vasoconstrictor) 
The direct vascular actions of EGCG were assessed using the constant-flow perfused 
rat hindlimb system. Hindlimb perfusion pressure under basal conditions at a flow rate 
of ~8 mL.min
-1
 for a single hindlimb was 40.5 ± 1.1 mmHg (n = 14). This preparation 
is fully vasodilated because of the absence of hormonal and neural inputs. Thus, to 
assess the vasodilatory properties of EGCG, the vasculature preparation was pre-
constricted with low dose NE (0.6 µM) to increase perfusion pressure to 76.1 ± 2.5 
mmHg (n = 14). Perfusion pressures of EGCG infused at 0.1, 1, 10, and 100 µM in 15 
min step-wise increments were not different from that of the saline infused NE-pre-
constrcited hindlimbs (Figure 3.7A). In all hindlimbs, SNP reversed NE-mediated 
vasoconstriction by >95%, representing maximal vasodilation and return of perfusion 
pressures to basal levels, indicating absence of oedema-mediated vascular resistance. 
 
  3.3.2.2 High dose NE (5 µM, Type B vasoconstrictor) 
Hindlimb perfusion pressure under basal conditions in this set of experiments was 39.5 
± 1.1 mmHg (n = 12). A high dose of NE (5 µM) increased the hindlimb perfusion 
pressure to 153.8 ± 5.7 mmHg (n = 12). In the presence of high dose NE, EGCG did 
not induce vasodilation at 0.1 and 1 µM. Compared with saline, EGCG induced 14% 
vasodilation (p = 0.032 vs. Saline) at 10 µM against high dose NE (Figure 3.7B). 
However, EGCG did not induce further dilation at 100 µM (Figure 3.7B). In all 
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hindlimbs, SNP reversed NE-mediated vasoconstriction by >95%, representing 
maximal vasodilation and return of perfusion pressures to basal levels. 
 
3.3.2.3 5-HT (Type B vasoconstrictor)  
Hindlimb perfusion pressure during this set of experiments was 39.3 ± 0.9 mmHg (n = 
15). The vasculature preparation was pre-constricted with 5-HT (0.15 – 0.24 µM) to 
achieve a comparable perfusion pressure to the low dose NE. Perfusion pressure 
following 30 min of 5-HT infusion was 76.0 ± 5.4 mmHg (n = 15). EGCG infused at 
0.1, 1, 10, and 100 µM in 15 min step-wise increments caused dose-dependent 
vasodilation in 5-HT pre-constricted hindlimbs (Figure 3.7C). Compared with saline, 1, 
10 and 100 µM EGCG significantly (P < 0.05) reduced 5-HT-mediated 
vasoconstriction. At the highest dose tested (100 µM), EGCG opposed 5-HT mediated 
vasoconstriction by 47 ± 6% (p < 0.05 vs. saline). In all hindlimbs, SNP reversed 5-
HT-mediated vasoconstriction by >95%, representing maximal vasodilation and return 
of perfusion pressures to basal levels. 
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Figure 3.7 Dose-response effects of EGCG on % vasoconstriction during (A) 0.6 
µM NE, (B) 5 µM NE, and (C) 5-HT infusions. Data represents % of constriction 
of the perfused rat hindlimb from 30 min after the infusion of vasoconstrictors. 
White – Saline, green – EGCG. n = 5 – 8 in each groups. * p < 0.05 vs. Saline (Two-
way repeated measures ANOVA).  
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3.4 Discussion 
The main findings from this study were i) EGCG does not stimulate muscle glucose 
uptake directly, and ii) EGCG opposed 5-HT-, but not NE-, mediated vasoconstriction 
in the skeletal muscle vasculature. Therefore, EGCG possesses some direct vascular, 
but not metabolic, actions in skeletal muscle. 
 
3.4.1 Metabolic studies  
In the present study, the direct metabolic action of EGCG on skeletal muscle glucose 
uptake was assessed using the constant-flow perfused rat hindlimb system. The 
vasculature in the constant-flow perfused hindlimb system is fully dilated, making this 
an ideal preparation for studying muscle glucose uptake independent of the vascular 
actions of insulin or EGCG. While EGCG has been reported to activate PI3-K and 
promote GLUT4 translocation in myocytes (172; 173), it is reasonable to hypothesise 
that EGCG would mimic or sensitise insulin’s metabolic action in the perfused rat 
hindlimb. This study demonstrated that EGCG at 10 µM alone or after 4 increasing 
doses (up to 100 µM) did not stimulate muscle glucose uptake or enhance insulin-
stimulated muscle glucose uptake. This indicates that EGCG does not have a direct 
metabolic action in skeletal muscle in situ and does not alter insulin-stimulated 
glucose uptake in the absence of vascular actions of insulin. 
The findings from this study are in contrast with the previous studies by Ueda et al. 
(172) and Jung et al. (173), which they reported that EGCG dose-dependently 
increased glucose uptake in L6 myotubes. One possible explanation for this difference 
could be that the effects of EGCG on glucose metabolism in muscle in previous 
71 | P a g e  
 
studies (157; 158; 172; 173) were assessed in vitro using L6 myotube culture systems. 
Metabolic effects observed in incubated muscles are likely to be the direct effects from 
the receptors on skeletal muscle sarcolemma as the nutrients and treatment substances 
are diffused to the myocytes (38; 196). Constant-flow perfused rat hindlimb 
preparation that was performed in the present study, as compared to the cell culture 
preparation, represents a closer approximation to that of an in vivo system. This 
present study showed that EGCG did not stimulate muscle glucose uptake in a 
perfused muscle system, indicating the vasculature might act as the barrier for EGCG. 
Thus higher concentrations of EGCG might be required to stimulate muscle glucose 
uptake when EGCG is being delivered via the vasculature. 
 
3.4.2 Vascular studies 
The direct vascular actions of EGCG in skeletal muscle were also characterised in this 
study using the constant-flow perfused rat hindlimb system. In this preparation, 
hindlimbs are fully vasodilated due to the absence of hormonal and neural input. Thus, 
this system allows the investigator to study the direct vascular effect of infused agents, 
such as EGCG, on the hindlimb vasculature. In protocol 1 and 2, EGCG (1 – 100 µM) 
infusion alone (in the absence of vasoconstrictor) has not altered basal perfusion 
pressure (data not shown). 
To determine whether EGCG is a vasodilator, the hindlimbs were pre-constricted to 
increase the perfusion pressure to 80 ‒ 150 mmHg with NE or 5-HT. These 
vasoconstrictors were chosen as they constrict at different sites in the vascular tree and 
each causes blood flow re-distribution through a different vascular pathway termed 
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nutritive and non-nutritive (Figure 3.8). Type A vasoconstrictors increase muscle 
metabolism (increase perfusion through the nutritive flow route), while type B 
vasoconstrictors decrease muscle metabolism (increase perfusion through the non-
nutritive flow route) (Figure 3.8) (See review by Clark et al. (38)). In the current study, 
vasodilator properties of EGCG in muscle vasculature were tested against a type A (low 
dose NE < 1 µM), and type B (5-HT and high dose NE ≥ 1 µM) vasoconstrictor. 
Although the metabolic responses to each vasoconstrictor were not directly measured in 
this study, the characteristics of these vasoconstrictors have been extensively studied in 
the past (188; 200-204). 
 
 
Figure 3.8 Schematic illustration of the two blood flow circulations in skeletal 
muscle – the nutritive and non-nutritive blood flows. Nutritive flow route is thought to 
be in close contact with the skeletal muscle cells, while non-nutritive flow route is 
thought to be closely associated with connective tissues such as intramuscular septa and 
tendons. A: sites for type A vasoconstrictors; B: sites for type B vasoconstrictors.  
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The present study showed that EGCG is a vasodilator in the 5-HT pre-constricted 
hindlimb. This is in accordance with other studies which showed that EGCG induced 
vasodilation in mesenteric vascular beds (119; 120) and aortic rings (178; 179; 182). 
The present study showed that EGCG at 10 µM induced a slight, but significant 
vasodilation against high dose NE, but not low dose NE. However, the vasodilator 
properties of EGCG were larger in the presence of 5-HT, where 10 µM EGCG 
stimulated 30% vasodilation in the 5-HT pre-constricted rat hindlimb. This study 
demonstrated that EGCG induces vasodilation in the 5-HT, but not NE pre-constricted 
hindlimb. Given that EGCG did not vasodilate against high dose NE, this implies that it 
is not specific to type A or type B vasoconstrictions. Therefore EGCG may dilate 
against soecific vasoconstrictors. 5-HT has been reported to reduce muscle metabolism 
in constant-flow perfused rat hindlimb (205) and can result in acute insulin resistance in 
vivo (206). The present study showed that EGCG induced vasodilation against 5-HT, 
suggesting that EGCG may increase muscle metabolism and overcome insulin 
resistance in vivo. 
The mechanism of EGCG-induced vasodilation in skeletal muscle vasculature is 
unknown. Previous studies have reported that EGCG shares a common signalling 
pathway with insulin in vascular endothelial cells (119; 179). However this pathway 
has not been previously verified in the skeletal muscle vasculature. Thus the next 
chapter of this thesis reports on investigations of the mechanism of EGCG-mediated 
vasodilation in skeletal muscle. 
In summary, this study has demonstrated that EGCG has some direct vascular but not 
metabolic actions in skeletal muscle. This study shows that EGCG did not directly 
stimulate muscle glucose uptake and did not enhance insulin-mediated muscle glucose 
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uptake. Furthermore, EGCG opposes 5-HT-mediated vasoconstriction. Given that 
EGCG is a vasodilator in skeletal muscle, whether this will in turn enhance nutrients 
delivery to skeletal muscle and thereby improve muscle glucose uptake is not known, 
and was investigated in studies reported in Chapter 5.   
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Chapter 4 
Mechanism of EGCG-induced 
vasodilation in muscle vasculature 
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4.1 Introduction 
The studies described in Chapter 3 showed that EGCG is a vasodilator in the muscle 
vasculature. In particular, EGCG vasodilated against 5-HT, the vasoconstrictor which 
results in increased non-nutritive perfusion of muscle (201) and can result in acute 
insulin resistance (206). The mechanism of EGCG-induced vasodilation in skeletal 
muscle has not been previously explored. Previous studies have reported that EGCG 
shares a common signalling pathway with insulin in cultured vascular endothelial cells 
(119; 179). However, whether this pathway is involved in EGCG-mediated dilation in 
the skeletal muscle vasculature is unknown. 
Insulin stimulates nitric oxide (NO) production in vascular endothelial cells (17; 119). 
Quon and colleagues have elucidated the insulin signalling pathway in vascular 
endothelial cells leading to NO production. This pathway requires activation of IRS-
1/PI3-K/PDK-1/Akt/eNOS pathway which leads to NO production (4; 8-10). 
Interestingly, EGCG also stimulates NO production in cultured vascular endothelial 
cells similar to insulin (119). Both insulin- and EGCG-mediated increases in NO 
production are dependent on the activation of PI3-K, since wortmannin blocks NO 
production (119; 179). Furthermore, like insulin, EGCG requires the activation of Akt 
and eNOS for NO production (119; 179; 181). However, activation of the PI3-
K/Akt/eNOS pathway by EGCG does not require the activation of the insulin receptor 
(119). Interestingly, these results highlight that the EGCG signalling pathway shares 
features in common with the insulin signalling pathway leading to activation of eNOS 
and NO production in endothelial cells (119) (Figure 4.1). Studies have reported that 
EGCG-induced vasodilation in various tissues, including aortic ring (178; 179), bovine 
ophthalmic artery (180), coronary artery ring (181), and mesenteric vascular bed (119) 
is mediated by the PI3-K/Akt/NO pathway. In addition, several studies (119; 181) also 
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suggested that EGCG-mediated vasodilation required the activation of reactive oxygen 
species (ROS). Quon and colleagues reported that Fyn, a member of Src family tyrosine 
kinases (SFK) (207), is a signalling molecule upstream of PI3-K which is activated by 
ROS. SFK can activate PI3-K by binding the p85 regulatory subunit of PI3-K (208; 209) 
or directly activate eNOS independent of PI3-K (210), however, the mechanism by 
which Fyn stimulates NO production in vascular endothelial cells is not known. 
Alternatively, EGCG activates AMPK in bovine aortic endothelial cells (211). Studies 
have shown that AMPK can activate eNOS on Ser
1177
 and Ser
633
 (212; 213), in which 
phosphorylation of eNOS on Ser
1177
 can lead to NO production (214) and 
phosphorylation on Ser
633
 enhance NO production independent of intracellular Ca
2+
 
level (215). The aim of this chapter was therefore to assess the molecular mechanism 
underlying the vascular actions of EGCG in skeletal muscle with enzyme inhibitory 
studies using the constant flow perfused rat hindlimb preparation (See Figure 4.1). 
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Figure 4.1 Potential pathways of EGCG mediated vasodilation in vascular 
endothelium of skeletal muscle. EGCG shares a common signalling pathway with 
insulin to mediated vasodilation in vascular endothelium. EGCG, like insulin, activates 
PI3-K/Akt pathway, phosphorylates, and activates eNOS to stimulate NO production. 
However, EGCG does not bind to insulin receptor. EGCG phosphorylates PI3-K via ROS 
and Fyn (a Src family kinase). EGCG could be activating AMPK, while AMPK is known 
to phosphorylate eNOS independent of PI3-K. Modified from Kim et al. (119)  
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4.2 Methods 
 
4.2.1 Animals 
Male Sprague-Dawley rats (n = 53) weighing 226 ± 4 g at 7 ‒ 9 weeks old were used in 
this study. The rats were allowed free access to drinking water and food ad libitum. 
Rats were provided with normal chow from Specialty Feeds, Glen Forest, WA, 
Australia (5FD, see Table 2.1). All experimental procedures were approved by the 
University of Tasmania Animal Ethics Committee (A11282) and performed in 
accordance with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes – 2004, 7th Edition. 
 
4.2.2 Experimental protocols 
The mechanism of EGCG-mediated vasodilation was assessed using the constant flow 
perfused rat hindlimb preparation. Surgery was carried out in the rats as described in 
2.3.2. Vascular studies in hindlimbs were carried out according to the protocol outlined 
in Figure 4.2. Following the surgery, rats were connected to the perfusion apparatus 
(See 2.3.3) and allowed a 30-min equilibration period to allow washout of red blood 
cells. The vasculature in the constant flow perfused hindlimb system is fully dilated. 
Therefore to study the potential vasodilatory response of EGCG, the hindlimb 
vasculature was pre-constricted with 5-HT (0.06 – 0.3 µM) or high dose NE (5 µM) to 
reach a perfusion pressure of ~80 and 150 mmHg respectively. EGCG was infused into 
the hindlimb to reach final concentrations of 0.1, 1, 10, and 100 µM in 15 min stepwise 
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increments. Saline (vehicle) was infused in a separate group of animals for the same 
length of time (total of 60 min). The vasoconstrictor was infused 30 min prior to and 
during infusion of saline or EGCG. At the end of each experiment, 500 µM SNP was 
infused to assess maximal vasodilatory capacity of the isolated hindlimb. Perfusion 
pressure was continually recorded using WinDaq data acquisition software (DataQ 
Instruments, Akron, OH, USA). 
The mechanism of EGCG-induced vasodilation in skeletal muscle was assessed 
according to the protocols outlined in Figure 4.2. The vascular actions of EGCG were 
examined in the presence of i) Protocol 1: the NOS inhibitor N
ω
-Nitro-L-arginine 
methyl ester (L-NAME, 10 µM), ii) Protocol 2: the PI3-K inhibitor wortmannin (100 
nM), iii) Protocol 3: the SFK inhibitor 4-Amino-3-(4-chlorophenyl)-1-(t-butyl)-1H-
pyrazolo[3,4-d]pyrimidine (PP2, 10 µM), and iv) Protocol 4: the AMPK inhibitor 
Compound C (10 µM) (Figure 4.3). L-NAME or wortmannin was present in perfusion 
buffer when the hindlimbs were connected to the perfusion apparatus, while PP2 or 
Compound C was infused via the infusion port directly into the arterial-line after the 
designated equilibration period. Wortmannin, PP2 and Compound C were dissolved in 
dimethyl sulfoxide (80% v/v) and infused at a rate of 1:200 to the perfusate flow rate. 
Given that EGCG produced the strongest vasodilatory effect against 5-HT (in Chapter 
3), the vascular actions of EGCG in the presence of L-NAME, wortmannin, and 
Compound C were examined in 5-HT pre-constricted hindlimbs.  However, because 5-
HT mediated vasoconstriction is mainly mediated by the 5-HT2A receptor, which is Src 
kinase dependent and therefore inhibited by PP2 (216), the effects of PP2 on EGCG-
mediated vasodilation were examined in NE pre-constricted hindlimb, which is not 
SFK dependent. 
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Figure 4.2 Experimental protocols. Protocol 1:  Effects of L-NAME on EGCG-induced vasodilation; Protocol 2: Effects of wortmannin on 
EGCG-induced vasodilation; Protocol 3: Effects of PP2 on EGCG-induced vasodilation; Protocol 4: Effects of Compound C on EGCG-
induced vasodilation. In all protocols, EGCG was infused to final concentrations of 0.1, 1, 10, and 100 µM in 15 min stepwise increments 
(See Figure 4.3). Perfusate effluent samples () were collected at times indicated in the figure. SNP (500 µM) was infused at the end of all 
experiment.   
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Figure 4.3 Schematic illustration of potential mechanism of EGCG-mediated 
vasodilation in skeletal muscle. EGCG-mediated vasodilation in skeletal muscle was 
assessed against various inhibitors. Inhibitors used in this study include i) L-NAME – 
eNOS, ii) Wortmannin – PI3-K, iii) PP2 – Src family kinase, and iv) Compound C – 
AMPK. Modified from Kim et al. (119) 
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4.2.3 Metabolic actions of wortmannin in constant perfused rat hindlimbs 
Wortmannin is known to block insulin-mediated glucose uptake in skeletal muscle 
(217). To confirm that the dose of wortmannin (100 nM) used in Protocol 2 was 
sufficient to inhibit PI3-K, the same dose of wortmannin was used to examine its effect 
on insulin-mediated muscle glucose uptake in isolated perfused rat hindlimb system. 
Surgery was carried out in overnight fasted rats as described in 2.3.2. Experiments were 
carried out following the protocol shown in Figure 4.4. Following the surgery, rats were 
connected to the perfusion apparatus (See 2.3.3) and allowed a 30-min equilibration 
period. Rat hindlimbs were perfused at a constant flow rate of 0.5 mL.min
-1
.g
-1
 of 
perfused muscle. Saline or insulin (15 nM) infusion started after the equilibration 
period. Wortmannin (100 nM) was added to the buffer 30 min prior to the insulin 
infusion. Perfusate effluents were collected before and every 10 min after experiment 
started. 
14
C-2-DG (25 nCi.min
-1
; American Radiolabeled Chemicals Inc.) infusion 
started 30 min before the end of experiment for the determination of muscle glucose 
uptake. Whole calf muscle was excised and freeze-clamped at the end of experiment. 
R’g was then determined as described in 3.2.2.4.  
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Figure 4.4 Effects of wortmannin on muscle glucose uptake. Rats were equilibrated 
for 30 min before saline or insulin (15 nM) infusion started. Wortmannin (100 nM) was 
added to the buffer 30 min prior to the insulin infusion. Perfusate effluent () was 
collected before and every 10 min after experiment started. 
14
C-2-DG (, 25 µCi.L-1) 
infusion started 30 min before the end of experiment. Whole calf muscle was excised 
() at the end of experiment. 
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4.2.4 AMPK Western blot 
To confirm that the dose of Compound C (10 µM) used in Protocol 3 was sufficient to 
inhibit AMPK, perfused common iliac arteries were collected at the end of the 
experiment and stored in – 80 °C for Western blot analysis. AMPK Western blotting 
was performed as described in 2.5 with some modifications. Common iliac artery 
samples were snipped to fine sections in solubilising buffer (1:12.5 wt/vol) and 
sonicated. After blocking with 5% low fat milk in Tris-buffered saline plus 0.1% 
Tween 20, nitrocellulose membranes were incubated with 1:1000 rabbit anti-phospho-
Thr
172
-AMPKα (p-AMPK, Cell Signalling, Danvers, MA, USA) or 1:1000 rabbit anti-
AMPKα (Cell Signalling) overnight at 4 °C. Following this, the membranes were 
probed with 1:1000 anti-rabbit secondary antibody (Cell Signalling) for 1 h at room 
temperature. To visualise the bands, equal volumes of West Pico Chemiluminescent 
Substrate (Thermo Fischer Scientific, Rockford, IL, USA) were mixed together and 
applied to the membrane. Band intensities were quantified by optical density using 
Image Station 4000mm Pro, Carestream Molecular Imaging (Carestream Health Inc., 
Rochester, NY, USA). 
 
4.2.5 Statistical analysis 
All data are expressed as means ± S.E.M. Two-way repeated measures ANOVA with 
Student-Newman-Keuls post hoc test was used to compare treatment groups over the 
time course of experiment. An unpaired student’s t-test or a one-way ANOVA with 
Student-Newman-Keuls post hoc test was used, where appropriate, to make 
comparisons of differences between endpoint values. All tests were performed using 
the SigmaPlot 11 (
©
Systat Software Inc. 2008). 
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4.3 Results 
 
4.3.1 Effects of NOS inhibition on EGCG-mediated vasodilation 
In the presence of L-NAME, 5-HT-induced vasoconstriction was augmented (218; 
219), therefore a lower dose of 5-HT (0.06 µM) was infused to raise perfusion 
pressure to a comparable 70 ‒ 80 mmHg as in the non-LNAME treated experiments. 
Perfusion pressure following 30 min of 5-HT infusion represented 100% constriction 
(Figure 4.5), 5-HT-mediated vasoconstriction increased steadily over the course of the 
experiment in the presence of L-NAME. Due to upward drift of pressure with 5-HT in 
the presence of L-NAME, EGCG dose-response was time matched with saline 
perfusion pressure. When compared with saline infusion, EGCG-induced vasodilation 
was completely inhibited by L-NAME at 0.1, 1 and 10 µM (Figure 4.5), indicating that 
EGCG at these doses vasodilates via a NOS-dependent process. However, 100 µM 
EGCG-mediated dilation was only partially blocked by L-NAME (Figure 4.5) 
indicating that EGCG at this dose vasodilates, at least in part, by a NOS-independent 
mechanism. In all experiments, SNP reversed 5-HT mediated vasoconstriction 
by >95%, representing maximal vasodilation and return of perfusion pressures to basal 
levels. 
 
4.3.2 Effects of PI3-K inhibition on EGCG-mediated vasodilation 
EGCG-mediated vasodilation was not affected by PI3-K inhibition at any doses of 
EGCG (Figure 4.6). There was a slight decreased in perfusion pressure drift with 
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saline infusion in the presence of wortmannin, EGCG dose-response was time 
matched with saline perfusion pressure. In the presence of wortmannin, each dose of 
EGCG induced vasodilation to a similar extent to that in animals treated with 5-HT 
alone (i.e. without wortmannin) (Figure 3.7C). As shown in Figure 4.7, insulin-
mediated R’g in the presence of 100 nM wortmannin was not different from saline R’g 
(5.07 ± 0.38 and 5.34 ± 0.62 µg.g
-1
.min
-1
 respectively), indicating that this dose of 
wortmannin completely inhibited insulin-mediated R’g. This implies that the failure of 
wortmannin to block EGCG-mediated vasodilation was not due to the lack of PI3-K 
inhibition. In all hindlimbs, SNP reversed 5-HT mediated vasoconstriction by >95%, 
representing maximal vasodilation and return of perfusion pressures to basal levels. 
 
4.3.3 Effects of SFKs inhibition on EGCG-mediated vasodilation 
5-HT mediated vasoconstriction is mainly mediated by the 5-HT2A receptor, where c-
Src tyrosine kinase is a key component for 5-HT2A receptor-mediated vasoconstriction 
(216). In the presence of 10 µM PP2, 5-HT-mediated vasoconstriction in the perfused 
rat hindlimb was completely inhibited (data not shown) indicating that the dose of PP2 
was sufficient to block SFK. Thus the involvement of SFKs in dilation by EGCG 
could not be assessed. However, some EGCG-mediated vasodilation occurred against 
high dose NE (Figure 3.7B). Therefore, effects of 10 µM PP2 on EGCG-mediated 
vasodilation were assessed in the NE (5 µM) pre-constricted hindlimbs which is not 
SFK-dependent. As detailed in Chapter 3 (Figure 3.7B), EGCG-mediated vasodilation 
against high dose NE (5 µM) is modest and only one dose of EGCG 10 µM was 
effective. Interestingly, vasodilation induced by 10 µM EGCG was not inhibited by 
PP2 (Figure 4.8), indicating EGCG-mediated vasodilation in skeletal muscle is 
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independent of SFKs. In all hindlimbs, SNP reversed NE mediated vasoconstriction 
by >95%, representing maximal vasodilation and return of perfusion pressures to basal 
levels. 
 
4.3.4 Effects of AMPK inhibition on EGCG-mediated vasodilation 
AMPK inhibition did not affect vasodilation at any EGCG doses (Figure 4.9). In the 
presence of Compound C, EGCG at all doses induced vasodilation to a similar extent 
compared to animals not treated with Compound C (Figure 3.7C). Activation of 
AMPK was assessed by Western blot to confirm that the dose of Compound C (10 µM) 
used was sufficient to inhibit AMPK. Figure 4.10 showed an 80% reduction in 
pAMPK/AMPKtotal ratio following 10 µM Compound C treatment, indicating AMPK 
was markedly inhibited by Compound C. This implies that the failure of Compound C 
to block EGCG-mediated vasodilation was not due to the lack of AMPK inhibition. 
Effects of Compound C on AMPK inhibition were not different between the saline and 
EGCG treated samples (data not shown), therefore the pAMPK/AMPKtotal ratio for the 
saline and EGCG samples were combined to increase the power of the statistics at 
testing. This indicates that the vasodilator action of EGCG in skeletal muscle is 
independent of AMPK. In all hindlimbs, SNP reversed 5-HT mediated 
vasoconstriction by >95%, representing maximal vasodilation and return of perfusion 
pressures to basal levels. 
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Figure 4.5 Dose-response effects of EGCG on % vasoconstriction in 5-HT pre-
constricted hindlimb during NO synthase inhibition in the presence of L-NAME. 
Data represents % of constriction of the perfused rat hindlimb from 30 min after the 
infusion of vasoconstrictors.  – Saline (n = 7),  – EGCG (n = 6). * p = 0.007 vs. 
Saline (Two-way repeated measures ANOVA). 
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Figure 4.6 Dose-response effects of EGCG on % vasoconstriction in 5-HT pre-
constricted hindlimb during PI3-K inhibition in the presence of wortmannin. 
Data represents % of constriction of the perfused rat hindlimb from 30 min after the 
infusion of vasoconstrictors.  – Saline (n = 7),  – EGCG (n = 7). * p < 0.005 vs. 
Saline (Two-way repeated measures ANOVA). 
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Figure 4.7 Effects of PI3-K inhibition by 100 nM wortmannin on muscle glucose 
uptake. Data represents R’g following 15 nM insulin infusion. n = 4 ‒ 6 in each 
groups. * p < 0.001 vs. Saline and Wortmannin + Insulin (One-way ANOVA).  
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Figure 4.8 Dose-response effects of EGCG on % vasoconstriction in high dose 
NE pre-constricted hindlimb during SFK inhibition in the presence of PP2. Data 
represents % of constriction of the perfused rat hindlimb from 30 min after the 
infusion of vasoconstrictors. – Saline (n = 6),  – EGCG (n = 5). * p = 0.032 vs. 
Saline (Two-way repeated measure ANOVA).  
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Figure 4.9 Dose-response effects of EGCG on % vasoconstriction in 5-HT pre-
constricted hindlimb during AMPK inhibition in the presence of Compound C. 
Data represents % of constriction of the perfused rat hindlimb from 30 min after the 
infusion of vasoconstrictors.  – Saline (n = 8),  – EGCG (n = 7). * p < 0.02 vs. 
Saline (Two-way repeated measures ANOVA). 
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Figure 4.10 Ratio of pAMPK/AMPKtotal in common iliac arteries following 10 
µM compound C treatments.  panel: Representative protein bands for Top
pAMPKα and AMPKαtotal in common iliac arteries. Compound C free: n = 6, 
Compound C: n = 14. * p < 0.001 vs. Compound C free samples (Student’s t-test). 
CC: Compound C 
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4.4 Discussion 
Previous studies have reported that vasodilator actions of EGCG are mediated by the 
PI3-K/Akt/NOS pathway in isolated aortic ring (178; 179), bovine ophthalmic artery 
(180), coronary artery ring (181), mesenteric vascular bed (119), and cultured vascular 
endothelial cells (119; 179; 181). Therefore, it was postulated that vasodilator actions of 
EGCG in skeletal muscle would be mediated by the same pathway. In contrast to the 
studies describe above, the main findings of this study were (i) EGCG, at low doses (0.1 
‒ 10 µM), vasodilates skeletal muscle vasculature in a NOS-dependent fashion and (ii) 
vasodilator actions of EGCG in skeletal muscle are independent of PI3-K, SFK and 
AMPK. 
The present study showed that the vasodilatory effects of 1 and 10 µM EGCG, but not 
100 µM EGCG, were inhibited by L-NAME. Similarly it was recently reported (178; 
179) that vasodilation in rat thoracic aorta induced by low concentrations (0.01 - 10 µM) 
of EGCG was abolished by NOS inhibition, but not higher doses of EGCG. Others 
have suggested that suprapharmacological doses of EGCG (>10 µM) can induce 
vasodilation through different pathways by acting directly on smooth muscle cells (178), 
by activating the cAMP- (179; 182) or cGMP-dependent protein kinase pathway (182). 
Furthermore, polyphenols from grape seed (Vitis Vinifera L.) have been shown to dose-
dependently induce vasodilation in human internal mammary aortic rings by 
stimulation of prostaglandin I2 (PGI2) release (220). EGCG has also been shown to 
increase PGI2 production in bovine aortic endothelial cells (221). Thus, high dose (100 
µM) EGCG-induced vasodilation (NOS-independent) could involve PGI2, however this 
was not tested in the current study. 
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The current study showed that EGCG-mediated vasodilation in skeletal muscle was not 
inhibited by wortmannin, indicating EGCG-mediated vasodilation in skeletal muscle is 
PI3-K-independent. The wortmannin dose that was used in this study inhibited insulin-
mediated muscle glucose uptake. Therefore failure of wortmannin to inhibit the EGCG-
mediated vasodilation is unlikely to be due to the lack of PI3-K inhibition. 
As mentioned before, EGCG has been reported to activate Fyn, a member of SFK, 
which can lead to activation of the PI3-K/Akt/NO pathway in cultured vascular 
endothelial cells (119). Besides activating PI3-K (208; 209), SFK can directly activate 
eNOS independent of PI3-K (210). The current study showed that EGCG-mediated 
vasodilation in skeletal muscle was not inhibited by PP2, an inhibitor of SFK. Since the 
dose of PP2 used in the current study inhibited 5-HT mediated vasodilation, failure of 
PP2 to inhibit the EGCG-mediated vasodilation is unlikely due to lack of SFK 
inhibition. Furthermore, previous studies suggested that AMPK can be activated by 
EGCG in cultured vascular endothelial cells (211) and cultured hepatocytes (174). 
AMPK can directly activate eNOS (212; 213), and lead to NO production (214). 
However, this study showed that EGCG-mediated vasodilation is not inhibited by 
Compound C, indicating EGCG-mediated vasodilation in skeletal muscle is AMPK-
independent. Immunoblot analysis showed that the dose of Compound C used in the 
present study reduced the pAMPK/AMPKtotal ratio, indicating failure of Compound C 
to inhibit the EGCG-mediated vasodilation is unlikely to lack of AMPK inhibition. 
Another pathway that EGCG could be operating through is the Ca
2+
/calmodulin–
dependent kinase II (CaMKII)/eNOS pathway. Polyphenols from red wine have been 
shown to induce Ca
2+
-dependent production of NO from bovine aortic endothelial cells 
(222) and induce vasodilation in rat aortic rings through the same pathway (223). 
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Epicatechin, another polyphenol in green tea, has been shown to activate eNOS 
phosphorylation via Ca
2+
/ CaMKII pathway (224). This highlights the possibility that 
EGCG at low doses is activating NOS-dependent vasodilation via the 
Ca
2+
/CaMKII/eNOS signalling pathway in skeletal muscle vasculature. On the other 
hand, studies showed that polyphenols from grapes and wines (reservatrol) (225; 226) 
and black tea (227) activate oestrogen receptors which lead to activation of p38 
mitogen activated protein kinase (MAPK) and eNOS in endothelial cells. EGCG has 
also been shown to activate oestrogen receptor in the amyloid precursor protein 
overexpressing murine neuroblastoma N2a cells (228), suggesting that low doses 
EGCG-induced vasodilation in skeletal muscle could be mediated by the oestrogen 
receptor. 
It is concluded that EGCG is a potent vasodilator in the skeletal muscle. EGCG 
vasodilates in skeletal muscle via NOS-dependent, and is in part NOS-independent at 
supra-pharmacological concentrations. Furthermore, EGCG vasodilates in skeletal 
muscle via a PI3K-, SFK- and AMPK-independent pathway.  To date, the mechanism 
of EGCG-mediated vasodilation in skeletal muscle remains uncertain.  
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Chapter 5 
Acute effects of EGCG in healthy rats in 
vivo 
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5.1 Introduction 
Acute green tea consumption has been reported to enhance insulin sensitivity (148) and 
glucose tolerance (147) in healthy humans. In addition, chronic green tea treatment has 
been reported to improve glucose tolerance and insulin sensitivity in healthy (156; 158; 
229) and insulin resistant (98; 147; 158-162; 164-167) animals. Taken together, these 
studies suggested that green tea treatment may be beneficial in managing metabolic 
health in animals, but the mechanism remains unknown. 
Previously, studies have proposed that green tea or EGCG possesses insulin-mimetic 
effects in vitro, whereby green tea or EGCG stimulates GLUT4 translocation in isolated 
myocytes (157; 158; 172) and adipocytes (159), glucose uptake in skeletal muscle (157; 
172) and adipocytes (156; 159), and suppresses hepatic glucose production (174; 175). 
Furthermore, EGCG has also been reported to be a potent vasodilator in isolated blood 
vessels (119; 178-182). However, the aforementioned studies were carried out in vitro, 
whether EGCG has insulin-mimetic actions in vivo has not been previously investigated. 
As shown in Chapter 3, EGCG is a vasodilator but does not have direct acute metabolic 
actions on skeletal myocytes. Importantly, Chapter 4 showed that EGCG-mediated 
vasodilation in skeletal muscle is NOS-dependent at doses up to 10 µM. 
Barrett and colleagues have reported that the insulin increases microvascular perfusion 
in skeletal muscle in normal healthy animals (18; 53) and humans (230) via a NOS-
dependent mechanism (18; 53). It is widely accepted that insulin-stimulated 
microvascular perfusion will increased delivery of nutrients, such as glucose and 
insulin, to skeletal muscle, resulting in increased muscle glucose uptake (231; 232). 
However, not all vasodilators can increase microvascular perfusion in skeletal muscle. 
Whether EGCG is a vasodilator that could increase microvascular perfusion and 
100 | P a g e  
 
thereby improve insulin sensitivity is not known. In this study, EGCG was 
intravenously infused to rats to acutely increase plasma EGCG to 10 µM. The aim of 
this study was to determine whether acute EGCG treatment in vivo improved i) whole 
insulin sensitivity, ii) microvascular perfusion, and iii) muscle glucose uptake. 
There are a number of techniques available for the measurement of microvascular 
perfusion, including the laser Doppler flowmetry (233), microdialysis (234), and 
intravital microscopy (235). While these are valuable methods, laser Doppler 
flowmetry, microdialysis, and intravital microscopy, are limited to blood flow 
measurement in small muscle regions. The application of microdialysis in humans may 
also be restricted due to invasive implantation of the measurement probe. Metabolism 
of 1-MX (21) is also widely used for the measurement of microvascular perfusion in 
rats. However, xanthine oxidase, which is required for the metabolism of 1-MX (see 
1.1.2.3), is inhibited by EGCG (236; 237). Therefore, the use of 1-MX metabolism 
technique in the present study is not feasible. Measurement of muscle microvascular 
perfusion was made using the CEU technique in this study. 
 
5.2 Methods 
 
5.2.1 Animals 
Male Sprague-Dawley rats (n = 32) weighing 246 ± 3 g at 9 – 10 weeks old were used 
in this study. The rats were allowed free access to drinking water and food ad libitum. 
Rats were provided with normal chow (5FD) from Specialty Feeds, Glen Forest, WA, 
Australia (Table 2.1). Rats were fasted overnight before the experiment was performed. 
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Rats were randomly allocated into 4 experimental groups- Saline, EGCG, Insulin and 
EGCG + Insulin groups. All experimental procedures were approved by the University 
of Tasmania Animal Ethics Committee (A11282) and performed in accordance with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes – 
2004, 7
th
 Edition. 
 
5.2.2 Experiment protocol 
Surgery was carried out in the overnight fasted rats as described in 2.4.1. Figure 5.1 
shows the experimental protocol of this study. Rats were allowed a 60-min 
equilibration period following the surgery to stabilise MAP, heart rate, and anaesthetic 
level. Plasma samples were collected after equilibration for measurement of glucose, 
insulin, and free fatty acids levels. EGCG infusion of 0.18 mg.min
-1
.kg
-1
 (refer to 5.2.3) 
was started after equilibration period to raise plasma EGCG levels to 10 µM. Saline or 
insulin (10 mU.min
-1
.kg
-1
) infusion was started 30 min after EGCG infusion. Glucose 
solution (30 %, w/v) was infused at variable rates to maintain the blood glucose levels 
at fasting levels. The glucose infusion rate (GIR), which is an indicator of the whole 
body insulin sensitivity, was recorded throughout the experiment. Microvascular blood 
flow measurement was made using CEU, as described in 2.4.7, at 0 min (30 min after 
EGCG infusion), and at 90min of the insulin clamp (Figure 5.1). Muscle glucose uptake 
were measured using 2-deoxy-D-[1,2-
3
H(N)]glucose (
3
H-2-DG; specific activity 5 – 10 
Ci.mmol
-1
; Perkin Elmer Inc.), as described in 2.4.8. At 110 min during the insulin 
clamp, a bolus of 
3
H-2-DG (50 µCi) was given to the rat via the jugular vein, 
immediately followed by a 10-min arterial blood withdrawal to assess average plasma 
3
H-2-DG specific activity. Plasma samples were collected at the end of insulin clamp 
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for measurement of glucose, insulin, and EGCG levels. Whole calf muscle, liver, heart, 
epididymal fat pad, and aortic arch were collected and stored at -80 °C for further 
analysis. 
 
Figure 5.1 Experimental protocol for in vivo study in healthy animals.  
Animals were allowed a 60 min equilibration period following the surgery. EGCG 
infusion (0.18 mg.min
-1
.kg
-1
) started 30 min before the saline or insulin (10 mU.min
-1
.kg
-1
) 
infusion. Glucose solution (30% w/v) was infused at variable rates to maintain 
euglycaemia throughout the experiment. For microvascular blood flow measurement, 
CEU images () were acquired at 0 min (30 min after EGCG infusion), and at 90 min. 
For muscle glucose uptake measurement, 
3
H-2-DG (, 50 µCi) was given as a bolus to 
the animals, followed by a 10-min arterial blood withdrawal. Blood sample () was 
collected at times indicated in the figure for glucose levels determination. Plasma sample 
( ) was collected at the start and at the end of experiment for determination of glucose, 
insulin, free fatty acids, and EGCG levels.  
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5.2.3 Pharmacokinetics of intravenously administered EGCG  
To determine the pharmacokinetics or clearance rate of EGCG in rat plasma, Sprague-
Dawley rats (n = 3) weighing 328 ± 12 g were fasted overnight, anaesthetised and 
surgery carried out as described in 2.4.1. A bolus of EGCG (50 mg.kg
-1
) was 
administered via the jugular vein as a bolus. Plasma samples (200 µL) were collected 5 
min before the administration of EGCG, and at 2 min and every 15 min following the 
administration of EGCG bolus for 2 hours. Plasma EGCG concentrations were 
determined by HPLC as described in 2.4.6.   
Plasma EGCG concentrations over the 2-hour period were fitted to the function            
y = ae
-bx
 (Figure 5.2), where a is the initial plasma EGCG concentrations (following the 
administration of EGCG bolus), and b is the decay constant. Clearance rate of EGCG 
was determined from b multiplied by volume of distribution (VD), where VD was 
determined from the amount of EGCG administered divided by a. Infusion rate of 
EGCG solution was determined by multiplying the desired concentration (10 µM) and 
clearance rate of EGCG. An EGCG infusion rate was calculated to be                       
0.18 mg.min
-1
.kg
-1
 to maintain 10 µM EGCG in rat plasma.  
 
5.2.4 Statistical Analysis 
All data are expressed as means ± S.E.M. Two-way repeated measures ANOVA with 
Student-Newman-Keuls post hoc test was used to compare treatment groups over the 
time course of experiment. One-way ANOVA with Student-Newman-Keuls post hoc 
test was used to make comparisons of differences between endpoint values. All tests 
were performed using the SigmaPlot 11 (
©
Systat Software Inc. 2008). 
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Figure 5.2 Plasma EGCG concentrations following the administration of 50 
mg.kg
-1
 EGCG bolus. This was fitted to the exponential decay function y = ae
-bx
, 
where a = 174, b = 0.134.  n = 3.  
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5.3 Results 
 
5.3.1 Animal characteristics 
Fasting plasma glucose and insulin levels were 7.14 ± 0.11 mM (n = 32) and 70 ± 8 pM 
(n = 32) respectively. Fasting plasma free fatty acids were 0.64 ± 0.03 mM (n = 17). 
Epididymal fat pads weighed 0.48 ± 0.02 % (n = 32) of the rat body weight. 
In the EGCG and EGCG + Insulin groups, EGCG was infused 30 min before and 
during the hyperinsulinaemic euglycaemic clamp. Plasma EGCG levels following 150 
min of EGCG infusion in the EGCG and EGCG + Insulin groups were 10.79 ± 0.63 
µM and 9.73 ± 0.33 µM respectively (p = 0.131) indicating that the target of 10 µM 
was reached. 
 
5.3.2 Whole body insulin sensitivity 
The GIR (Figure 5.3 A) of the Insulin group during steady state of glucose infusion was 
24.19 ± 1.10 mg.min
-1
.kg
-1
, and acute infusion of EGCG in the EGCG + Insulin group 
did not alter the GIR (24.04 ± 0.66 mg.min
-1
.kg
-1
). Plasma insulin levels post-insulin 
clamp of Insulin and EGCG + Insulin groups were 799 ± 57 pM and 800 ± 31 pM 
respectively (p = 0.901), indicating that EGCG did not affect plasma insulin levels. In 
the EGCG group, some glucose was required to maintain euglycaemia in the beginning 
of the experiment, however, this was not required through to the end of the experiment. 
Blood glucose (Figure 5.3B) measured throughout the experiments were not different 
between each group.   
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Figure 5.3 (A) Glucose infusion rate and (B) blood glucose levels during 
hyperinsulinaemic euglycaemic clamp.  - Saline,  - EGCG,  - Insulin,  - 
EGCG + Insulin; n = 8 in all groups. * p < 0.001 vs. Saline and EGCG (Two-way 
repeated measures ANOVA); # p < 0.05 vs. Saline (Two-way repeated measures 
ANOVA).  
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5.3.3 Haemodynamic parameters 
Figure 5.4 shows the mean arterial blood pressure (MAP) of the rats during the course 
of the experiment. MAP was not different between all groups indicating acute EGCG 
infusion has no effect on the MAP.  
Femoral artery blood blow (FBF) was measured during the hyperinsulinaemic 
euglycaemic clamp (Figure 5.5). FBF before the experiments were not different 
between all groups (data not shown). As expected, at the end of hyperinsulinaemic 
euglycaemic clamp, FBF of the Insulin group (1.47 ± 0.15 ml.min
-1
) was significantly 
higher than the Saline group (0.96 ± 0.16 ml.min
-1
) (Figure 5.5). However, acute EGCG 
did not alter FBF (1.02 ± 0.13 ml.min
-1
) or enhance insulin-stimulated FBF (1.51 ± 0.12 
ml.min
-1
) 
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Figure 5.4 Mean arterial blood pressure during hyperinsulinaemic euglycaemic 
clamp.  - Saline,  - EGCG,  - Insulin,  - EGCG + Insulin; n = 8 in all groups. 
Data not statistically significant at all time points (Two-way repeated measures 
ANOVA).  
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Figure 5.5 Femoral artery blood flow at the end of experiment. n = 8 in all 
groups * p < 0.015 vs. Saline and EGCG (Two-way ANOVA).  
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5.3.4 Microvascular blood volume 
CEU was used to measure the MBV before and 90 min after the hyperinsulinaemic 
euglycaemic clamp (Figure 5.6). At 0 min, MBV (Figure 5.6) were not different 
between groups. As expected, MBV of the Saline group was not different at 0 and 90 
min (3.10 ± 0.21 and 2.92 ± 0.26 acoustic intensity units respectively, p = 0.50). At 90 
min into the insulin clamp, MBV of the EGCG, Insulin and EGCG + Insulin groups 
had significantly increased from 0 min (Figure 5.6). This indicates that EGCG alone 
has stimulated microvascular perfusion to a similar extent as the insulin treatment. 
However, EGCG was not additive to insulin on its effect on MBV. 
 
5.3.5 Muscle insulin sensitivity 
Figure 5.7 shows results for muscle specific glucose uptake at the end of the experiment. 
Insulin stimulated muscle glucose uptake by 3.5-fold, where R’g of the Saline and 
Insulin groups were 2.81 ± 0.17 and 9.73 ± 0.71 µg.g
-1
.min
-1
 respectively. Acute EGCG 
did not alter muscle glucose uptake (2.36 ± 0.22 µg.g
-1
.min
-1
) or enhance insulin-
stimulated glucose uptake (7.89 ± 0.52 µg.g
-1
.min
-1
).  
Western blot analysis (Figure 5.8) showed that insulin stimulated phosphorylation of 
Akt in skeletal muscle by 6.4-fold, while EGCG did not stimulate or enhance Akt 
phosphorylation in skeletal muscle either in the absence or presence of insulin. 
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Figure 5.6 Microvascular blood volume before and during hyperinsulinaemic 
euglycaemic clamp.  = 0 min,  = 90 min; n = 8 in all groups. * p < 0.05 vs. 
respective 0 min (Two-way repeated measures ANOVA); † p < 0.05 vs. 90 min 
Saline (Two-way repeated measures ANOVA). 
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Figure 5.7 Muscle 
3
H-2-DG uptake after hyperinsulinaemic euglycaemic clamp. 
n = 8 in all groups. * p < 0.001 vs. Saline and EGCG (One-way ANOVA).  
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Figure 5.8 Western blot of pAkt and total Akt in skeletal muscle. Top panel: 
Representative blots; Bottom panel: Ratio of pAkt/Akttotal. n = 8 in all groups. * p < 
0.05 vs. Saline and EGCG (One-way ANOVA). 
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5.4 Discussion 
The main findings of the present study are that EGCG acutely increases MBV in 
skeletal muscle, but has no effect on muscle glucose uptake and whole body insulin 
sensitivity. Interestingly, EGCG alone increases MBV to a similar extent as raising 
plasma insulin to ~ 800 pM, however, EGCG did not further enhance insulin-stimulated 
increases in MBV. This indicates that EGCG mimics, but does not sensitize, insulin’s 
action on microvascular perfusion. 
The dose of EGCG used in this study raised plasma EGCG to 10 µM. As shown in 
Chapters 3 and 4, 10 µM EGCG induced an intermediate level of vasodilation in the 
perfused rat hindlimb. It was also the highest dose that vasodilated via a NOS-
dependent process in skeletal muscle. This is crucial as Vincent and colleagues have 
previously demonstrated that insulin increases microvascular perfusion in normal 
healthy animals (18; 53) and humans (230) via a NOS-dependent mechanism (18; 53). 
It is important to note that 10 µM EGCG is within the no-observed adverse effect level, 
as it has been shown previously that EGCG is not toxic to rats in vivo at doses up to 500 
mg.kg
-1
.d
-1
 (197), which is equivalent to ~12 µM EGCG in the plasma (197).  
In the current study, 10 µM EGCG stimulated microvascular perfusion, but not total 
blood flow in muscle. EGCG did not mimic or sensitize insulin’s action on total hindleg 
blood flow indicating that EGCG acts on the microvasculature in skeletal muscle, with 
no effect on total blood flow. EGCG-stimulated microvascular perfusion was similar in 
magnitude to raising plasma insulin concentrations to 800 pM. However the 
microvascular actions of EGCG and insulin were not additive, suggesting that EGCG 
does not have insulin-sensitizing actions in the muscle microvasculature in normal 
healthy rats.  
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Previous studies have demonstrated that increased microvascular perfusion is associated 
with augmented muscle glucose uptake (18; 53; 80). The present study shows that 
EGCG increases MBV in skeletal muscle, but this was not accompanied by increased 
muscle glucose uptake. In contrast to studies by Ashida et al. (157) and Ueda et al. 
(172), the outcomes of this study showed that acute EGCG alone did not mimic 
insulin’s action to stimulate glucose uptake in skeletal muscle. Similarly, EGCG does 
not alter muscle Akt phosphorylation, which is a downstream signalling molecule of 
PI3-K involved in the insulin signalling pathway leading to glucose uptake. This is in 
accordance with the results shown in Chapter 3, where EGCG does not have direct 
metabolic effects on skeletal muscle in perfused rat hindlimb.  
The present study shows that whole body insulin sensitivity of the healthy rats was not 
significantly altered by acute EGCG treatment. Previously, regular green tea 
consumption has been reported to reduce the risk for developing type 2 diabetes (106; 
125). Additionally, previous studies (156; 158; 229) have claimed that chronic green tea 
treatment improved glucose tolerance in rats. As demonstrated in Chapter 4, EGCG-
mediated vasodilation in skeletal muscle through a separate (in part) signalling pathway 
to insulin, and therefore the unknown signalling pathway might be intact in insulin 
resistant rats. This suggests that acute EGCG treatment may be insufficient to improve 
whole body insulin sensitivity in healthy animals. However, there is still possibility that 
acute EGCG treatment may be effective in insulin resistant rats, which are lacking 
insulin-mediated microvascular recruitment or that chronic EGCG administration may 
be required to exert its health-promoting benefit.  
In conclusion, this study shows that although 10 µM EGCG increased microvascular 
blood volume in vivo, this was not sufficient to increase muscle glucose uptake in 
healthy insulin responsive animals. Previous studies by Shao et al. (238) and Tsuneki et 
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al. (147) reported that acute green tea or EGCG exerts opposite effects in healthy and 
insulin resistant mice. Green tea or EGCG acutely lowered blood glucose in db/db mice 
but not healthy mice (147), and improved glucose tolerance in insulin resistance but not 
healthy mice (238). The acute effects of EGCG on microvascular perfusion and muscle 
glucose uptake in an insulin resistant model, where both the microvasculature and 
myocyte are insulin resistant, are not known and thus were investigated in studies 
described in Chapter 6. 
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Chapter 6 
Acute effects of EGCG in insulin 
resistant rats in vivo  
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6.1 Introduction 
Animal models of insulin resistance and diabetes have been widely used to gain better 
understanding of the pathogenesis of insulin resistance and type 2 diabetes. Rodents fed 
a high fat diet (HFD) mimic the mechanisms responsible for the development of insulin 
resistance in humans (239). Kraegen et al. (240) showed that rats developed liver 
insulin resistance after 3 days of HFD feeding, followed by insulin resistance in other 
insulin sensitive tissues by 3 weeks. Studies showed that rats fed a HFD for ≥ 3 weeks 
developed whole body insulin resistance (82; 240-245), which is characterised by 
hyperinsulinaemia (241-244), impaired glucose uptake in skeletal muscle and adipose 
tissue (82; 242-245), and impaired insulin-mediated microvascular perfusion (82; 245).  
As demonstrated in Chapter 5, acute administration of EGCG stimulated microvascular 
perfusion in skeletal muscle of healthy animals, but had no effects on muscle and whole 
body insulin sensitivity. Recent studies (147; 238) showed that acute administration of 
green tea or EGCG exerts opposite effects in healthy versus insulin resistant animals, in 
which acute green tea or EGCG treatment was metabolically beneficial for insulin 
resistant but not healthy animals.  
In insulin resistant animals, studies have suggested that chronic green tea or EGCG 
treatment ameliorates insulin resistance by promoting GLUT4 translocation and 
glucose uptake in myocytes (157; 158) and adipocytes (159) in the absence of insulin. 
Furthermore, chronic EGCG treatment increases plasma adiponectin (120; 160), and 
reduces the gene expression of resistin (246) and peroxisome proliferator-activated 
receptor γ (PPARγ) (98) in adipocytes of insulin resistant animals. The studies in 
Chapter 5 demonstrated that EGCG is a vasodilator that does not acutely alter muscle 
glucose uptake or enhance insulin’s metabolic or vascular actions in healthy rats. 
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Chapter 4 demonstrated that EGCG vasodilates in skeletal muscle via NOS-dependent 
but PI3-K- and AMPK-independent pathway, which is a NOS-dependent pathway that 
is distinct from insulin. The use of a separate NOS-dependent vasodilation signalling 
pathway from insulin suggests the possibility that EGCG may still be able to recruit 
microvascular flow in insulin resistant animals. Whether EGCG administration can thus 
ameliorate insulin resistance in skeletal muscle, by bypassing a defect in delivery of 
glucose and/or insulin to myocytes, is not known and is the main purpose of the current 
chapter. 
The aims of the present study were therefore to determine (i) whether EGCG has direct 
vascular actions in insulin resistant rat hindlimb and (ii) whether acute administration 
of EGCG (10 µM) ameliorates insulin resistance by improving whole body insulin 
sensitivity, microvascular perfusion, and muscle glucose uptake. 
 
6.2 Methods 
 
6.2.1 Animals 
Male Sprague-Dawley rats (n = 49) at 6 ‒ 7 weeks old were provided a 22.6% (w/w) fat 
semi-pure rodent diet (23FD) from Specialty Feeds, Glen Forest, WA, Australia (See 
Table 2.1) for 3 – 4 weeks. The rats were allowed free access to drinking water and 
food ad libitum. All experimental procedures were approved by the University of 
Tasmania Animal Ethics Committee (A11282 & A13384) and performed in accordance 
with the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes – 2004, 7th Edition. 
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6.2.2 Experimental protocol 
 
6.2.2.1 Constant-flow perfused rat hindlimb 
Surgery was carried out in the rats as described in 2.3.2. Vascular studies in hindlimbs 
were carried out according to the protocol outlined in 3.2.3 with some modifications 
(Figure 6.1). In the insulin resistant rats, the hindlimb vasculature was pre-constricted 
with 5-HT (0.15 – 0.24 µM) to increase perfusion pressure to approximately 70 – 80 
mmHg, perfusion pressure that is comparable with the pressure of 5-HT studies in 
Chapter 3. 5-HT was infused 30 min prior to and during infusion of saline or EGCG 
(0.1, 1, 10, 100 µM in 15 min stepwise increments). At the end of each experiment, 500 
µM SNP was infused to assess maximal vasodilatory capacity of the isolated hindlimb, 
in order to determine the absence of oedema-mediated increase in perfusion pressure 
which may mask the vasodilation effects of EGCG.  
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Figure 6.1 Experimental protocol of perfused rat hindlimb vascular studies.  
23FD-fed rats were equilibrated for 30 min before infusion of 5-HT. EGCG was infused 
to final concentrations of 0.1, 1, 10, 100 µM in 15 min stepwise increments 30 min after 
the infusion of vasoconstrictor. Perfusate effluent () was collected before and every 15 
min after the experiment started. At the end of each experiment, 500 µM SNP was 
infused to assess maximal vasodilatory capacity of the isolated hindlimb.  
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6.2.2.2 In vivo study 
Surgery was carried out in the overnight fasted rats as described in 2.4.1. The 
experimental protocol of this study was as described in 5.2.2 with some modifications 
(Figure 6.2). Muscle glucose uptake was measured using 
14
C-2-DG (specific activity 50 
– 60 mCi.mmol-1, American Radiolabelled Chemicals, Saint Louis, MO, USA), as 
described in 2.4.8. A bolus of 
14
C-2-DG (10 µCi) was given to the rat via jugular vein, 
followed by a 10-min arterial blood withdrawal.  
 
 
Figure 6.2 Experimental protocol for in vivo study in insulin resistant animals. 
Animals were allowed a 60 min equilibration period following the surgery. EGCG infusion 
(0.18 mg.min
-1
.kg
-1
) started 30 min before the saline or insulin (10 mU.min
-1
.kg
-1
) infusion. 
Glucose solution (30% w/v) was infused at variable rates to maintain euglycaemia 
throughout the experiment. For microvascular blood flow measurement, CEU images () 
were acquired at 0 min (30 min after EGCG infusion), and at 90 min. For muscle glucose 
uptake measurement, 
14
C-2-DG (, 10 µCi) was given as a bolus to the animals, followed 
by a 10-min arterial blood withdrawal. Blood samples () were collected at times indicated 
in the figure for determination of glucose concentrations. Plasma samples ( ) were 
collected at the start and at the end of the experiment for determination of glucose, insulin, 
free fatty acids, and EGCG levels. 
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6.2.3 Statistical Analysis 
All data are expressed as means ± S.E.M. Two-way repeated measures ANOVA with 
Student-Newman-Keuls post hoc test was used to compare treatment groups over the 
time course of experiment. One-way ANOVA with Student-Newman-Keuls post hoc 
test was used to make comparisons of differences between endpoint values. All tests 
were performed using the SigmaPlot 11 (
©
Systat Software Inc. 2008). 
 
6.3 Results 
 
6.3.1 Animal characteristics 
Following 3 – 4 weeks of HFD feeding, body weight of the fasting rats was 265 ± 7 g 
(n = 35). Table 6.1 shows the basal metabolic characteristics of the rats fed with 5FD 
(Chapter 5) and 23FD. Following 4 weeks of dietary intervention, fasting plasma 
glucose of the 23FD rats was not different from the 5FD rats. As expected, fasting 
plasma insulin and free fatty acids, and epididymal fat pad weights were higher in the 
23FD rats than the 5FD rats.  Homeostatic model assessment of insulin resistance 
(HOMA-IR), a surrogate measure of insulin resistance, was higher in the 23FD rats. 
These indicate that rats developed insulin resistance following 4 weeks of 23FD 
treatment. 
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Table 6.1 Animal characteristics following 3 – 4 weeks of HFD treatment. 
 5FD            
(n = 32) 
23FD         
(n = 35) 
P value 
Fasting plasma glucose (mM) 7.14 ± 0.11 7.07 ± 0.14 0.720 
Fasting plasma insulin (pM) 70 ± 8 205 ± 17 <0.001 
Fasting plasma free fatty acids (mM) 0.64 ± 0.03 0.76 ± 0.02 0.001 
Epididymal fat pad (% of body weight) 0.48 ± 0.02 0.86 ± 0.05 < 0.001 
HOMA-IR 3.27 ± 0.04 9.50 ± 0.91 < 0.001 
Data are expressed as Means ± SEM. 
 
6.3.2 Vascular actions of EGCG in the perfused rat hindlimb 
The direct vascular actions of EGCG in insulin resistant rat skeletal muscle were 
assessed in the constant-flow perfused rat hindlimb system. Hindlimb perfusion 
pressure under basal conditions at a flow rate of ~8 mL.min
-1
 was 38.8 ± 1.0 mmHg (n 
= 14). The vascular preparation was pre-constricted with 5-HT (0.15 – 0.24 µM) to 
increase perfusion pressure to 79.4 ± 6.7 mmHg (n = 14), and this is comparable with 
the perfusion pressure induced by 5-HT in healthy rats (See 3.3.2.3). EGCG infused at 
0.1, 1, 10, and 100 µM in 15 min step-wise increments caused dose-dependent 
vasodilation in 5-HT pre-constricted hindlimbs (Figure 6.3). Compared with saline, at 
10 and 100 µM doses, EGCG infusion significantly (P < 0.05) reduced 5-HT-mediated 
vasoconstriction. At the highest dose tested (100 µM), EGCG opposed 5-HT mediated 
vasoconstriction by 43 ± 5 % (p < 0.001 vs. saline). Interestingly, the magnitude of 
EGCG-induced vasodilation in insulin resistant rat hindlimbs is similar to that of the 
normal healthy rat hindlimbs (Figure 3.7C), in which 100 µM EGCG opposed 5-HT 
125 | P a g e  
 
mediated vasoconstriction by 47± 6 %. In all hindlimbs, SNP reversed 5-HT mediated 
vasoconstriction by >95 %, representing maximal vasodilation and return of perfusion 
pressures to basal levels. 
 
 
Figure 6.3 Dose-response effects of EGCG on % vasoconstriction during 5-HT 
infusions in insulin resistant rat hindlimbs. Data represents % of constriction of 
the perfused rat hindlimb from 30 min after the infusion of vasoconstrictors.  – 
Saline,  – EGCG. n = 7 in each groups. * p < 0.05 vs. Saline (Two-way repeated 
measures ANOVA).  
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6.3.3 Acute effects of EGCG in insulin resistant rats in vivo 
 
6.3.3.1 Whole body insulin sensitivity 
The GIR (Figure 6.4A) of the Insulin group during steady state of glucose infusion was 
17.42 ± 0.63 mg.min
-1
.kg
-1
, and the GIR of the EGCG + Insulin group increased 
significantly (19.48 ± 0.70 mg.min
-1
.kg
-1
, p < 0.015) when compared to Insulin alone. 
This indicates that acute EGCG has improved whole body insulin sensitivity in the 
insulin resistant rats by 12%. Plasma insulin levels post-insulin clamp in the Insulin and 
EGCG + Insulin groups were 1495 ± 113 pM and 1337 ± 63 pM respectively (p = 
0.253), indicating that EGCG did not significantly affect plasma insulin levels. In the 
EGCG group, some glucose was required to maintain euglycaemia in the beginning of 
the experiment, however, this was not required through to the end of experiment. Blood 
glucose (Figure 6.4B) measured throughout the experiments was not different between 
each group.  
In the EGCG and EGCG + Insulin groups, EGCG was infused 30 min before the 
hyperinsulinaemic euglycaemic clamp. Plasma EGCG levels following 150 min EGCG 
infusion in the EGCG and EGCG + Insulin groups were 9.30 ± 0.90 µM and 10.88 ± 
0.44 µM respectively (p = 0.14). 
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Figure 6.4 Acute effects of EGCG on whole body insulin sensitivity in insulin resistant 
rats. (A) Glucose infusion rate and (B) blood glucose levels during hyperinsulinaemic 
euglycaemic clamp.  - Saline (n = 9),  - EGCG (n = 7),  - Insulin (n = 10),  - EGCG 
+ Insulin (n = 9); * p < 0.05 vs. Saline (Two-way repeated measures ANOVA); † p < 0.015 
vs. Insulin (Two-way repeated measures ANOVA). 
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6.3.3.2 Haemodynamic parameters 
Figure 6.5 shows the MAP and heart rate of the rats during the course of the 
experiments. MAP and heart rate were not different between groups during the course 
of experiments indicating acute EGCG infusion has no effect on these cardiovascular 
measures.  
FBF was measured during the hyperinsulinaemic euglycaemic clamp (Figure 6.6). FBF 
before the experiments were not different between all groups (data not shown). In the 
23FD rats, FBF of the Insulin group (1.16 ± 0.13 ml.min
-1
) was not different from that 
of the Saline group (1.16 ± 0.13 ml.min
-1
) at the end of experiment (Figure 6.6). Acute 
EGCG did not alter FBF (1.17 ± 0.03 ml.min
-1
) or enhance insulin-stimulated FBF 
(1.15 ± 0.14 ml.min
-1
) in the 23FD rats. 
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Figure 6.5 Effects of EGCG on haemodynamic parameters in insulin resistant 
rats. (A) Mean arterial blood pressure and (B) heart rate during hyperinsulinaemic 
euglycaemic clamp.  - Saline (n = 9),  - EGCG (n = 7),  - Insulin (n = 10),  - 
EGCG + Insulin (n = 9). Data not statistically significant at all time points (Two-way 
repeated measures ANOVA) 
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Figure 6.6 Femoral artery blood flow at the end of experiment in insulin 
resistant rats.   - Saline (n = 9),  - EGCG (n = 7), - Insulin (n = 10), - 
EGCG + Insulin (n = 9). Data not statistically significant (Two-way ANOVA).   
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  6.3.3.3 Muscle microvascular perfusion 
CEU was used to measure the MBV before and 90 min during the hyperinsulinaemic 
euglycaemic clamp (Figure 6.7). At 0 min (Figure 6.7), MBV of the EGCG and EGCG 
+ Insulin groups were significantly higher than the Saline and Insulin groups (5.41 ± 
0.34 and 5.33 ± 0.58 acoustic intensity units vs. 2.85 ± 0.09 and 3.54 ± 0.50 acoustic 
intensity units respectively, p < 0.005 vs. Saline and Insulin groups). In the EGCG and 
EGCG + Insulin groups, first CEU measurement was acquired 30 min after EGCG 
infusion, indicating acute EGCG infusion for 30 min has increased microvascular 
perfusion in skeletal muscle of the insulin resistant rats. 
At 90 min, the Saline group had a modest but significant increase in MBV (23 ± 9 %, p 
= 0.038). The Insulin group also had a significant increase in the MBV by 90 min of 
insulin clamp (45 ± 12 %, p < 0.001), while MBV of EGCG and EGCG + Insulin 
groups remained unchanged from 0 min (Figure 6.7). MBV of the EGCG, Insulin and 
EGCG + Insulin groups at 90 min were not different, but significantly (p < 0.05) higher 
than the Saline group. This indicates that EGCG stimulated microvascular perfusion to 
a similar extent as insulin, but did not further enhance insulin’s vascular action in 
skeletal muscle. 
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Figure 6.7 Microvascular blood volume before and during hyperinsulinaemic 
euglycaemic clamp in insulin resistant rats.  - Saline (n = 9),  - EGCG (n = 7), - 
Insulin (n = 10), - EGCG + Insulin (n = 9); † p < 0.005 vs. Saline and Insulin at 0 min 
(Two-way repeated measures ANOVA); ‡ p < 0.05 vs. respective 0 min (Two-way 
repeated measures ANOVA); * p < 0.05 vs. Saline at 90 min (Two-way repeated 
measures ANOVA).  
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6.3.3.4 Muscle insulin sensitivity 
Muscle glucose uptake was assessed at the end of the experiment using an isotopic 
glucose tracer 
14
C-2-DG. In insulin resistant rats, insulin stimulated muscle glucose 
uptake by 4.5-fold (Figure 6.8). Muscle glucose uptake was not different between the 
Insulin and EGCG + Insulin groups (8.18 ± 0.37 and 8.43 ± 0.92 µg.g
-1
.min
-1
 
respectively). In addition, muscle glucose uptake was not different between Saline and 
EGCG groups (1.77 ± 0.19 and 1.95 ± 0.24 µg.g
-1
.min
-1
 respectively). In insulin 
resistant rats, EGCG did not improve muscle glucose uptake or enhance insulin-
stimulated muscle glucose uptake. 
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Figure 6.8 Muscle 
14
C-2-DG uptake at the end of hyperinsulinaemic euglycaemic 
clamp in insulin resistant rats.  - Saline (n = 9),  - EGCG (n = 7), - Insulin (n = 10), 
- EGCG + Insulin (n = 9). * p < 0.001 vs. Saline and EGCG (One-way ANOVA).  
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6.4 Discussion 
In the present chapter, the acute vascular and metabolic actions of EGCG were 
explored in skeletal muscle of HFD-induced insulin resistant rats. The main findings 
from the current study are i) EGCG vasodilates skeletal muscle vasculature in situ, ii) 
EGCG acutely stimulates skeletal muscle microvascular perfusion, but does not 
augment glucose uptake in vivo, and these effects are not additive to insulin, iii) 
however, EGCG acutely improves whole body insulin sensitivity of the insulin resistant 
rats. Therefore, EGCG possesses insulin-mimetic vascular, but not metabolic, actions in 
skeletal muscle of HFD-induced insulin resistant rats. 
The present study shows that rats fed with 23FD for 4 weeks develop whole body 
insulin resistance, with a marked increase in epididymal fat pad weights, fasting plasma 
insulin and plasma free fatty acids. In recent years, Rattigan and colleagues have 
reported that insulin mediated increases in total blood flow and microvascular perfusion 
are impaired in obese humans (230) and HFD-induced insulin resistant rats (82; 245). 
In the perfused rat hindlimb preparations, EGCG dose-dependently vasodilated in 5-HT 
pre-constricted hindlimb of the insulin resistant rats. Interestingly, the magnitude of 
EGCG-induced vasodilation in rat hindlimb of insulin resistant rats was comparable to 
that observed in normal healthy rats (Chapter 3, Figure 6.3). Studies in Chapter 3 and 4 
showed that EGCG is a NOS-dependent vasodilator in skeletal muscle. Similarly, 
microvascular perfusion mediated by insulin is NOS-dependent (18; 53), but this is 
impaired during insulin resistant states (80; 82). EGCG-induced vasodilation in muscle 
vasculature is mediated via a partially separate signalling pathway from that of the 
insulin, suggesting that vascular responses to acute EGCG are intact in the HFD-
induced insulin resistant rats and this may in turn improve insulin sensitivity in the 
insulin resistant rats.  
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Chapter 5 showed that acute EGCG treatment had no effect on whole body insulin 
sensitivity in healthy rats. However, in the present study, acute EGCG treatment 
significantly increased the GIR in the insulin resistant rats by 12%, indicating 
improvement in whole body insulin sensitivity. This is in accordance with a recent 
study (238) which showed that acute administration of EGCG (50 mg.kg
-1
) improved 
glucose tolerance and insulin sensitivity in macrophage-induced insulin resistant, but 
not normal, mice. Similarly, another study (147) showed that green tea acutely lowered 
blood glucose in diabetic, but not healthy, mice.  
This study shows that acute EGCG infusion has no effect on the MAP or insulin-
stimulated increase in FBF. However, acute EGCG infusion for 30 min increased MBV 
in the skeletal muscle of the insulin resistant rats. Interestingly, EGCG-stimulated 
microvascular perfusion was similar in magnitude to raising plasma insulin 
concentrations to 1.5 nM in insulin resistant rats. Nonetheless, acute infusion of EGCG 
did not further enhance insulin-mediated microvascular perfusion, indicating EGCG 
mimics but does not enhance insulin’s action in muscle microvasculature. As compared 
to the healthy rats (Chapter 5), the microvasculature of the insulin resistant rats 
appeared to be more sensitive to EGCG, in which there was a significant increase in 
MBV following 30 min of EGCG infusion. Some (247; 248), but not all (249; 250), 
studies suggested an elevated ROS production following HFD treatment, and ROS have 
been implicated in EGCG-mediated NO production in endothelial cells (119; 181). This 
suggests that EGCG-mediated microvascular perfusion is more sensitive in the insulin 
resistant rats could be due to an elevation in ROS levels, however, further studies are 
required to determine this.  
Despite the increase in whole body insulin sensitivity and microvascular perfusion, 
acute EGCG treatment did not cause glucose disposal by itself or enhance insulin-
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stimulated glucose uptake in skeletal muscle. Previously, EGCG has been reported to 
stimulate glucose uptake in adipocytes (156; 159; 238) and inhibit hepatic 
gluconeogenesis (174; 175). Therefore, it is highly likely that acute EGCG treatment 
has improved insulin sensitivity in adipose tissue and/or liver, which resulted in 
increased GIR. However, adipose tissue and liver insulin sensitivity were not measured 
in the present study. 
Insulin resistance in skeletal muscle is caused by the impairment in both delivery and 
extraction of glucose to skeletal muscle (243). While muscle microvascular perfusion 
plays a key role in determining the movement of glucose in blood to skeletal muscle 
(review by Barrett and Rattigan (251)), transmembrane glucose transport regulated by 
GLUT4 is an important rate-limiting step of glucose uptake into muscle and adipose 
tissue (252). HFD-induced muscle insulin resistance is characterised by elevated 
intracellular triglycerides in myocytes (253; 254), reduced muscle lipid oxidation (255; 
256), reduced muscle GLUT4 content and insulin-stimulated GLUT4 translocation 
(257; 258), and reduced gene expressions of IRS-1 and PI3-K in skeletal muscle (259). 
Previous studies suggested that EGCG increased muscle lipid oxidation in HFD-fed 
mice in vivo (260; 261), reduced intracellular lipid accumulation (262) and stimulated 
GLUT4 translocation (158) in incubated myocytes in vitro. However, the present study 
showed that acute EGCG treatment stimulated muscle microvascular perfusion but not 
muscle glucose uptake in insulin resistant rats in vivo, suggesting that the GLUT4 
translocation was not improved by acute EGCG treatment. This is in accordance with 
the findings from Chapter 3 where EGCG was shown to have direct vascular but not 
metabolic actions in skeletal muscle. 
Studies in the past showed that chronic green tea or EGCG treatment improved glucose 
tolerance and insulin sensitivity in both healthy (156-158; 229) and insulin resistant (98; 
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158-167) animals. The present study showed that acute EGCG treatment improved 
whole body insulin sensitivity modestly in insulin resistant, but not healthy (Chapter 5) 
rats. Acute EGCG treatment has been shown to stimulate microvascular perfusion in 
healthy (Chapter 5) and HFD-induced insulin resistant rats. Whether chronic EGCG 
treatment could ameliorate insulin resistance by preventing the impairment of 
microvascular perfusion and muscle glucose uptake in HFD-fed rats is not known and 
was investigated in studies reported in Chapter 7. 
  
139 | P a g e  
 
 
 
 
 
 
Chapter 7 
Chronic effects of EGCG in insulin 
resistant rats in vivo 
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7.1 Introduction 
Several clinical studies (116; 128-149) have been carried out to investigate the anti-
diabetic effects of green tea or EGCG. However, the outcome of these clinical trials 
was not conclusive. To date, there is mounting evidence (98; 120; 158-162; 164-167) 
that suggests that chronic green tea or EGCG treatment has anti-diabetic effects in 
insulin resistant mice and rats. However, the underlying mechanism of EGCG to 
ameliorate insulin resistance in vivo has not been fully elucidated.  
Chapters 3 and 4 demonstrated that EGCG is a NOS-dependent vasodilator against 5-
HT. Furthermore, Chapters 5 and 6 showed that acute administration of EGCG in vivo 
mimics insulin’s action to stimulate muscle microvascular perfusion in healthy and 
insulin resistant rats. However, muscle glucose uptake was not improved following the 
increase in microvascular perfusion in the acute EGCG-treated rats. Acute 
administration of EGCG improved whole body insulin sensitivity of insulin resistant rat. 
This suggests that 10 µM EGCG could acutely improve whole body insulin sensitivity 
in insulin resistant animals. In epidemiological studies, however, green tea/EGCG is 
present chronically. Therefore it is important to determine whether chronic 
administration of EGCG could prevent the development of insulin resistance.  
Under normal healthy conditions, insulin stimulates microvascular perfusion to 
facilitate muscle glucose uptake (21; 263). However, in the presence of insulin 
resistance, insulin-mediated microvascular perfusion is impaired and leads to reduced 
insulin-stimulated muscle glucose uptake (245). Recently, a study (82) showed that 
impaired insulin-mediated microvascular perfusion could result in impaired insulin-
stimulated muscle glucose uptake despite the myocytes being insulin sensitive. The 
reciprocal relationships between insulin-mediated microvascular perfusion and muscle 
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glucose uptake indicate that treatments to improve microvascular dysfunction may 
simultaneously improve muscle glucose uptake and insulin sensitivity. Thus the aim of 
this study was to determine whether chronic administration of EGCG prevents the 
development of insulin resistance by improving microvascular function and glucose 
metabolism in skeletal muscle of insulin resistant rats. 
EGCG at the dose of 200 mg.kg
-1
.d
-1
 has been previously reported to improve 
cardiovascular and metabolic functions in SHRs (120). In the present study, rats fed a 
high fat diet were treated with EGCG (200 mg.kg
-1
.d
-1
) in drinking water for 4 weeks to 
determine the chronic effects of EGCG on whole body insulin sensitivity, insulin-
mediated microvascular perfusion and insulin-mediated muscle glucose uptake.  
 
7.2 Methods 
 
7.2.1 Animals 
Male Sprague-Dawley rats (n = 13) at 7 – 8 weeks old were provided a 22.6% (w/w) fat 
semi-pure rodent diet (23FD) from Specialty Feeds, Glen Forest, WA, Australia (See 
Table 2.1) for 4 weeks. The rats were allowed free access to drinking water and food ad 
libitum. During the dietary intervention period, EGCG (200 mg.kg
-1
.d
-1
) was prepared 
freshly every 2 days and added to the drinking water. Food and water intake were 
monitored daily during the dietary intervention period. Following the dietary 
intervention, rats were fasted overnight before experiments were carried out, and 
EGCG water was removed and replaced with normal drinking water during the 
overnight fast. All experimental procedures were approved by the University of 
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Tasmania Animal Ethics Committee (A11282 & A13384) and performed in accordance 
with the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes – 2004, 7th Edition. 
 
7.2.2 Experimental protocol  
Surgery was carried out in the overnight fasted rats as described in 2.4.1. The 
experimental protocol of this study was as described in 6.2.2.2 (Figure 7.1). Importantly, 
EGCG was not infused into the rats intravenously.  
In the present study, data from the rats fed with 23FD and EGCG water for 4 weeks 
(23FD + chEGCG) was compared with the 23FD rats (Saline group- 23FDsal and 
Insulin group- 23FDins) in Chapter 6 (Figure 7.2). 
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Figure 7.1 Experimental protocol for in vivo study in chronic EGCG-treated 
animals. 
Animals were allowed a 60 min equilibration period following the surgery. Insulin (10 
mU.min
-1
.kg
-1
) infusion started at 0 min. Glucose solution (30% w/v) was infused at 
variable rates to maintain euglycaemia throughout the experiment. For microvascular 
blood flow measurement, CEU images () were acquired at 0 min, and at 90 min. For 
muscle glucose uptake measurement, 
14
C-2-DG (, 10 µCi) was given as a bolus to the 
animals, followed by a 10-min arterial blood withdrawal. Blood samples () were 
collected at times indicated in the figure for glucose levels determination. Plasma samples 
( ) were collected at the start and at the end of the experiment to determine glucose, 
insulin, free fatty acids, and EGCG concentrations.   
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Figure 7.2 An illustration of experimental groups used for Chapter 6 and Chapter 7. 
In this chapter, data from the rats fed with 23FD and EGCG water for 4 weeks (23FD + 
chEGCG) was compared with the 23FD rats (Saline group- 23FDsal and Insulin group- 
23FDins) in Chapter 6,   
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7.2.3 Western blot 
Phosphorylation of Akt and TBC1D1
Thr590
, both proteins involve in insulin signalling in 
skeletal muscle to stimulate glucose uptake, was assessed using Western blotting.  
Western blot analysis of Akt was performed as described in 2.5. Western blot analysis 
of the TBC1D1
Thr590
 was performed as described in 2.5 with some modifications. 
Primary antibodies used were rabbit anti-phospho-Thr
590
-TBC1D1 (pTBC1D1, 1:1000; 
Cell Signalling) and rabbit-anti-α-tubulin (α-tubulin, 1:1000; Cell Signalling) as a 
loading control. Following incubation with primary antibody, the membranes were 
probed with 1:1000 anti-rabbit secondary antibody (Cell Signalling). To visualise the 
bands, equal volumes of West Pico Chemiluminescent Substrate (Thermo Fischer 
Scientific, Rockford, IL, USA) were mixed together and applied to the membrane. 
Band intensities were quantified by optical density using Image Station 4000mm Pro, 
Carestream Molecular Imaging (Carestream health Inc., Rochester, NY, USA). 
 
7.2.4 Statistical analysis 
All data are expressed as means ± S.E.M. Two-way repeated measures ANOVA with 
Student-Newman-Keuls post hoc test was used to compare treatment groups over the 
time course of experiment. An unpaired Student’s t-test was used to make comparisons 
of differences between 2 groups. One-way ANOVA with Student-Newman-Keuls post 
hoc test was used to make comparisons of differences between endpoint values. All 
tests were performed using the SigmaPlot 11 (
©
Systat Software Inc. 2008). 
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7.3 Results 
7.3.1 Animal characteristics 
During dietary interventions, body weights of the rats fed with 23FD (23FD) were not 
different from that of the rats fed with 23FD and EGCG water (23FD + chEGCG) 
(Figure 7.3), indicating that EGCG treatment for 4 weeks had no effect on the rat’s 
body weight. EGCG treatment did not alter food, energy and water intake of the rats 
(Figure 7.4 and 7.5A). During the dietary intervention, EGCG water was prepared fresh 
every 2 days to provide a dose up to 200 mg.kg
-1
.d
-1
. Accordingly, the actual average 
daily EGCG intake for the 23FD + chEGCG rats measured from water intake was 189 
± 3 mg.kg
-1
.d
-1
 (Figure 7.5B). 
Following 4 weeks of dietary intervention, body weight, epididymal fat pad weight, 
fasting plasma glucose, insulin and free fatty acids, and HOMA-IR were not different 
between the 23FD and 23FD + chEGCG rats (Table 7.1). Following an overnight fast, 
EGCG was not detected in the plasma of the 23FD + chEGCG rats. This indicates that 
chronic EGCG treatment for 4 weeks did not improve the abovementioned basal 
metabolic profiles of the insulin resistant rats. 
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Figure 7.3 Rat body weight during dietary intervention. Day 0 represents the day 
rats were commenced on dietary intervention.  - 23FD (n = 19),  - 23FD + 
chEGCG (n = 13). Data are expressed as Means ± SEM. 
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Figure 7.4 Food (A) and energy (B) intake of rats during dietary intervention.
Day 0 represents the day rats were commenced on dietary intervention.  - 23FD (n 
= 19),  - 23FD + chEGCG (n = 13). Data are expressed as Means ± SEM. 
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Figure 7.5 Water (A) and EGCG (B) intake of rats during dietary intervention. 
Day 0 represents the day rats were commenced on dietary intervention.  - 23FD (n 
= 19),  - 23FD + chEGCG (n =13), green line: EGCG 200 mg.kg
-1
.d
-1
 target. Data 
are expressed as Means ± SEM. 
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Table 7.1 Chronic effects of EGCG on basal characteristics of the rats. 
 23FD 
(n = 35) 
23FD + chEGCG 
(n = 13) 
P value 
Body weight (g) 265 ± 7 289 ± 7 0.060 
Fasting plasma glucose (mM) 7.07 ± 0.14 7.14 ± 0.21 0.795 
Fasting plasma insulin (pM) 205 ± 17 233 ± 21 0.366 
Fasting plasma free fatty acids (mM) 0.76 ± 0.02 0.75 ± 0.03 0.743 
Epididymal fat pad (% of body weight) 0.86 ± 0.05 0.85 ± 0.03 0.927 
HOMA-IR 9.50 ± 0.91 10.87 ± 1.14 0.411 
Data are expressed as Means ± SEM. 
 
 7.3.2 Chronic effects of EGCG on whole body insulin sensitivity in insulin 
resistant rats. 
Figure 7.6A shows the GIR of the 23FDins and 23FDins + chEGCG rats. GIR of the 
23FDins rats during steady state glucose infusion was 17.42 ± 0.63 mg.min
-1
.kg
-1
, while 
GIR of the 23FDins + chEGCG rats was 21.12 ± 0.76 mg.min
-1
.kg
-1
 (p < 0.001 vs. 
23FD). This indicates that the chronic EGCG treatment for 4 weeks has improved 
whole body insulin sensitivity of the insulin resistant rats. Plasma insulin 
concentrations post-insulin clamp of the 23FDins and 23FDins + chEGCG rats were 
1495 ± 114 and 1522 ± 78 pM respectively (p = 0.845), indicating both groups were 
clamped with comparable amounts of insulin. Blood glucoses (Figure 7.6B) measured 
throughout the experiments were not different between groups. 
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Figure 7.6 Chronic effects of EGCG on whole body insulin sensitivity in insulin 
resistance rats. (A) Glucose infusion rate and (B) blood glucose levels during 
hyperinsulinaemic euglycaemic clamp.  - 23FDins (n = 10),  - 23FDins + 
chEGCG (n = 13); * p < 0.05 vs. 23FDins (Two-way repeated measures ANOVA); † 
p < 0.001 vs. 23FDins (Two-way repeated measures ANOVA).  
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7.3.3 Chronic effects of EGCG on haemodynamic parameters in vivo. 
Figure 7.7 shows the MAP and heart rate of the rats during the course of the 
experiments. MAP and heart rate were not different between groups during the course 
of the experiment indicating chronic EGCG treatment has no effect on these 
cardiovascular parameters.  
FBF was measured during the experiments. At basal, FBF were not different between 
23FDsal, 23FDins, and 23FDins + chEGCG rats (1.09 ± 0.12, 0.97 ± 0.10, and 0.96 ± 
0.06 ml.min
-1
 respectively). At the end of hyperinsulinaemic euglycaemic clamp, FBF 
was not different between treatment groups (Figure 7.8). This indicates that chronic 
EGCG treatment did not alter insulin-mediated increased in total blood flow in the 
insulin resistant rats. 
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Figure 7.7 Chronic effects of EGCG on haemodynamic parameters. (A) Mean 
arterial blood pressure and (B) heart rate during hyperinsulinaemic euglycaemic 
clamp.  - 23FDins (n = 10),  - 23FDins + chEGCG (n = 13). Data not 
statistically significant at all times (Two-way repeated measures ANOVA). 
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Figure 7.8 Chronic effects of EGCG on femoral artery blood flow at the end of 
hyperinsulinaemic euglycaemic clamp in insulin resistant rats.  - 23FDsal (n = 
9),   - 23FDins (n = 10), Data not statistically - 23FDins + chEGCG (n = 13). 
significant between groups (One-way ANOVA) 
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7.3.4 Chronic effects of EGCG on muscle microvascular perfusion in vivo. 
CEU was used to measure the MBV before and 90 min after the hyperinsulinaemic 
euglycaemic clamp (Figure 7.9). At basal, MBV was not different between the 23FDsal, 
23FDins, and 23FDins + chEGCG rats (2.85 ± 0.09, 3.54 ± 0.50, and 3.65 ± 0.25 
acoustic intensity respectively). In the 23FDins rats, insulin stimulated MBV by 1.44 
fold at 90 min (p < 0.001). In the 23FDins + chEGCG, MBV at 90 min was not 
different from its basal (3.78 ± 0.36 acoustic intensity, p = 0.632), and was not different 
from the MBV of the 23FDsal and 23FDins rats at 90 min. This indicates that chronic 
EGCG treatment has blunted the effect of insulin to stimulate microvascular perfusion 
in muscle.  
 
7.3.5 Chronic effects of EGCG on muscle insulin sensitivity in vivo.  
Muscle glucose uptake was assessed using an isotopic glucose tracer which was 
measured at the end of the experiment. At the end of hyperinsulinaemic euglycaemic 
clamp, R’g of the 23FDins + chEGCG rats was significantly higher than the 23FDins 
rats (8.18 ± 0.37 vs. 13.64 ± 0.50 µg.g
-1
.min
-1
, p < 0.001, Figure 7.10). This indicates 
that chronic EGCG treatment has significantly improved muscle insulin sensitivity of 
the insulin resistant rats. 
Western blot analysis (Figure 7.11) of the signalling pathway of insulin-stimulated 
glucose uptake in skeletal muscle showed that the phosphorylation of Akt and 
TBC1D1
Thr590
 were not different between the 23FDins and 23FDins + chEGCG rats 
following the insulin clamp. This indicates that chronic EGCG treatment has not 
improved insulin signalling in skeletal muscle at the end of the insulin clamp.  
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Figure 7.9 Microvascular blood volume during hyperinsulinaemic euglycaemic 
clamp.  - 23FDsal (n = 9),  - 23FDins (n = 10), - 23FDins + chEGCG (n = 13). 
 * p < 0.001 vs. 0 min (Two-way repeated measures ANOVA) 
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Figure 7.10 Muscle 
14
C-2-DG uptake after hyperinsulinaemic euglycaemic 
clamp.  - 23FDsal (n = 9),  - 23FDins (n = 10), - 23FDins + chEGCG (n = 13). 
* p < 0.001 vs. 23FDsal (One-way ANOVA); † p < 0.001 vs. 23FDins (One-way 
ANOVA). 
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Figure 7.11 Western blot of insulin signalling in skeletal muscle. (A) Top panel: Representative blots; Bottom panel: Ratio of 
pAkt/Akttotal, (B) Top panel: Representative blots; Bottom panel: Ratio of pTBC1D1/α-tubulin.   - 23FDins (n = 10), - 23FDins + 
chEGCG (n = 13). Data not statistically significant between two groups (Student’s t-test) 
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7.4 Discussion 
The main findings of this study are that chronic EGCG treatment for 4 weeks improved 
whole body insulin sensitivity and insulin-stimulated muscle glucose uptake in insulin 
resistant rats, and this occurred in the absence of enhanced muscle microvascular 
perfusion. Chronic EGCG treatment in HFD-fed rats had no effect on basal metabolic 
profiles, including body weight, epididymal fat pad weight, HOMA-IR, and fasting 
plasma glucose, insulin and free fatty acids. 
This is the first study that has assessed the chronic effects of EGCG treatment on whole 
body insulin sensitivity in insulin resistant rats using hyperinsulinaemic euglycaemic 
clamp. The hyperinsulinaemic euglycaemic clamp is the gold standard method to assess 
whole body insulin sensitivity (264). The present study showed that chronic EGCG 
treatment (200 mg.kg
-1
.d
-1
) for 4 weeks significantly improved whole body insulin 
sensitivity. It is noted that the basal fasting plasma glucose and insulin levels, which 
were used for the calculations of the HOMA-IR index, were not improved following 
chronic EGCG treatment, indicating that the chronic EGCG treated rats were insulin 
resistant. This contrasts with the data from the hyperinsulinaemic euglycaemic clamp 
which showed improved whole body insulin sensitivity. However, the HOMA-IR, 
fasting plasma glucose and insulin at basal state are representations of the balance 
between hepatic glucose output and insulin secretion in the fasting state (265; 266), 
which reflect the liver insulin sensitivity and pancreatic β-cells function. Furthermore, 
the use of the HOMA model has not been previously validated in animal models (267). 
Therefore, the hyperinsulinaemic euglycaemic represents a more appropriate indication 
of whole body insulin sensitivity in rats. 
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As reported in Chapters 5 and 6, EGCG acutely stimulated MBV to a similar extent as 
the insulin. Unexpectedly, the present study showed that insulin-stimulated 
microvascular perfusion was blunted in the chronic EGCG-treated rats. A recent study 
(268) showed that chronic EGCG treatment (50 – 100 mg.kg-1.d-1) for 4 weeks reduced 
capillary density in breast tumour tissue, but not in normal heart and skeletal muscle. 
Therefore it seems unlikely that the capillary density in the skeletal muscle of the rats 
has been affected by the chronic EGCG treatment. A previous study (120) has reported 
that chronic EGCG treatment (200 mg.kg
-1
.d
-1
 x 3 weeks) improves insulin’s vascular 
action in mesenteric vascular bed of SHRs ex vivo. The insulin dose (3 µM) used in 
Potenza’s study (120) was suprapharmacological, while the present study showed that 
EGCG had no effect on vascular action of the more physiological 1.5 nM insulin dose 
in vivo.  
Previous studies showed that insulin-stimulated microvascular perfusion is independent 
of total blood blow (21) and is NO-dependent (18; 53). It was somewhat surprising to 
see a blunted effect in insulin-stimulated increase in MBV of the chronic EGCG-treated 
rats. One possible explanation could be NO desensitisation in the muscle 
microvasculature following chronic EGCG treatment. As seen in Chapters 5 and 6, 
muscle microvasculature of the insulin resistant rats was more sensitive than in the 
healthy rats to acute EGCG treatment. In the insulin resistant rats, but not healthy rats, 
acute EGCG infusion increased MBV within 30 min. Furthermore, Chapter 4 showed 
that EGCG-mediated vasodilation in skeletal muscle is NOS-dependent. In the event 
that the insulin resistant rats were sensitive to EGCG-stimulated increases in MBV, 
there might be a chronic stimulation of NO in muscle microvasculature during the 4-
week EGCG treatment in the insulin resistant rats. Studies suggested that NO 
desensitisation (similar to “nitrate tolerance”) may occur following prolonged exposure 
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to NO (269-271). Following this chronic NO stimulation during EGCG treatment, the 
muscle microvasculature in the chronic EGCG-treated rats might have become 
insensitive to NO stimulated by insulin. Nonetheless, EGCG-stimulated NO production 
in the muscle microvasculature has not been measured in the present study, and 
whether the NO stimulated by EGCG has reached the level to induce NO 
desensitisation is not known.  
Recently,  Jang et al. (163) reported that high fat-fed mice treated with EGCG (50 
mg.kg
-1
.d
-1
) for 10 weeks have lower fasting plasma glucose and insulin, indicating 
improved insulin sensitivity. Furthermore, they showed that chronic EGCG treatment 
improved insulin-stimulated vasodilation in the mesentery arteries in high fat-fed mice 
(163). This suggests that lower doses of EGCG might be beneficial to improve insulin 
sensitivity both vascularly and metabolically. However, whether chronic treatment with 
lower dose of EGCG can improve insulin-stimulated muscle microvascular perfusion 
and muscle glucose uptake is not known and will be important to investigate. 
The present study is also the first study to assess the chronic effects of EGCG treatment 
on insulin-stimulated muscle glucose uptake in vivo. Despite the insulin-mediated 
microvascular perfusion being blunted following chronic EGCG treatment, insulin-
stimulated muscle glucose uptake was significantly enhanced in the chronic EGCG-
treated insulin resistant rats. This suggests that chronic EGCG treatment may have 
improved the muscle insulin sensitivity directly in the myocytes. Previous studies (172; 
173) showed that EGCG stimulates GLUT4 translocation in cultured myotubes via the 
PI3-K/Akt pathway to promote glucose uptake. However, in the present study, the 
insulin signalling pathway that modulates glucose uptake in skeletal muscle, involving 
Akt and TBC1D1, was not enhanced in the chronic EGCG-treated rats. Therefore, the 
enhanced insulin-stimulated muscle glucose uptake following chronic EGCG treatment 
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may be mediated via an Akt-independent pathway. Studies have reported that insulin 
can stimulate GLUT4 translocation and glucose uptake in skeletal muscle via the Akt-
independent pathway, which include the adapter protein with pleckstrin homology and 
Src homology 2 domains (APS) (272), PKC λ/ζ (273-275) and/or Munc18c (276). 
Furthermore, berberine (277; 278) and ginsenosides (279), which both are plant-derived 
naturally occurring products, have been shown to stimulate glucose uptake in cultured 
myocytes via the AMPK pathway. EGCG has also been reported to regulate its actions 
on inhibition of ET-1 production (211) and suppression of hepatic gluconeogenesis 
(174) via an AMPK-dependent pathway. This suggests that insulin-stimulated muscle 
glucose uptake in the chronic EGCG-treated rats might be mediated via the Akt-
independent or AMPK-dependent pathways. However, whether glucose uptake in 
skeletal muscle following chronic EGCG treatment was mediated via the 
abovementioned pathway is yet to be confirmed. 
In contrast, one study (261) showed that 0.5 % (w/w) EGCG treatment in HFD-fed 
mice for 8 days increased lipid oxidation and reduced incorporation of lipid into 
skeletal muscle, liver and adipose tissue. Interestingly, another study (260) has reported 
that HFD-fed mice treated with 0.32 % (w/w) EGCG for 15 weeks increased 
expressions of genes related to lipid oxidation in skeletal muscle , including nuclear 
respiratory factor (nrf) 1, medium chain acyl coA decarboxylase (mcad), uncoupling 
protein (ucp) 3, and peroxisome proliferator responsive element (ppar) α. These studies 
suggest that chronic EGCG treatment may have improved muscle insulin sensitivity by 
enhancing lipid oxidation and reducing intracellular lipid accumulation in skeletal 
muscle. 
Other studies have shown that plasma adiponectin is elevated following chronic green 
tea or EGCG treatment in animals (120; 160; 280) and humans (144; 145). Adiponectin 
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is a metabolism stimulator adipokine secreted by adipocytes (281). Previous studies 
(282-284) have demonstrated that adiponectin stimulates GLUT4 translocation and 
glucose uptake in cultured myocytes via the AMPK pathway. Whether plasma 
adiponectin was elevated in the present study, which in turn resulted in increased 
muscle glucose uptake was not addressed. 
It is important to note that following an overnight fast, EGCG was not detected in the 
plasma of the chronic EGCG-treated rats. Therefore the metabolic and vascular effects 
observed in the present study were due to the effects of long term green tea (EGCG) 
consumption. Although the underlying mechanisms of the chronic metabolic effects of 
EGCG have yet to be determined, it is concluded that chronic EGCG treatment 
ameliorates whole body and muscle insulin resistance in HFD-fed rats.  
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Chapter 8 
Discussion 
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8.1 Summary of findings 
The main hypothesis tested in this thesis was that EGCG has insulin-mimetic and/or 
insulin-sensitizing effects in vivo on vascular function to improve glucose metabolism 
in skeletal muscle. Prior to assessing the effects of EGCG in vivo, the direct vascular 
and metabolic actions of EGCG were characterised in situ. The data from the present 
thesis demonstrates that EGCG is a NOS-dependent, but PI3-K- and AMPK-
independent vasodilator in skeletal muscle. In contrast, EGCG has no direct metabolic 
actions in skeletal muscle. While acute EGCG infusion increases microvascular blood 
volume in both healthy and insulin resistant rats in vivo, it does not stimulate muscle 
glucose uptake. However, acute EGCG infusion improves whole body insulin 
sensitivity in insulin resistant, but not healthy rats. Chronic EGCG treatment prevents 
the development of insulin resistance in rats, in which whole body insulin sensitivity 
and muscle glucose uptake are improved. 
 
8.2 Vascular actions of EGCG in skeletal muscle 
EGCG has been previously reported to be a vasodilator in various isolated blood 
vessels, including aortic ring (178; 179), bovine ophthalmic artery (180), coronary 
artery ring (181), and mesenteric vascular bed (119). The vascular actions of EGCG in 
skeletal muscle were characterised in Chapters 3 and 4 using the constant-flow perfused 
rat hindlimb system. Using this in situ preparation, the direct vascular effect of EGCG 
in the hindlimb vasculature can be assessed in the absence of humoral and neural input.  
Since the hindlimb vasculature is free from humoral and neural input, the vasculature is 
fully dilated. Therefore, the hindlimb was pre-constricted using different 
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vasoconstrictors to study the potential vasodilatory response of EGCG. There are two 
distinct circulatory systems in skeletal muscle, designated as nutritive and non-nutritive 
flow routes (37-41). Two classes of vasoconstrictor, type A and B, have been identified 
based on the metabolic effects of each constrictor types. Type A vasoconstrictors (eg. 
low dose NE) induce vasoconstriction at the non-nutritive flow route directing flow 
through the nutritive route. These increase basal muscle metabolism, whereas type B 
vasoconstrictors (eg. 5-HT, high dose NE) stimulate vasoconstriction at the nutritive 
flow route and decrease muscle metabolism (Figure 3.8, see review by Clark et al. (38)). 
As EGCG did not dilate against high dose NE, indicating that EGCG-mediated 
vasodilation in skeletal muscle is not specific to type B vasoconstrictions. Data from 
Chapter 3 characterised a novel vascular action of EGCG to specifically oppose the 
vasoconstriction induced by 5-HT, but not NE. This is important as vasoconstriction 
induced by 5-HT acutely have been reported to reduce whole body and muscle insulin 
sensitivity in vivo (50).  
The mechanism of EGCG’s vascular actions in skeletal muscle was characterised in 
Chapter 4. Previous studies showed that EGCG mimics insulin to stimulate NO 
production in cultured vascular endothelial cells, via the PI3-K/Akt/eNOS pathway 
(119; 178-181). Studies showed that inhibition of PI3-K and NOS blunted the 
vasodilation induced by EGCG (119; 120; 179). However, data from Chapter 4 showed 
that EGCG-mediated vasodilation in skeletal muscle was blunted by L-NAME, but not 
wortmannin, indicating vascular action of EGCG in skeletal muscle is NOS-dependent, 
but PI3-K-independent. This implies that vasodilation induced by EGCG in skeletal 
muscle vasculature is mediated via a separate pathway from that of the other vascular 
tissues.  
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The mechanisms of EGCG-mediated vasodilation in skeletal muscle were assessed with 
other pathways that have been documented to stimulate a NOS-dependent vasodilation. 
One possible signalling pathway is via AMPK and activation of eNOS by 
phosphorylation on Ser
1177
 and Ser
633
 (212; 213). Previously, EGCG has been reported 
to activate AMPK in bovine aortic endothelial cells (211). However, data from Chapter 
4 showed that vasodilation induced by EGCG in skeletal muscle is not inhibited by 
Compound C, an inhibitor of AMPK, indicating that EGCG-mediated vasodilation in 
skeletal muscle is AMPK-independent. Alternatively, Quon and colleagues (119) 
reported that Fyn, a member of SFK (207), is a signalling molecule upstream of PI3-K 
which resulted in eNOS activation and NO production. Interestingly, that study showed 
that SFK can directly activate eNOS independent of PI3-K (210). Data from Chapter 4 
showed that PP2, an inhibitor of SFK, did not inhibit the vasodilation induced by 
EGCG, indicating EGCG-mediated vasodilation in skeletal muscle is SFK-independent. 
The mechanism of EGCG-mediated vasodilation in skeletal muscle thus remains 
unknown. Other naturally occurring polyphenols (eg. epicatechin and reservatrol) have 
been reported to mediate vasodilation via the Ca
2+
/CaMK/eNOS (222-224) or MAPK 
(225-227) signalling pathway. Whether vasodilation induced by EGCG in the skeletal 
muscle is mediated through these signalling pathways is yet to be investigated.  
Data from Chapters 5 and 6 showed that EGCG acutely stimulated microvascular 
perfusion, but had no effects on FBF, during hyperinsulinaemic euglycaemic clamp in 
both healthy and insulin resistant rats in vivo. The insulin resistant rats appeared to be 
more sensitive to EGCG-mediated microvascular perfusion, in which there was a 
significant increase in MBV following 30 min of EGCG infusion. Some (247; 248), but 
not all (249; 250), studies suggested an elevated ROS production following HFD 
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treatment, and ROS have been implicated in EGCG-mediated NO production in 
endothelial cells (119; 181). In the insulin resistant rat model used in the present study, 
whether there is an elevation in ROS production and the ROS level is sufficient to 
provoke a more sensitive response of EGCG-mediated microvascular perfusion in 
insulin resistant rats requires further investigation. 
In another set of experiments, the chronic effects of EGCG on microvascular perfusion 
were assessed in insulin resistant rats. While there was no effect on insulin-stimulated 
FBF, microvascular perfusion responses to insulin were blunted following chronic 
EGCG treatment in the insulin resistant rats. This is in contrast to a study (120) which 
reported chronic EGCG treatment (200 mg.kg
-1
.min
-1
 x 3 weeks) improved insulin’s 
vascular action in mesenteric vascular bed of SHRs ex vivo. However, the effective 
insulin dose that was used in Potenza’s study (120) was suprapharmacological (3 µM), 
while the present study showed that EGCG had no effect on vascular action of 1.5 nM 
insulin in vivo. In Potenza’s study (120), chronic EGCG treatment did not improve 
vascular action of insulin when a lower dose (1.5 nM) of insulin was tested. In contrast, 
EGCG has been reported to have anti-angiogenesis effects (285) and reduced capillary 
density in melanoma (286) and breast cancer (268) tissues. A recent study (268) 
showed that chronic EGCG treatment (50 – 100 mg.kg-1.d-1) for 4 weeks reduced 
capillary density in breast tumour tissue, but not normal heart or skeletal muscle. 
Therefore it seems unlikely that the capillary density in the skeletal muscle of the rats 
has been affected by the chronic EGCG treatment, although this was not directly tested 
in the current study. One possible explanation for the blunted microvascular response 
following chronic EGCG treatment could be NO desensitisation. Some studies have 
suggested that NO desensitisation (similar to “nitrate tolerance”) may occur following 
prolonged exposure to NO (269-271). EGCG is a NOS-dependent vasodilator in muscle 
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vasculature, suggesting that there might be a chronic stimulation of NO in muscle 
microvasculature during the 4-week EGCG treatment in the insulin resistant rats. 
Following this chronic NO stimulation during EGCG treatment, the muscle 
microvasculature in the chronic EGCG treated rats might have become insensitive to 
NO stimulated by insulin. Nonetheless, EGCG-stimulated NO production in the muscle 
microvasculature has not been measured in the present study, and whether the NO 
stimulated by EGCG has reached the level to induce NO desensitisation could be 
investigated in future.  
It has been suggested that insulin-stimulated microvascular perfusion can increase 
delivery of nutrients, such as glucose and insulin, to skeletal muscle, resulting in 
increased muscle glucose uptake (231; 232). Because EGCG vasodilates in muscle 
vasculature and acutely stimulates microvascular perfusion in skeletal in vivo, it was 
postulated that EGCG could stimulate muscle microvascular perfusion and result in 
increased insulin-stimulated muscle glucose uptake in vivo.  
 
8.3 Metabolic actions of EGCG in skeletal muscle 
Skeletal muscle is the largest tissue in the human body responsible for storing 80 – 90 % 
of postprandial glucose as glycogen in healthy humans (62; 63). During insulin 
resistance, insulin-stimulated glucose uptake in skeletal muscle is impaired (80; 82; 239; 
242). Previously, EGCG has been reported to mimic insulin’s metabolic action to 
stimulate muscle glucose uptake in vitro via the PI3-K/Akt signalling pathway in 
cultured myotubes (172; 173; 176). In Chapter 3, the constant-flow perfused rat 
hindlimb preparation was used to assess the direct metabolic actions of EGCG in 
skeletal muscle. The direct metabolic actions of EGCG were assessed at four different 
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doses (0.1, 1, 10, and 100 µM). Plasma EGCG concentrations of 0.1 – 1 µM could be 
achieved by drinking 8 – 16 cups of green tea respectively (151; 186). Data from 
Chapter 3 showed that none of the EGCG doses tested have direct metabolic actions in 
skeletal muscle, and insulin-stimulated glucose uptake was not altered in perfused 
hindlimb. Another set of experiments was conducted to assess the metabolic effects of 
10 µM EGCG for a longer period of time. However, muscle glucose uptake and insulin-
stimulated muscle glucose uptake were not altered by 10 µM EGCG over the course of 
60 min infusion. These findings contradict to previous studies in cultured myocytes 
(172; 173) in which EGCG dose-dependently stimulated GLUT4 translocation and 
glucose uptake. Furthermore, chronic green tea or EGCG treatment has been reported 
to promote GLUT4 translocation and glucose uptake in isolated myocytes in the 
absence of insulin in both healthy (157; 172) and insulin resistant (158) animals.  
One possible explanation for this conflict could be that the metabolic actions of green 
tea or EGCG were assessed using myocyte incubations in vitro (157; 158; 172; 173), 
where glucose and EGCG were in direct contact with the myocytes rather than being 
delivered via vasculature (196). The constant-flow perfused rat hindlimb preparation 
that was employed in Chapter 3 more closely represents the in vivo system, in which 
nutrients and hormones (insulin, glucose and EGCG) are delivered to the skeletal 
muscle via the vasculature. Thus, the discrepancies between the in vitro and in situ 
studies suggest that the vasculature might act as a barrier for EGCG to stimulate 
glucose uptake in skeletal muscle. Cultured myocytes might be exposed to higher 
concentrations of EGCG without the vascular barrier, but microdialysis would need to 
be done to confirm this. Jung et al. (173) showed that 100 µM EGCG did not affect the 
viability of the cultured myocytes. However, it has been demonstrated that the highest 
tolerated dose of EGCG in rats in vivo was 12 µM (500 mg.kg
-1
.d
-1
) (197; 198), thus 
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assessing higher doses of EGCG is not physiologically relevant. Furthermore, plasma 
EGCG of 1 µM can only be achieved with 16 cups of green tea per day, but health 
benefits are seen at much lower doses of green tea (> 3 cups) in humans (102; 123; 
124). Therefore, it is not physiologically or even toxicologically possible to achieve 
doses like those used in isolated or cultured myocytes, and even less likely to be 
achieved if vascular system acts as a barrier. Thus, it is concluded that EGCG does not 
have direct metabolic actions in skeletal muscle. 
Although EGCG acutely stimulated microvascular perfusion in vivo, this was not 
accompanied by increased muscle glucose uptake or insulin-stimulated muscle glucose 
uptake. While muscle microvascular perfusion plays a key role in determining the 
movement of glucose in blood to skeletal muscle (review by Barrett and Rattigan (251)), 
transmembrane glucose transport regulated by GLUT4 is also an important rate-
limiting step of glucose uptake into muscle and adipose tissue (252). Chapter 3 showed 
that EGCG did not directly stimulate glucose uptake in the skeletal muscle in situ, 
suggesting that EGCG does not stimulate GLUT4 translocation into the plasma 
membrane of the muscle cell. Since EGCG does not stimulate GLUT4 translocation in 
skeletal muscle in situ, this may explain why the acute EGCG treatment in vivo 
stimulated muscle microvascular perfusion, but not muscle glucose uptake. 
On the other hand, acute EGCG treatment resulted in a modest improvement (12%) in 
whole body insulin sensitivity of insulin resistant, but not healthy, rats. This is in 
accordance with findings by others (147; 238) which report acute green tea or EGCG 
treatment is metabolically beneficial for insulin resistant, but not healthy animals. 
EGCG has been reported to stimulate glucose uptake in adipocytes (156; 159; 238) and 
inhibit hepatic gluconeogenesis (174; 175) in vitro. Insulin-stimulated muscle glucose 
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uptake in the insulin resistant rats was not improved following the acute EGCG 
treatment, indicating that the acute EGCG treatment has improved insulin sensitivity in 
adipose tissue and/or liver. However, acute effects of EGCG on adipose tissue and liver 
insulin sensitivity in vivo have not been previously investigated. Therefore, more work 
is required before the acute effects of EGCG on whole body glucose metabolism can be 
fully understood. 
Chronic EGCG treatments have been suggested to have anti-obesity effects (158; 161-
163). Studies have suggested that EGCG treatment reduces food digestibility (261; 287) 
and fat absorption (161; 261) in HFD-fed mice. However, data from Chapter 7 showed 
that chronic EGCG treatment for 4 weeks did not alter the basal metabolic profile of the 
insulin resistant rats, including the body weight, epididymal fat pad weight, and fasting 
plasma glucose, insulin and free fatty acids. Previous studies (158; 161-163) showed 
that the effects of green tea or EGCG treatment on lowering body weight and fasting 
plasma glucose did not become apparent until week 7 of treatment. This indicates that 
longer EGCG treatment might be required to have apparent effects on the basal 
metabolic profiles. Compared to the acute EGCG treatment in insulin resistant rats, 
chronic EGCG treatment (200 mg.kg
-1
.d
-1
) resulted in a greater improvement in whole 
body insulin sensitivity within 4 weeks (improved GIR by 21% vs. 12%). This suggests 
that initially the benefits of EGCG are not mediated by improved metabolic profile. 
This supports the findings by other studies which showed that chronic green tea or 
EGCG treatment improved glucose tolerance or insulin sensitivity in both healthy (156-
158; 229) and insulin resistant (98; 158-162; 164-167) animals.  
In the chronic EGCG-treated rats, the improvement in whole body insulin sensitivity is, 
at least in part, attributable to an improvement in muscle insulin sensitivity. Data from 
Chapter 7 showed that insulin-stimulated muscle glucose uptake is enhanced without 
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increased in microvascular perfusion, suggesting that chronic EGCG treatment has 
improved myocyte insulin sensitivity rather than glucose or insulin delivery. Further 
supported by observation that in the chronic EGCG treated rats, insulin-stimulated 
muscle glucose uptake was improved without improving Akt-dependent muscle insulin 
signalling suggesting insulin delivery was not altered. Several proteins, including the 
APS (272), PKC λ/ζ (273-275), and Munc18c (276), have been found to stimulate 
GLUT4 translocation in skeletal muscle independent of Akt. Furthermore, berberine 
(277; 278) and ginsenosides (279), both plant-derived, naturally occurring products, 
have been shown to stimulate glucose uptake in cultured myocytes via the AMPK 
pathway. Whether chronic EGCG treatment improves the Akt-independent and/or 
AMPK-dependent signalling pathway in the skeletal muscle of insulin resistant rats 
requires further investigation. 
Improvements in myocyte insulin sensitivity may have resulted from reduced 
intramyocellular lipid levels following chronic EGCG treatment. One study (261) 
showed that chronic EGCG treatment in HFD-fed mice had increased lipid oxidation 
and reduced lipid incorporation into skeletal muscle, liver and adipose tissue. Chronic 
EGCG treatment may have also improved myocyte insulin sensitivity by modulating 
lipid metabolism genes in skeletal muscle. Chronic EGCG treatment in HFD-mice 
increased expression of genes related to lipid oxidation in skeletal muscle, including the 
inrf1, mcad, ucp2, ucp3, and pparα (260; 287). These studies suggest that chronic 
EGCG treatment may have improved muscle insulin sensitivity by enhancing lipid 
oxidation and reducing intramyocellular lipid accumulation. 
However, another possible mechanism of action of chronic EGCG is via reducing 
oxidative stress. Oxidative stress is one of the mechanisms postulated to have led to 
HFD-induced insulin resistance (288). Elevated fatty acids level during HFD is thought 
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to induce oxidative stress by increased mitochondrial uncoupling and β oxidation, 
which resulted in increased ROS production (289; 290). Several studies (291-294) 
showed that imbalance between the body antioxidant defence and ROS production 
resulted in insulin resistance, while restoration of this imbalance by antioxidants, such 
as α-lipoic acid, N-acetylcysteine, and taurine, ameliorates insulin resistance in rats and 
humans. Given that EGCG is a potent antioxidant in vivo (295; 296), whether chronic 
EGCG treatment ameliorated insulin resistance in HFD-induced insulin resistant rats by 
reducing oxidative stress requires further investigation. 
 
8.4 Implications 
Obesity, insulin resistance, and type 2 diabetes are growing to epidemic levels 
worldwide. It was estimated that in 2010, 50% of the Chinese population are pre-
diabetic (297). During 2000 – 2010, prevalence of diabetes has doubled in Chinese 
population, increased from 5.5% to 11.6% (297; 298). Current medications and 
treatments for diabetes have side effects and often lose their effectiveness over time due 
to the progressive nature of the disease. Epidemiological studies (102; 106; 123-125) 
suggested long term green tea consumption of ≥ 3 cups.d-1 may lower the risk of type 2 
diabetes. This thesis explores the potential of EGCG to be used as an alternative 
medicine to prevent insulin resistance and type 2 diabetes. This thesis provides 
potential mechanisms between green tea consumption and reduced risk for type 2 
diabetes (Figure 8.1). The overarching aim of this thesis was to explore the vascular and 
metabolic effects of EGCG in rats in situ and in vivo 
The present study showed that acute administration of EGCG to raise plasma EGCG to 
10 µM had significantly increased insulin-mediated microvascular perfusion, but had 
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no effect on muscle glucose uptake. It has been recently reported that insulin resistance 
in muscle microvasculature can be developed independently of insulin resistance in 
myocytes (82), the current thesis suggests that acute EGCG treatment might be 
beneficial to subjects that display microvascular dysfunction but not myocyte insulin 
resistance.  
However, the major benefit of EGCG is from chronic treatment, EGCG administration 
(200 mg.kg
-1
.d
-1
) for 4 weeks prevented the development of muscle insulin resistance 
with marked improvements in whole body insulin sensitivity in HFD insulin resistant 
rats. This suggests that EGCG is a prophylactic agent against insulin resistance, 
however, whether EGCG acts as a therapeutic agent to reverse insulin resistance 
requires further investigation. The most important outcome from animal data is its 
potential to be translated to human studies. It is noted that EGCG has poor oral 
bioavailability (186; 299-301), and extensive research has been undertaken to study 
approaches to improve the EGCG bioavailability. EGCG bioavailability could be 
enhanced by co-treatment of EGCG with ω3 polyunsaturated fatty acids (302-304) or 
piperine (an alkaloid derived from black pepper) (305), EGCG encapsulation in 
chitosan nanoparticles (306; 307), and co-crystallization of EGCG (308). Nonetheless, 
further studies are required to assess the biological effects of these forms of EGCG.  
It has been reported that EGCG undergoes high degree of glucuronidation in mice 
following oral administration, and only 10 – 50 % of free (unconjugated) EGCG is 
present in the plasma of mice (300). However, a study by Kim and colleagues (309) 
reported that there was 40 – 80 % of free (unconjugated) EGCG in the plasma of 
Sprague Dawley rats following oral administration of green tea cathechins for 4 weeks. 
During green tea catechin administration in rats, most of the EGCG appeared to be in 
the colon, followed by the oesophagus and bladder (309). Kim and colleagues (309) 
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indicated that EGCG has low bioavailability in rats, in which EGCG is poorly absorbed 
and highly excreted through the faeces. However regardless of this low bioavailability, 
chronic EGCG administration to rats for 4 weeks in the present study produced 
profound effects on whole body and muscle insulin sensitivity indicating it is 
biologically potent. 
The pharmacokinetics of EGCG in rats (299; 309) and humans (151; 186; 310) have 
been assessed under a variety of conditions. Furthermore, there is sufficient 
pharmacokinetic data in rats and humans to determine dietary versus pharmacological 
doses of plasma EGCG. It has been reported that in human, dietary relevant plasma 
doses of EGCG range from 0.1 to 1 µM (151; 186). Studies in the current thesis have 
been designed to test EGCG doses spanning the dietary (0.1 – 1 µM) to 
pharmacological (10 – 100 µM) range. EGCG levels in commercial tea leaves are 
approximately 20 mg.g
-1
 (107). Most tea bags have approximately 1.5 – 2 g of tea 
leaves per tea bag, indicating there is about 30 – 40 mg of EGCG in each tea bag. 
However, studies (186; 299; 310) reported that bioavailability of EGCG is higher in 
human than in Sprague-Dawley rats, in which maximum plasma EGCG concentrations 
following oral administration of 75 mg.kg
-1
 EGCG to rats and 2 mg.kg
-1
 EGCG to 
humans were 19.8 ng.mL
-1
 and 34.71 ng.mL
-1
 respectively. This suggests that humans 
might be able to drink fewer cups of green tea per day to achieve the plasma EGCG 
concentration found to be prophylactic in Chapter 7. However, further studies are 
required to determine the relevant dose for human use. 
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Figure 8.1 Vascular and metabolic actions of EGCG in vivo. Acute, but not chronic, 
EGCG stimulates muscle microvascular perfusion. However, EGCG chronically, but 
not acutely, enhances insulin-stimulated muscle glucose uptake. EGCG acutely 
enhances whole body insulin sensitivity (GIR) of insulin resistant, but not healthy rats, 
and chronic EGCG treatment further improves whole body insulin sensitivity of insulin 
resistant rats. 5FD- normal healthy rats; 23FD- insulin resistant rats.  
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8.5 Limitations and future directions 
In this thesis, EGCG treatment, both acutely and chronically, may have been more 
effective at lower insulin doses. In healthy rats, insulin dose-dependently (1 – 10 
mU.min
-1
.kg
-1
) stimulates muscle glucose uptake, while insulin-mediated microvascular 
perfusion reached maximal at the lowest dose of insulin (1 mU.min
-1
.kg
-1
) (27). 
However, in HFD-induced (36% fat w/w) insulin resistant rats, while insulin-mediated 
microvascular perfusion was unresponsive to both physiological (3 mU.min
-1
.kg
-1
) and 
pharmacological (10 mU.min
-1
.kg
-1
) doses of insulin, loss of the skeletal muscle 
glucose uptake response to insulin was less evident at the higher insulin dose. The 
insulin dose used in this thesis was 10 mU.min
-1
.kg
-1
, so whole body and muscle insulin 
sensitivity of the acute EGCG-treated rats might have been masked and overlooked. 
A number of questions have arisen from the current thesis that requires future studies. 
The mechanisms of EGCG-mediated vasodilation in skeletal muscle have not been 
fully elucidated. Determining the mechanisms may provide a better insight into the 
vascular actions of EGCG in skeletal muscle and identify potential therapeutic agents 
that may augment EGCG actions. Whilst EGCG-mediated vasodilation in skeletal 
muscle is NOS-dependent and PI3-K-independent, Ca
2+
/CaMK or MAPK signalling 
pathways are potential pathways that activate NOS. Further studies using Western blot 
analysis are required to determine the activation of CaMK or MAPK by EGCG in the 
common iliac arteries of the perfused hindlimb. Besides that, inhibitory studies using a 
specific inhibitor of CaMK or MAPK, such as autocamtide-2 related inhibitory peptide 
and SB 202190 respectively, could be used to determine whether inhibition of these 
kinases inhibits EGCG-mediated vasodilation in the constant perfused rat hindlimb. 
Further studies are needed to assess liver and adipose tissue insulin sensitivity 
following acute and chronic EGCG treatment in insulin resistant rats. Furthermore, 
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acute EGCG treatment stimulates microvascular perfusion, indicating that EGCG might 
augment currently used anti-diabetic medications (eg. metformin and acarbose) that do 
not act on the muscle vasculature. Whether co-treatment of EGCG with current anti-
diabetic medications can improve treatment outcome is not known and will be 
important to investigate.  
The present study showed that chronic EGCG treatment for 4 weeks has improved 
muscle insulin sensitivity, however, the cellular mechanisms have not been fully 
elucidated. Some studies (260; 261) suggest that chronic treatment with EGCG may 
improve muscle lipid oxidation and reduce intracellular lipid accumulation in skeletal 
muscle. Therefore it is of important to assess the expression of genes related to muscle 
lipid oxidation as well as muscle lipid levels of rats treated with EGCG chronically. 
The present study indicated that chronic EGCG treatment might have led to NO 
desensitisation which led to blunted insulin-mediated microvascular perfusion. Studies 
have suggested that reduced activity of NO-sensitive guanylyl cyclase (271) and 
increased activity of phosphodiesterase (311) results in desensitisation of the 
NO/cGMP signalling pathway. This could be further examined and confirmed by 
assessing the activity of NO-sensitive guanylyl cyclase and phosphodiesterase to assess 
the effect of EGCG on NO sensitivity in the vasculature. Recently, one study (163) 
reported that chronic treatment with lower dose of EGCG (50 mg.kg
-1
.d
-1
) improved 
insulin resistance and endothelial dysfunction in HFD-fed mice. If chronic EGCG 
treatment at 200 mg.kg
-1
.d
-1
 led to NO desensitisation in the muscle vasculature, it may 
be that a lower dose of EGCG preserves NO sensitivity and thereby further enhances 
muscle insulin sensitivity. Furthermore, it would be useful to determine whether acute 
and chronic actions of EGCG combine to give greater insulin sensitisation, since both 
vascular and metabolic (muscle glucose uptake) actions were improved by acute and 
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chronic EGCG administration, respectively. Similarly, whether chronic co-
administration of EGCG with quinapril, an angiotensin converting enzyme inhibitor 
reported (52) to partially restore insulin-mediated microvascular perfusion in ZDF rats, 
could improve insulin sensitivity in both muscle microvascular and skeletal muscle 
requires further investigation. Finally, while this thesis has shown that chronic EGCG 
treatment prevented the development of insulin resistance in HFD-fed rats, it is 
important to establish whether chronic EGCG treatment reverses insulin resistance and 
diabetes. 
 
8.6 Conclusion 
The current thesis characterizes the direct metabolic and vascular effects of EGCG in 
skeletal muscle in situ using the constant-flow perfused rat hindlimb. EGCG is a NOS-
dependent vasodilator in muscle vasculature, but had no direct metabolic actions on 
skeletal muscle in situ. For the first time, EGCG is demonstrated to induce vasodilation 
in skeletal muscle and more importantly oppose 5-HT, but not NE, vasoconstriction. 
When EGCG is administered acutely in vivo, whole body insulin sensitivity of insulin 
resistant, but not healthy rats is improved moderately. This thesis also showed that 
acute EGCG treatment stimulated muscle microvascular perfusion without enhancing 
muscle glucose uptake in both healthy and insulin resistant rats. This suggests that 
acute EGCG treatment might be beneficial for microvascular dysfunction in early 
stages of insulin resistance. On the other hand, chronic EGCG treatment improved 
insulin-stimulated muscle glucose uptake and ameliorated insulin resistance in insulin 
resistant rats. However, chronic EGCG treatment had no effects on insulin-stimulated 
microvascular perfusion. This was unexpected, and suggests that chronic EGCG 
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treatment might have led to NO-desensitization in the muscle microvasculature. 
Chronic EGCG treatment might have prevented insulin resistance in muscle via a non-
vascular pathway. Collectively, the work presented in the current thesis showed that 
acute administration of EGCG is beneficial for microvascular dysfunction while 
chronic administration of EGCG may act as a new prophylactic agent against insulin 
resistance.  
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